<!DOCTYPE html>
<html><head><meta charset="UTF-8">
<title>Earnings Call ë²ˆì—­</title>
<style>
    body { font-family: Arial; margin: 40px; background-color: #fdfdfd; }
    h1 { text-align: center; }
    h2 { margin-top: 50px; color: #003366; }
    h3 { color: #333; }
    table { border: 1px solid #ddd; width: 100%; border-collapse: collapse; }
    th { background: #f0f0f0; padding: 10px; border-bottom: 2px solid #ccc; }
    td { padding: 10px; border-bottom: 1px dotted #ccc; vertical-align: top; }
    p { line-height: 1.6; }
    hr { margin: 50px 0; border: none; border-top: 1px solid #ccc; }
    .back-button {
        display: inline-block;
        background-color: #5f5f5f;
        color: white;
        padding: 10px 16px;
        border-radius: 6px;
        text-decoration: none;
        font-weight: 500;
        box-shadow: 0 2px 6px rgba(0,0,0,0.1);
        margin-bottom: 30px;
    }
</style>
</head><body>
<a href="../../index.html" class="back-button">â†</a>
<h1>ğŸ“„ Earnings Call Transcript ë²ˆì—­ ê²°ê³¼</h1>

    <h2>ğŸ“Š Presentation</h2>
    <table style="width:100%; border-collapse:collapse; margin-bottom: 40px;">
        <tr>
            <th style="width:50%; border-bottom: 2px solid #333;">Original</th>
            <th style="width:50%; border-bottom: 2px solid #333;">Translation</th>
        </tr>
        <tr><td>Regeneron Pharmaceuticals, Inc.</td><td># ë¦¬ì œë„ˆë¡  íŒŒë§ˆìŠˆí‹°ì»¬ìŠ¤(Regeneron Pharmaceuticals, Inc.)<br><br>ë¦¬ì œë„ˆë¡  íŒŒë§ˆìŠˆí‹°ì»¬ìŠ¤ëŠ” ë¯¸êµ­ì˜ ìƒëª…ê³µí•™ ì œì•½íšŒì‚¬ë¡œ, í˜ì‹ ì ì¸ ì˜ì•½í’ˆ ê°œë°œì— ì£¼ë ¥í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì£¼ìš” ì œí’ˆìœ¼ë¡œëŠ” ì•ˆê³¼ì§ˆí™˜ ì¹˜ë£Œì œ ì•„ì¼ë¦¬ì•„(Eylea), ì•„í† í”¼ í”¼ë¶€ì—¼ ì¹˜ë£Œì œ ë“€í”½ì„¼íŠ¸(Dupixent), ê³ ì½œë ˆìŠ¤í…Œë¡¤í˜ˆì¦ ì¹˜ë£Œì œ í”„ë„ë£¨ì—”íŠ¸(Praluent) ë“±ì´ ìˆìŠµë‹ˆë‹¤.<br><br>**ì£¼ìš” ì‚¬ì—… ë¶„ì•¼:**<br>- ì•ˆê³¼ ì§ˆí™˜ ì¹˜ë£Œì œ<br>- ë©´ì—­í•™ ë° ì—¼ì¦ì„± ì§ˆí™˜ ì¹˜ë£Œì œ<br>- ì¢…ì–‘í•™<br>- ì‹¬í˜ˆê´€ ì§ˆí™˜ ì¹˜ë£Œì œ<br>- í¬ê·€ ì§ˆí™˜ ì¹˜ë£Œì œ<br><br>**ì¬ë¬´ ì •ë³´ ë° ì‹¤ì :**<br>ë¦¬ì œë„ˆë¡ ì€ ì§€ì†ì ì¸ ë§¤ì¶œ ì„±ì¥ê³¼ ê°•ë ¥í•œ ì œí’ˆ í¬íŠ¸í´ë¦¬ì˜¤ë¥¼ ë°”íƒ•ìœ¼ë¡œ ì•ˆì •ì ì¸ ì¬ë¬´ ì„±ê³¼ë¥¼ ë³´ì´ê³  ìˆìŠµë‹ˆë‹¤. íŠ¹íˆ ë“€í”½ì„¼íŠ¸ì˜ ì ì‘ì¦ í™•ëŒ€ì™€ ì•„ì¼ë¦¬ì•„ì˜ ì‹œì¥ ì§€ë°°ë ¥ì´ ì£¼ìš” ì„±ì¥ ë™ë ¥ì…ë‹ˆë‹¤.<br><br>**íˆ¬ì í¬ì¸íŠ¸:**<br>- ê°•ë ¥í•œ ì—°êµ¬ê°œë°œ íŒŒì´í”„ë¼ì¸<br>- ì£¼ìš” ì œí’ˆì˜ ì‹œì¥ ì ìœ ìœ¨ í™•ëŒ€<br>- ì‚¬ë…¸í”¼(Sanofi)ì™€ì˜ ì „ëµì  íŒŒíŠ¸ë„ˆì‹­<br>- ì§€ì†ì ì¸ ì‹ ì•½ ê°œë°œ ë° ì ì‘ì¦ í™•ëŒ€</td></tr>
<tr><td>(REGN) Q4 2025 Earnings Call January 30, 2026 8:30 AM EST<br><br>Company Participants<br><br>Ryan Crowe - Senior Vice President of Investor Relations & Strategic Analysis<br>Leonard Schleifer - Co-Founder, President, CEO & Co-Chairman<br>George Yancopoulos - Co-Founder, President, Chief Scientific Officer & Co-Chairman<br>Marion McCourt - Executive Vice President of Commercial<br>Christopher Fenimore - Executive VP of Finance & CFO<br><br>Conference Call Participants<br><br>Alexandria Hammond - Wolfe Research, LLC<br>Christopher Raymond - Raymond James & Associates, Inc., Research Division<br>Salveen Richter - Goldman Sachs Group, Inc., Research Division<br>Tyler Van Buren - TD Cowen, Research Division<br>David Risinger - Leerink Partners LLC, Research Division<br>Tazeen Ahmad - BofA Securities, Research Division<br>Geoffrey Meacham - Citigroup Inc., Research Division<br>Akash Tewari - Jefferies LLC, Research Division<br>Terence Flynn - Morgan Stanley, Research Division<br>Evan Seigerman - BMO Capital Markets Equity Research<br><br>Presentation<br><br>Operator<br><br>Welcome to the Regeneron Pharmaceuticals Fourth Quarter 2025 Earnings Conference Call.</td><td># (REGN) 2025ë…„ 4ë¶„ê¸° ì‹¤ì  ë°œí‘œ ì»¨í¼ëŸ°ìŠ¤ ì½œ 2026ë…„ 1ì›” 30ì¼ ì˜¤ì „ 8ì‹œ 30ë¶„ (ë¯¸ ë™ë¶€ í‘œì¤€ì‹œ)<br><br>## íšŒì‚¬ ì°¸ì„ì<br><br>Ryan Crowe - íˆ¬ìì ê´€ê³„ ë° ì „ëµ ë¶„ì„ ë‹´ë‹¹ ìˆ˜ì„ ë¶€ì‚¬ì¥<br>Leonard Schleifer - ê³µë™ ì°½ë¦½ì, ì‚¬ì¥, CEO ê²¸ ê³µë™ íšŒì¥<br>George Yancopoulos - ê³µë™ ì°½ë¦½ì, ì‚¬ì¥, ìµœê³  ê³¼í•™ ì±…ì„ì ê²¸ ê³µë™ íšŒì¥<br>Marion McCourt - ìƒì—… ë¶€ë¬¸ ì „ë¬´ì´ì‚¬<br>Christopher Fenimore - ì¬ë¬´ ë‹´ë‹¹ ì „ë¬´ì´ì‚¬ ê²¸ CFO<br><br>## ì»¨í¼ëŸ°ìŠ¤ ì½œ ì°¸ì„ ì• ë„ë¦¬ìŠ¤íŠ¸<br><br>Alexandria Hammond - Wolfe Research, LLC<br>Christopher Raymond - Raymond James & Associates, Inc., ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>Salveen Richter - Goldman Sachs Group, Inc., ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>Tyler Van Buren - TD Cowen, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>David Risinger - Leerink Partners LLC, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>Tazeen Ahmad - BofA Securities, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>Geoffrey Meacham - Citigroup Inc., ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>Akash Tewari - Jefferies LLC, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>Terence Flynn - Morgan Stanley, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>Evan Seigerman - BMO Capital Markets ì£¼ì‹ ë¦¬ì„œì¹˜<br><br>## ë°œí‘œ<br><br>ì‚¬íšŒì<br><br>Regeneron Pharmaceuticals 2025ë…„ 4ë¶„ê¸° ì‹¤ì  ë°œí‘œ ì»¨í¼ëŸ°ìŠ¤ ì½œì— ì˜¤ì‹  ê²ƒì„ í™˜ì˜í•©ë‹ˆë‹¤.</td></tr>
<tr><td>My name is Shannon, and I will be your operator for today's call. [Operator Instructions] Please note that this conference call is being recorded. I will now turn the call over to Ryan Crowe, Senior Vice President, Investor Relations. You may begin. Ryan Crowe<br>Senior Vice President of Investor Relations & Strategic Analysis<br><br>Thank you, Shannon. Good morning, good afternoon, and good evening to everyone listening around the world. Thank you for your interest in Regeneron, and welcome to our fourth quarter 2025 earnings conference call. An archive and transcript of this call will be available on the Regeneron Investor Relations website shortly after our call concludes.</td><td>ì œ ì´ë¦„ì€ Shannonì´ë©°, ì˜¤ëŠ˜ ì»¨í¼ëŸ°ìŠ¤ ì½œì˜ ì§„í–‰ì„ ë§¡ê²Œ ë˜ì—ˆìŠµë‹ˆë‹¤. [ìš´ì˜ì ì•ˆë‚´ì‚¬í•­] ë³¸ ì»¨í¼ëŸ°ìŠ¤ ì½œì€ ë…¹ìŒë˜ê³  ìˆìŒì„ ì•Œë ¤ë“œë¦½ë‹ˆë‹¤. ì´ì œ Ryan Crowe íˆ¬ìì ê´€ê³„ ë‹´ë‹¹ ìˆ˜ì„ ë¶€ì‚¬ì¥ì—ê²Œ ì§„í–‰ì„ ë„˜ê¸°ê² ìŠµë‹ˆë‹¤. ì‹œì‘í•˜ì‹œê¸° ë°”ëë‹ˆë‹¤.<br><br>Ryan Crowe<br>íˆ¬ìì ê´€ê³„ ë° ì „ëµ ë¶„ì„ ë‹´ë‹¹ ìˆ˜ì„ ë¶€ì‚¬ì¥<br><br>Shannon, ê°ì‚¬í•©ë‹ˆë‹¤. ì „ ì„¸ê³„ì—ì„œ ì²­ì·¨í•˜ê³  ê³„ì‹  ëª¨ë“  ë¶„ë“¤ê»˜ ì¢‹ì€ ì•„ì¹¨, ì¢‹ì€ ì˜¤í›„, ê·¸ë¦¬ê³  ì¢‹ì€ ì €ë… ì¸ì‚¬ë¥¼ ë“œë¦½ë‹ˆë‹¤. Regeneronì— ê´€ì‹¬ì„ ê°€ì ¸ì£¼ì…”ì„œ ê°ì‚¬ë“œë¦¬ë©°, 2025ë…„ 4ë¶„ê¸° ì‹¤ì  ë°œí‘œ ì»¨í¼ëŸ°ìŠ¤ ì½œì— ì˜¤ì‹  ê²ƒì„ í™˜ì˜í•©ë‹ˆë‹¤. ë³¸ ì»¨í¼ëŸ°ìŠ¤ ì½œì˜ ë…¹ì·¨ë¡ê³¼ ì•„ì¹´ì´ë¸ŒëŠ” ì½œ ì¢…ë£Œ ì§í›„ Regeneron íˆ¬ìì ê´€ê³„ ì›¹ì‚¬ì´íŠ¸ì—ì„œ í™•ì¸í•˜ì‹¤ ìˆ˜ ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Joining me on today's call are Dr. Leonard Schleifer, Board Co-Chair, Co-Founder, President and Chief Executive Officer; Dr. George Yancopoulos, Board Co-Chair, Co-Founder, President and Chief Scientific Officer; Marion McCourt, Executive Vice President of Commercial; and Chris Fenimore, Executive Vice President and Chief Financial Officer. After our prepared remarks, the remaining time will be available for your Q&A. I would like to remind you that remarks made on today's call may include forward-looking statements about Regeneron.</td><td>ì˜¤ëŠ˜ ì»¨í¼ëŸ°ìŠ¤ ì½œì—ëŠ” ë ˆë„ˆë“œ ìŠë¼ì´í¼(Leonard Schleifer) ì´ì‚¬íšŒ ê³µë™ì˜ì¥, ê³µë™ì°½ë¦½ì, ì‚¬ì¥ ê²¸ ìµœê³ ê²½ì˜ì, ì¡°ì§€ ì–€ì½”í’€ë¡œìŠ¤(George Yancopoulos) ì´ì‚¬íšŒ ê³µë™ì˜ì¥, ê³µë™ì°½ë¦½ì, ì‚¬ì¥ ê²¸ ìµœê³ ê³¼í•™ì±…ì„ì, ë§¤ë¦¬ì–¸ ë§¥ì½”íŠ¸(Marion McCourt) ìƒì—…ë¶€ë¬¸ ì „ë¬´ì´ì‚¬, ê·¸ë¦¬ê³  í¬ë¦¬ìŠ¤ í˜ë‹ˆëª¨ì–´(Chris Fenimore) ì „ë¬´ì´ì‚¬ ê²¸ ìµœê³ ì¬ë¬´ì±…ì„ìê°€ í•¨ê»˜í•©ë‹ˆë‹¤. ì¤€ë¹„ëœ ë°œí‘œê°€ ëë‚œ í›„ ë‚¨ì€ ì‹œê°„ì€ ì§ˆì˜ì‘ë‹µ ì‹œê°„ìœ¼ë¡œ ì§„í–‰í•˜ê² ìŠµë‹ˆë‹¤. ì˜¤ëŠ˜ ì»¨í¼ëŸ°ìŠ¤ ì½œì—ì„œ ì–¸ê¸‰ë˜ëŠ” ë‚´ìš©ì—ëŠ” ë¦¬ì œë„ˆë¡ ì— ê´€í•œ ë¯¸ë˜ì˜ˆì¸¡ì§„ìˆ (forward-looking statements)ì´ í¬í•¨ë  ìˆ˜ ìˆìŒì„ ì•Œë ¤ë“œë¦½ë‹ˆë‹¤.</td></tr>
<tr><td>Such statements may include, but are not limited to, those related to Regeneron and its products and business, financial forecast and guidance, development programs and related anticipated milestones, collaborations, finances, regulatory matters, payer coverage and reimbursement, intellectual property, pending litigation and other proceedings and competition. Each forward-looking statement is subject to risks and uncertainties that could cause actual results and events to differ materially from those projected in that statement.</td><td>ì´ëŸ¬í•œ ì§„ìˆ ì—ëŠ” ë¦¬ì œë„¤ë¡ ê³¼ ê·¸ ì œí’ˆ ë° ì‚¬ì—…, ì¬ë¬´ ì „ë§ ë° ê°€ì´ë˜ìŠ¤, ê°œë°œ í”„ë¡œê·¸ë¨ ë° ê´€ë ¨ ì˜ˆìƒ ë§ˆì¼ìŠ¤í†¤, í˜‘ë ¥ê´€ê³„, ì¬ë¬´, ê·œì œ ì‚¬í•­, ë³´í—˜ì ë³´ì¥ ë° ìƒí™˜, ì§€ì ì¬ì‚°ê¶Œ, ê³„ë¥˜ ì¤‘ì¸ ì†Œì†¡ ë° ê¸°íƒ€ ì ˆì°¨, ê·¸ë¦¬ê³  ê²½ìŸê³¼ ê´€ë ¨ëœ ë‚´ìš©ì´ í¬í•¨ë  ìˆ˜ ìˆìœ¼ë‚˜ ì´ì— êµ­í•œë˜ì§€ ì•ŠìŠµë‹ˆë‹¤. ê° ë¯¸ë˜ì˜ˆì¸¡ì§„ìˆ ì€ í•´ë‹¹ ì§„ìˆ ì—ì„œ ì˜ˆìƒí•œ ê²ƒê³¼ ì‹¤ì œ ê²°ê³¼ ë° ì‚¬ê±´ì´ ì‹¤ì§ˆì ìœ¼ë¡œ ë‹¬ë¼ì§ˆ ìˆ˜ ìˆëŠ” ìœ„í—˜ê³¼ ë¶ˆí™•ì‹¤ì„±ì˜ ì˜í–¥ì„ ë°›ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>A more complete description of these and other material risks can be found in Regeneron's filings with the United States Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2025, which we plan to file with the SEC next week. Regeneron does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. In addition, please note that GAAP and non-GAAP financial measures will be discussed on today's call.</td><td>ì´ëŸ¬í•œ ìœ„í—˜ ìš”ì¸ë“¤ê³¼ ê¸°íƒ€ ì¤‘ìš”í•œ ìœ„í—˜ ìš”ì¸ë“¤ì— ëŒ€í•œ ë³´ë‹¤ ìƒì„¸í•œ ì„¤ëª…ì€ ë¦¬ì œë„ˆë¡ ì´ ë¯¸êµ­ ì¦ê¶Œê±°ë˜ìœ„ì›íšŒ(SEC)ì— ì œì¶œí•œ ì„œë¥˜ë“¤, íŠ¹íˆ 2025ë…„ 12ì›” 31ì¼ë¡œ ì¢…ë£Œëœ íšŒê³„ì—°ë„ì— ëŒ€í•œ Form 10-K ë³´ê³ ì„œì—ì„œ í™•ì¸í•˜ì‹¤ ìˆ˜ ìˆìœ¼ë©°, í•´ë‹¹ ë³´ê³ ì„œëŠ” ë‹¤ìŒ ì£¼ ì¤‘ SECì— ì œì¶œí•  ì˜ˆì •ì…ë‹ˆë‹¤. ë¦¬ì œë„ˆë¡ ì€ ìƒˆë¡œìš´ ì •ë³´, í–¥í›„ ì‚¬ê±´ ë˜ëŠ” ê¸°íƒ€ ì‚¬ìœ ë¡œ ì¸í•´ ë¯¸ë˜ì˜ˆì¸¡ì§„ìˆ ì„ ì—…ë°ì´íŠ¸í•  ì˜ë¬´ë¥¼ ë¶€ë‹´í•˜ì§€ ì•ŠìŠµë‹ˆë‹¤. ë˜í•œ, ì˜¤ëŠ˜ ì»¨í¼ëŸ°ìŠ¤ ì½œì—ì„œëŠ” GAAP ê¸°ì¤€ ë° non-GAAP ê¸°ì¤€ ì¬ë¬´ì§€í‘œê°€ ëª¨ë‘ ë…¼ì˜ë  ì˜ˆì •ì„ì„ ìœ ì˜í•´ ì£¼ì‹œê¸° ë°”ëë‹ˆë‹¤.</td></tr>
<tr><td>Information regarding our use of non-GAAP financial measures and a reconciliation of those measures to GAAP is available in our quarterly results press release and our corporate presentation, both of which can be found on the Regeneron Investor Relations website. Once our call concludes, the IR team will be available to answer any further questions. With that, let me turn the call over to our President and Chief Executive Officer, Dr. Leonard Schleifer. Len, take it away. Leonard Schleifer<br>Co-Founder, President, CEO & Co-Chairman<br><br>Thanks, Ryan, and thanks to everyone for joining today's call.</td><td>ê°ì‚¬í•©ë‹ˆë‹¤, ë¼ì´ì–¸. ê·¸ë¦¬ê³  ì˜¤ëŠ˜ ì»¨í¼ëŸ°ìŠ¤ ì½œì— ì°¸ì„í•´ ì£¼ì‹  ëª¨ë“  ë¶„ë“¤ê»˜ ê°ì‚¬ë“œë¦½ë‹ˆë‹¤.<br><br>ë¹„GAAP ì¬ë¬´ì§€í‘œ ì‚¬ìš©ì— ê´€í•œ ì •ë³´ì™€ í•´ë‹¹ ì§€í‘œì˜ GAAP ì¡°ì •ë‚´ì—­ì€ ë¶„ê¸°ë³„ ì‹¤ì  ë³´ë„ìë£Œì™€ ê¸°ì—… í”„ë ˆì  í…Œì´ì…˜ ìë£Œì—ì„œ í™•ì¸í•˜ì‹¤ ìˆ˜ ìˆìœ¼ë©°, ë‘ ìë£Œ ëª¨ë‘ ë¦¬ì œë„¤ë¡  íˆ¬ìì ê´€ê³„(Investor Relations) ì›¹ì‚¬ì´íŠ¸ì—ì„œ ì°¾ì•„ë³´ì‹¤ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì»¨í¼ëŸ°ìŠ¤ ì½œì´ ì¢…ë£Œë˜ë©´ IRíŒ€ì´ ì¶”ê°€ ì§ˆë¬¸ì— ë‹µë³€í•´ ë“œë¦´ ì˜ˆì •ì…ë‹ˆë‹¤. ê·¸ëŸ¼ ì´ì œ ë Œ ìŠë¼ì´í¼(Leonard Schleifer) ì‚¬ì¥ ê²¸ ìµœê³ ê²½ì˜ìì—ê²Œ ë§ˆì´í¬ë¥¼ ë„˜ê¸°ê² ìŠµë‹ˆë‹¤. ë Œ, ì‹œì‘í•˜ì‹œì£ .<br><br>ë Œ ìŠë¼ì´í¼<br>ê³µë™ì°½ë¦½ì, ì‚¬ì¥, CEO ê²¸ ê³µë™íšŒì¥<br><br>ê°ì‚¬í•©ë‹ˆë‹¤, ë¼ì´ì–¸. ê·¸ë¦¬ê³  ì˜¤ëŠ˜ ì»¨í¼ëŸ°ìŠ¤ ì½œì— ì°¸ì„í•´ ì£¼ì‹  ëª¨ë“  ë¶„ë“¤ê»˜ ê°ì‚¬ë“œë¦½ë‹ˆë‹¤.</td></tr>
<tr><td>Regeneron capped 2025 with another solid quarter of commercial execution with fourth quarter total revenue up 3% year-over-year, driven by double-digit net sales growth for 3 of our leading products. Compared to the fourth quarter of last year, global net product sales for DUPIXENT as reported by Sanofi, increased by 32% and LIBTAYO by 13% at constant exchange rates, while EYLEA HD in the United States grew by 66%. Global DUPIXENT net sales were $4.9 billion in the fourth quarter and $17.8 billion for the full year 2025. DUPIXENT is currently the most widely used innovative branded antibody medicine with more than 1.4 million patients on therapy globally.</td><td>ë¦¬ì œë„¤ë¡ ì€ 2025ë…„ì„ ë˜ í•œ ë²ˆì˜ ê²¬ê³ í•œ ë¶„ê¸° ì‹¤ì ìœ¼ë¡œ ë§ˆë¬´ë¦¬í–ˆìœ¼ë©°, 4ë¶„ê¸° ì´ ë§¤ì¶œì€ ì „ë…„ ë™ê¸° ëŒ€ë¹„ 3% ì¦ê°€í–ˆìŠµë‹ˆë‹¤. ì´ëŠ” ì£¼ìš” ì œí’ˆ 3ê°œì˜ ë‘ ìë¦¿ìˆ˜ ìˆœë§¤ì¶œ ì„±ì¥ì— í˜ì…ì€ ê²ƒì…ë‹ˆë‹¤. ì‘ë…„ 4ë¶„ê¸° ëŒ€ë¹„, ì‚¬ë…¸í”¼ê°€ ë³´ê³ í•œ DUPIXENTì˜ ê¸€ë¡œë²Œ ìˆœì œí’ˆ ë§¤ì¶œì€ ê³ ì •í™˜ìœ¨ ê¸°ì¤€ 32% ì¦ê°€í–ˆìœ¼ë©°, LIBTAYOëŠ” 13% ì¦ê°€í–ˆê³ , ë¯¸êµ­ ë‚´ EYLEA HDëŠ” 66% ì„±ì¥í–ˆìŠµë‹ˆë‹¤. DUPIXENTì˜ ê¸€ë¡œë²Œ ìˆœë§¤ì¶œì€ 4ë¶„ê¸°ì— 49ì–µ ë‹¬ëŸ¬, 2025ë…„ ì „ì²´ ì—°ë„ ê¸°ì¤€ 178ì–µ ë‹¬ëŸ¬ë¥¼ ê¸°ë¡í–ˆìŠµë‹ˆë‹¤. DUPIXENTëŠ” í˜„ì¬ ì „ ì„¸ê³„ì ìœ¼ë¡œ 140ë§Œ ëª… ì´ìƒì˜ í™˜ìê°€ ì¹˜ë£Œë°›ê³  ìˆëŠ” ê°€ì¥ ë„ë¦¬ ì‚¬ìš©ë˜ëŠ” í˜ì‹ ì ì¸ ë¸Œëœë“œ í•­ì²´ ì˜ì•½í’ˆì…ë‹ˆë‹¤.</td></tr>
<tr><td>Now approved in 8 indications, most of which remain significantly under-penetrated, DUPIXENT is well positioned for future growth. Global LIBTAYO net product sales were $425 million in the fourth quarter and $1.45 billion for the full year 2025. In the U.S., LIBTAYO continues to be the market-leading immunotherapy for advanced non-melanoma skin cancers. Following FDA and EC approvals of LIBTAYO for adjuvant CSCC in the fourth quarter, we are making great progress launching this potential blockbuster opportunity with this indication expected to be a significant growth driver for LIBTAYO in 2026 and beyond.</td><td>í˜„ì¬ 8ê°œ ì ì‘ì¦ì—ì„œ ìŠ¹ì¸ì„ ë°›ì•˜ìœ¼ë©°, ëŒ€ë¶€ë¶„ì˜ ì ì‘ì¦ì´ ì—¬ì „íˆ ìƒë‹¹íˆ ë‚®ì€ ì¹¨íˆ¬ìœ¨ì„ ë³´ì´ê³  ìˆëŠ” DUPIXENTëŠ” í–¥í›„ ì„±ì¥ì„ ìœ„í•œ ì¢‹ì€ ìœ„ì¹˜ë¥¼ í™•ë³´í•˜ê³  ìˆìŠµë‹ˆë‹¤. LIBTAYOì˜ ê¸€ë¡œë²Œ ìˆœì œí’ˆë§¤ì¶œì€ 4ë¶„ê¸°ì— 4ì–µ 2,500ë§Œ ë‹¬ëŸ¬, 2025ë…„ ì „ì²´ ì—°ë„ì—ëŠ” 14ì–µ 5,000ë§Œ ë‹¬ëŸ¬ë¥¼ ê¸°ë¡í–ˆìŠµë‹ˆë‹¤. ë¯¸êµ­ì—ì„œ LIBTAYOëŠ” ì§„í–‰ì„± ë¹„í‘ìƒ‰ì¢… í”¼ë¶€ì•”ì— ëŒ€í•œ ì‹œì¥ ì„ ë„ì ì¸ ë©´ì—­í•­ì•”ì œë¡œì„œì˜ ì…ì§€ë¥¼ ê³„ì† ìœ ì§€í•˜ê³  ìˆìŠµë‹ˆë‹¤. 4ë¶„ê¸°ì— ë³´ì¡°ìš”ë²• CSCC(í”¼ë¶€í¸í‰ì„¸í¬ì•”)ì— ëŒ€í•œ FDA ë° EC ìŠ¹ì¸ì„ ë°›ì€ í›„, ìš°ë¦¬ëŠ” ì´ ì ì¬ì  ë¸”ë¡ë²„ìŠ¤í„° ê¸°íšŒë¥¼ ì„±ê³µì ìœ¼ë¡œ ì¶œì‹œí•˜ê³  ìˆìœ¼ë©°, ì´ ì ì‘ì¦ì€ 2026ë…„ ì´í›„ LIBTAYOì˜ ì¤‘ìš”í•œ ì„±ì¥ ë™ë ¥ì´ ë  ê²ƒìœ¼ë¡œ ì˜ˆìƒë©ë‹ˆë‹¤.</td></tr>
<tr><td>LIBTAYO also continues to build share in advanced non-small cell lung cancer, where in the U.S., it is now the second most prescribed immunotherapy in the first-line setting with new patient market share in this setting greater than OPDIVO, TECENTRIQ and IMFINZI combined. EYLEA HD net product sales in the United States were $506 million in the fourth quarter, up 66% and $1.6 billion for the full year 2025, up 36% despite continued patient co-pay affordability issues that have dampened branded anti-VEGF category growth.</td><td>LIBTAYOëŠ” ì§„í–‰ì„± ë¹„ì†Œì„¸í¬íì•” ë¶„ì•¼ì—ì„œë„ ì§€ì†ì ìœ¼ë¡œ ì ìœ ìœ¨ì„ í™•ëŒ€í•˜ê³  ìˆìœ¼ë©°, ë¯¸êµ­ì—ì„œ 1ì°¨ ì¹˜ë£Œ ì„¸íŒ…ì—ì„œ í˜„ì¬ ë‘ ë²ˆì§¸ë¡œ ë§ì´ ì²˜ë°©ë˜ëŠ” ë©´ì—­í•­ì•”ì œë¡œ, ì´ ì„¸íŒ…ì—ì„œì˜ ì‹ ê·œ í™˜ì ì‹œì¥ì ìœ ìœ¨ì´ OPDIVO, TECENTRIQ, IMFINZIë¥¼ í•©ì¹œ ê²ƒë³´ë‹¤ ë†’ìŠµë‹ˆë‹¤. EYLEA HDì˜ ë¯¸êµ­ ë‚´ ìˆœë§¤ì¶œì€ 4ë¶„ê¸°ì— 5ì–µ 600ë§Œ ë‹¬ëŸ¬ë¡œ 66% ì¦ê°€í–ˆìœ¼ë©°, í™˜ì ë³¸ì¸ë¶€ë‹´ê¸ˆ ë¶€ë‹´ ë¬¸ì œë¡œ ì¸í•´ ë¸Œëœë“œ í•­-VEGF ì¹´í…Œê³ ë¦¬ ì„±ì¥ì´ ë‘”í™”ë˜ì—ˆìŒì—ë„ ë¶ˆêµ¬í•˜ê³  2025ë…„ ì „ì²´ ì—°ë„ ê¸°ì¤€ìœ¼ë¡œëŠ” 16ì–µ ë‹¬ëŸ¬ë¥¼ ê¸°ë¡í•˜ì—¬ 36% ì¦ê°€í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>In November, the FDA approved EYLEA HD for macular edema following retinal vein occlusion or RVO, and monthly dosing across all approved indications, further strengthening the EYLEA HD compelling profile. Our FDA submission seeking approval of the EYLEA HD prefilled syringe using a new manufacturer has been accepted for review. A standard pre-licensing inspection has been scheduled and a decision on our filing is expected in late April. In addition, as a backup, Catalent, Indiana continues to work with the FDA to resolve findings from a previous inspection. We continue to believe that all 3 of these product enhancements are key to fully unlocking EYLEA's HD commercial potential.</td><td>11ì›”ì— FDAëŠ” ë§ë§‰ì •ë§¥íì‡„(RVO) í›„ í™©ë°˜ë¶€ì¢…ì— ëŒ€í•œ EYLEA HDì™€ ëª¨ë“  ìŠ¹ì¸ëœ ì ì‘ì¦ì— ëŒ€í•œ ì›”ê°„ íˆ¬ì—¬ë¥¼ ìŠ¹ì¸í•˜ì—¬ EYLEA HDì˜ ê°•ë ¥í•œ í”„ë¡œíŒŒì¼ì„ ë”ìš± ê°•í™”í–ˆìŠµë‹ˆë‹¤. ìƒˆë¡œìš´ ì œì¡°ì—…ì²´ë¥¼ í†µí•œ EYLEA HD í”„ë¦¬í•„ë“œ ì‹œë¦°ì§€ ìŠ¹ì¸ì„ ìš”ì²­í•˜ëŠ” FDA ì œì¶œì´ ê²€í† ë¥¼ ìœ„í•´ ì ‘ìˆ˜ë˜ì—ˆìŠµë‹ˆë‹¤. í‘œì¤€ ì‚¬ì „ í—ˆê°€ ì‹¤ì‚¬ê°€ ì˜ˆì •ë˜ì–´ ìˆìœ¼ë©°, ì œì¶œ ê±´ì— ëŒ€í•œ ê²°ì •ì€ 4ì›” ë§ì— ì˜ˆìƒë©ë‹ˆë‹¤. ë˜í•œ ë°±ì—…ìœ¼ë¡œ, ì¸ë””ì• ë‚˜ì£¼ ì†Œì¬ CatalentëŠ” ì´ì „ ì‹¤ì‚¬ì—ì„œ ì§€ì ëœ ì‚¬í•­ë“¤ì„ í•´ê²°í•˜ê¸° ìœ„í•´ FDAì™€ ê³„ì† í˜‘ë ¥í•˜ê³  ìˆìŠµë‹ˆë‹¤. ìš°ë¦¬ëŠ” ì´ ì„¸ ê°€ì§€ ì œí’ˆ ê°œì„  ì‚¬í•­ ëª¨ë‘ê°€ EYLEA HDì˜ ìƒì—…ì  ì ì¬ë ¥ì„ ì™„ì „íˆ ì‹¤í˜„í•˜ëŠ” ë° í•µì‹¬ì ì´ë¼ê³  ê³„ì† ë¯¿ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>While we anticipate continued growth in EYLEA HD this year, EYLEA 2 milligrams will continue to be under competitive pressure, which is expected to intensify in the second half of 2026 as multiple biosimilar products are launched in the United States. Regarding patient affordability, we are pleased that we matched a $60 million donation to the Good Days' Retinal Vascular and Neovascular Disease Fund in the fourth quarter. Today, we reiterated our commitment to helping patients afford their medicines by extending our matching program through the end of this year up to $200 million.</td><td>ì˜¬í•´ EYLEA HDì˜ ì§€ì†ì ì¸ ì„±ì¥ì„ ê¸°ëŒ€í•˜ê³  ìˆì§€ë§Œ, EYLEA 2ë°€ë¦¬ê·¸ë¨ ì œí’ˆì€ ê³„ì†í•´ì„œ ê²½ìŸ ì••ë ¥ì„ ë°›ì„ ê²ƒì´ë©°, ì´ëŠ” 2026ë…„ í•˜ë°˜ê¸° ë¯¸êµ­ì—ì„œ ì—¬ëŸ¬ ë°”ì´ì˜¤ì‹œë°€ëŸ¬ ì œí’ˆì´ ì¶œì‹œë˜ë©´ì„œ ë”ìš± ì‹¬í™”ë  ê²ƒìœ¼ë¡œ ì˜ˆìƒë©ë‹ˆë‹¤. í™˜ì ë¶€ë‹´ ê°€ëŠ¥ì„±ê³¼ ê´€ë ¨í•˜ì—¬, ì €í¬ëŠ” 4ë¶„ê¸°ì— Good Daysì˜ ë§ë§‰í˜ˆê´€ ë° ì‹ ìƒí˜ˆê´€ ì§ˆí™˜ ê¸°ê¸ˆì— 6ì²œë§Œ ë‹¬ëŸ¬ë¥¼ ê¸°ë¶€ ë§¤ì¹­í•œ ê²ƒì„ ê¸°ì˜ê²Œ ìƒê°í•©ë‹ˆë‹¤. ì˜¤ëŠ˜ ì €í¬ëŠ” ì˜¬í•´ ë§ê¹Œì§€ ìµœëŒ€ 2ì–µ ë‹¬ëŸ¬ ê·œëª¨ë¡œ ë§¤ì¹­ í”„ë¡œê·¸ë¨ì„ ì—°ì¥í•¨ìœ¼ë¡œì¨ í™˜ìë“¤ì´ ì˜ì•½í’ˆì„ êµ¬ë§¤í•  ìˆ˜ ìˆë„ë¡ ë•ê² ë‹¤ëŠ” ì•½ì†ì„ ì¬í™•ì¸í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Turning now to our negotiations with the United States government regarding efforts to reduce drug costs for American patients. We are actively engaging in constructive discussions with the Center for Medicare and Medicaid Services and other federal agencies, and we anticipate reaching agreement that aligns with the frameworks previously established by other companies.</td><td>ì´ì œ ë¯¸êµ­ í™˜ìë“¤ì˜ ì•½ê°€ ì¸í•˜ ë…¸ë ¥ê³¼ ê´€ë ¨í•œ ë¯¸êµ­ ì •ë¶€ì™€ì˜ í˜‘ìƒìœ¼ë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤. ì €í¬ëŠ” í˜„ì¬ ë©”ë””ì¼€ì–´ ë° ë©”ë””ì¼€ì´ë“œ ì„œë¹„ìŠ¤ ì„¼í„°(CMS)ì™€ ê¸°íƒ€ ì—°ë°© ê¸°ê´€ë“¤ê³¼ ê±´ì„¤ì ì¸ ë…¼ì˜ë¥¼ ì ê·¹ì ìœ¼ë¡œ ì§„í–‰í•˜ê³  ìˆìœ¼ë©°, ë‹¤ë¥¸ ì œì•½ì‚¬ë“¤ì´ ì´ì „ì— ìˆ˜ë¦½í•œ í”„ë ˆì„ì›Œí¬ì— ë¶€í•©í•˜ëŠ” í•©ì˜ì— ë„ë‹¬í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>We remain optimistic about striking a deal with the administration to achieve our shared goals, ensuring timely and affordable access to groundbreaking medical advancements for American patients, maintaining the United States leadership in biotechnology, innovation and manufacturing and addressing the longstanding imbalance in the distribution of cost for medical innovation, which has historically placed a disproportionate burden on American patients. Finally, looking ahead to the next 12 months, Regeneron has several key objectives that I'd like to share.</td><td>ìš°ë¦¬ëŠ” ë¯¸êµ­ í™˜ìë“¤ì—ê²Œ íšê¸°ì ì¸ ì˜ë£Œ ë°œì „ì— ëŒ€í•œ ì ì‹œì ì´ê³  ì €ë ´í•œ ì ‘ê·¼ì„ ë³´ì¥í•˜ê³ , ìƒëª…ê³µí•™, í˜ì‹  ë° ì œì¡° ë¶„ì•¼ì—ì„œ ë¯¸êµ­ì˜ ë¦¬ë”ì‹­ì„ ìœ ì§€í•˜ë©°, ì—­ì‚¬ì ìœ¼ë¡œ ë¯¸êµ­ í™˜ìë“¤ì—ê²Œ ë¶ˆê· í˜•ì ì¸ ë¶€ë‹´ì„ ì•ˆê²¨ì™”ë˜ ì˜ë£Œ í˜ì‹  ë¹„ìš© ë¶„ë°°ì˜ ì˜¤ëœ ë¶ˆê· í˜•ì„ í•´ê²°í•˜ëŠ” ë“± ìš°ë¦¬ì˜ ê³µë™ ëª©í‘œë¥¼ ë‹¬ì„±í•˜ê¸° ìœ„í•´ í–‰ì •ë¶€ì™€ í•©ì˜ë¥¼ ì´ë£¨ëŠ” ê²ƒì— ëŒ€í•´ ë‚™ê´€ì ì…ë‹ˆë‹¤. ë§ˆì§€ë§‰ìœ¼ë¡œ, í–¥í›„ 12ê°œì›”ì„ ë‚´ë‹¤ë³´ë©´, ë¦¬ì œë„¤ë¡ ì€ ì œê°€ ê³µìœ í•˜ê³ ì í•˜ëŠ” ëª‡ ê°€ì§€ í•µì‹¬ ëª©í‘œë¥¼ ê°€ì§€ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>First, we anticipate at least 4 FDA approvals, including 3 for new molecular entities across 3 distinct modalities plus approval for the EYLEA HD prefilled syringe as well as several additional regulatory submissions. We expect registration-enabling data from multiple programs, including fianlimab, our LAG-3 antibody in combination with LIBTAYO in advanced melanoma as well as the combination of cemdisiran and pozelimab in PNH.</td><td>ë¨¼ì €, ìš°ë¦¬ëŠ” ìµœì†Œ 4ê±´ì˜ FDA ìŠ¹ì¸ì„ ì˜ˆìƒí•˜ê³  ìˆìœ¼ë©°, ì´ëŠ” 3ê°€ì§€ ì„œë¡œ ë‹¤ë¥¸ ëª¨ë‹¬ë¦¬í‹°ì— ê±¸ì¹œ 3ê°œì˜ ì‹ ê·œ ë¶„ì ë¬¼ì§ˆ(NME)ê³¼ EYLEA HD ì‚¬ì „ì¶©ì „ ì£¼ì‚¬ê¸° ìŠ¹ì¸ì„ í¬í•¨í•˜ë©°, ì—¬ëŸ¬ ì¶”ê°€ ê·œì œ ì œì¶œë„ ì˜ˆì •ë˜ì–´ ìˆìŠµë‹ˆë‹¤. ìš°ë¦¬ëŠ” ì§„í–‰ì„± í‘ìƒ‰ì¢…ì—ì„œ LIBTAYOì™€ ë³‘ìš©í•˜ëŠ” LAG-3 í•­ì²´ì¸ fianlimab, ê·¸ë¦¬ê³  PNHì—ì„œ cemdisiranê³¼ pozelimabì˜ ë³‘ìš©ìš”ë²•ì„ í¬í•¨í•œ ì—¬ëŸ¬ í”„ë¡œê·¸ë¨ìœ¼ë¡œë¶€í„° í—ˆê°€ ê°€ëŠ¥í•œ ë°ì´í„°ë¥¼ ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>In addition to the ongoing pivotal studies in key areas such as myeloma, anticoagulation and complement-mediated diseases, 2026 will be an important clinical development execution year as we anticipate initiating 18 additional Phase III studies with cumulative target enrollment of approximately 35,000 patients over multiple years, setting the foundation for Regeneron's next wave of potential blockbuster products. We also plan to begin clinical development of at least 3 first-in-class antibodies that address novel targets, of which 2 were discovered and validated by Regeneron Genetics Center as well as our long-acting IL-13 antibody in atopic dermatitis.</td><td>ë‹¤ë°œì„± ê³¨ìˆ˜ì¢…, í•­ì‘ê³ ì œ ë° ë³´ì²´ ë§¤ê°œ ì§ˆí™˜ê³¼ ê°™ì€ í•µì‹¬ ì˜ì—­ì—ì„œ ì§„í–‰ ì¤‘ì¸ í”¼ë²— ì—°êµ¬ ì™¸ì—ë„, 2026ë…„ì€ ì¤‘ìš”í•œ ì„ìƒ ê°œë°œ ì‹¤í–‰ì˜ í•´ê°€ ë  ê²ƒì…ë‹ˆë‹¤. ìš°ë¦¬ëŠ” í–¥í›„ ìˆ˜ë…„ê°„ ëˆ„ì  ëª©í‘œ ë“±ë¡ í™˜ì ìˆ˜ ì•½ 35,000ëª… ê·œëª¨ì˜ 18ê°œ ì¶”ê°€ 3ìƒ ì„ìƒì‹œí—˜ì„ ê°œì‹œí•  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ë©°, ì´ëŠ” ë¦¬ì œë„¤ë¡ ì˜ ì°¨ì„¸ëŒ€ ì ì¬ì  ë¸”ë¡ë²„ìŠ¤í„° ì œí’ˆêµ°ì˜ ê¸°ë°˜ì„ ë§ˆë ¨í•  ê²ƒì…ë‹ˆë‹¤. ë˜í•œ ìš°ë¦¬ëŠ” ìµœì†Œ 3ê°œì˜ ì‹ ê·œ íƒ€ê²Ÿì„ ë‹¤ë£¨ëŠ” ë™ì¢… ìµœì´ˆ(first-in-class) í•­ì²´ì˜ ì„ìƒ ê°œë°œì„ ì‹œì‘í•  ê³„íšì´ë©°, ì´ ì¤‘ 2ê°œëŠ” ë¦¬ì œë„¤ë¡  ìœ ì „í•™ì„¼í„°(Regeneron Genetics Center)ì—ì„œ ë°œê²¬ ë° ê²€ì¦ë˜ì—ˆìŠµë‹ˆë‹¤. ì•„ìš¸ëŸ¬ ì•„í† í”¼ í”¼ë¶€ì—¼ ì¹˜ë£Œë¥¼ ìœ„í•œ ì¥ê¸° ì§€ì†í˜• IL-13 í•­ì²´ ê°œë°œë„ ì°©ìˆ˜í•  ì˜ˆì •ì…ë‹ˆë‹¤.</td></tr>
<tr><td>We expect strong commercial execution to continue maximizing the potential of our leading brands across key therapeutic areas. And finally, we plan to continue prudently deploying capital through share repurchases, dividends and complementary business development, all with the goal of driving long-term shareholder value. Obviously, a busy and ambitious year ahead, one that I'm particularly energized and excited to embark upon. We look forward to reporting our programs on these goals as we move through the year. With that, I'll turn the call over to George. George Yancopoulos<br>Co-Founder, President, Chief Scientific Officer & Co-Chairman<br><br>Thanks, Len.</td><td>ìš°ë¦¬ëŠ” ì£¼ìš” ì¹˜ë£Œ ì˜ì—­ì—ì„œ ì„ ë„ì ì¸ ë¸Œëœë“œë“¤ì˜ ì ì¬ë ¥ì„ ê·¹ëŒ€í™”í•˜ê¸° ìœ„í•œ ê°•ë ¥í•œ ìƒì—…ì  ì‹¤í–‰ì´ ì§€ì†ë  ê²ƒìœ¼ë¡œ ê¸°ëŒ€í•©ë‹ˆë‹¤. ë§ˆì§€ë§‰ìœ¼ë¡œ, ìš°ë¦¬ëŠ” ìì‚¬ì£¼ ë§¤ì…, ë°°ë‹¹ê¸ˆ ì§€ê¸‰, ê·¸ë¦¬ê³  ë³´ì™„ì ì¸ ì‚¬ì—… ê°œë°œì„ í†µí•´ ìë³¸ì„ ì‹ ì¤‘í•˜ê²Œ ë°°ë¶„í•  ê³„íšì´ë©°, ì´ ëª¨ë“  ê²ƒì€ ì¥ê¸°ì ì¸ ì£¼ì£¼ ê°€ì¹˜ ì°½ì¶œì„ ëª©í‘œë¡œ í•©ë‹ˆë‹¤. ë¶„ëª…íˆ ì•ìœ¼ë¡œ ë°”ì˜ê³  ì•¼ì‹¬ì°¬ í•œ í•´ê°€ ë  ê²ƒì´ë©°, ì €ëŠ” íŠ¹íˆ ì´ë¥¼ ì‹œì‘í•˜ëŠ” ê²ƒì— ëŒ€í•´ í™œë ¥ê³¼ í¥ë¶„ì„ ëŠë¼ê³  ìˆìŠµë‹ˆë‹¤. ìš°ë¦¬ëŠ” ì—°ì¤‘ ì´ëŸ¬í•œ ëª©í‘œë“¤ì— ëŒ€í•œ ì§„í–‰ ìƒí™©ì„ ë³´ê³ í•˜ê¸°ë¥¼ ê¸°ëŒ€í•©ë‹ˆë‹¤. ì´ì œ Georgeì—ê²Œ ë°œì–¸ê¶Œì„ ë„˜ê¸°ê² ìŠµë‹ˆë‹¤.<br><br>George Yancopoulos<br>ê³µë™ ì°½ë¦½ì, ì‚¬ì¥, ìµœê³  ê³¼í•™ ì±…ì„ì ê²¸ ê³µë™ íšŒì¥<br><br>ê°ì‚¬í•©ë‹ˆë‹¤, Len.</td></tr>
<tr><td>Earlier this month at the JPMorgan conference, we highlighted the breadth and depth of our pipeline, which is expected to generate clinical data over the next few years, spanning oncology, hematology, complement-mediated diseases, anticoagulation and obesity as well as in other areas. In 2026, we plan to build on our established leadership in ophthalmology as well as immunology and inflammation while advancing key late-stage programs. Starting with ophthalmology. EYLEA HD was recently approved by the FDA for monthly dosing and for the treatment of RVO, further strengthening its clinical profile.</td><td>ì´ë²ˆ ë‹¬ ì´ˆ JPëª¨ê±´ ì»¨í¼ëŸ°ìŠ¤ì—ì„œ ìš°ë¦¬ëŠ” í–¥í›„ ëª‡ ë…„ê°„ ì„ìƒ ë°ì´í„°ë¥¼ ì°½ì¶œí•  ê²ƒìœ¼ë¡œ ì˜ˆìƒë˜ëŠ” íŒŒì´í”„ë¼ì¸ì˜ í­ê³¼ ê¹Šì´ë¥¼ ê°•ì¡°í–ˆìŠµë‹ˆë‹¤. ì´ëŠ” ì¢…ì–‘í•™, í˜ˆì•¡í•™, ë³´ì²´ ë§¤ê°œ ì§ˆí™˜, í•­ì‘ê³ ì œ, ë¹„ë§Œ ë° ê¸°íƒ€ ì˜ì—­ì— ê±¸ì³ ìˆìŠµë‹ˆë‹¤. 2026ë…„ì—ëŠ” ì•ˆê³¼ ë¶„ì•¼ì™€ ë©´ì—­í•™ ë° ì—¼ì¦ ë¶„ì•¼ì—ì„œ í™•ë¦½ëœ ë¦¬ë”ì‹­ì„ ê¸°ë°˜ìœ¼ë¡œ í•˜ë©´ì„œ ì£¼ìš” í›„ê¸° ë‹¨ê³„ í”„ë¡œê·¸ë¨ë“¤ì„ ì§„ì „ì‹œí‚¬ ê³„íšì…ë‹ˆë‹¤. ì•ˆê³¼ ë¶„ì•¼ë¶€í„° ì‹œì‘í•˜ê² ìŠµë‹ˆë‹¤. EYLEA HDëŠ” ìµœê·¼ FDAë¡œë¶€í„° ì›” 1íšŒ íˆ¬ì—¬ì™€ ë§ë§‰ì •ë§¥íì‡„ì¦(RVO) ì¹˜ë£Œì— ëŒ€í•œ ìŠ¹ì¸ì„ ë°›ì•„ ì„ìƒ í”„ë¡œíŒŒì¼ì„ ë”ìš± ê°•í™”í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Data supporting these approvals will be presented at the upcoming Angiogenesis meeting, further highlighting the efficacy, safety and durability of EYLEA HD, along with dosing flexibility designed to support more personalized patient care. In terms of our ophthalmology pipeline, for our C5 program for geographic atrophy, we expect interim data from our Phase III study in the second half of 2026. We are currently evaluating our C5 siRNA cemdisiran as monotherapy and also with pozelimab, our potentially best-in-class C5 antibody with the goal of providing a systemic treatment that avoids the safety issues from repeated intravitreal injections associated with currently approved GA therapies.</td><td>ì´ëŸ¬í•œ ìŠ¹ì¸ì„ ë’·ë°›ì¹¨í•˜ëŠ” ë°ì´í„°ëŠ” ë‹¤ê°€ì˜¤ëŠ” í˜ˆê´€ì‹ ìƒ(Angiogenesis) í•™íšŒì—ì„œ ë°œí‘œë  ì˜ˆì •ì´ë©°, EYLEA HDì˜ íš¨ëŠ¥, ì•ˆì „ì„± ë° ì§€ì†ì„±ê³¼ í•¨ê»˜ ë³´ë‹¤ ê°œì¸ ë§ì¶¤í˜• í™˜ì ì¹˜ë£Œë¥¼ ì§€ì›í•˜ë„ë¡ ì„¤ê³„ëœ íˆ¬ì—¬ ìœ ì—°ì„±ì„ ë”ìš± ë¶€ê°ì‹œí‚¬ ê²ƒì…ë‹ˆë‹¤. ì•ˆê³¼ íŒŒì´í”„ë¼ì¸ ì¸¡ë©´ì—ì„œ, ì§€ë„ìœ„ì¶•ì¦(geographic atrophy)ì— ëŒ€í•œ C5 í”„ë¡œê·¸ë¨ì˜ ê²½ìš° 2026ë…„ í•˜ë°˜ê¸°ì— 3ìƒ ì„ìƒì‹œí—˜ì˜ ì¤‘ê°„ ë°ì´í„°ë¥¼ ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤. í˜„ì¬ ì €í¬ëŠ” C5 siRNAì¸ cemdisiranì„ ë‹¨ë…ìš”ë²•ìœ¼ë¡œ, ê·¸ë¦¬ê³  ì ì¬ì ìœ¼ë¡œ ë™ê¸‰ ìµœê³ (best-in-class)ì˜ C5 í•­ì²´ì¸ pozelimabê³¼ ë³‘ìš©í•˜ì—¬ í‰ê°€í•˜ê³  ìˆìœ¼ë©°, ì´ëŠ” í˜„ì¬ ìŠ¹ì¸ëœ GA ì¹˜ë£Œì œë“¤ê³¼ ê´€ë ¨ëœ ë°˜ë³µì ì¸ ìœ ë¦¬ì²´ê°•ë‚´ ì£¼ì‚¬ë¡œ ì¸í•œ ì•ˆì „ì„± ë¬¸ì œë¥¼ í”¼í•  ìˆ˜ ìˆëŠ” ì „ì‹  ì¹˜ë£Œë²•ì„ ì œê³µí•˜ëŠ” ê²ƒì„ ëª©í‘œë¡œ í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>In case intravitreal delivery is required to adequately treat this disease, we've also begun clinical development of an intravitreal formulation of pozelimab to evaluate local C5 inhibition for appropriate patients. Beyond GA and ophthalmology, we have initiated a study of a novel intravitreally delivered T cell receptor blocking antibody for non-infectious uveitis, a disease generally driven by autoimmune T cells. This advance was made possible by our unique antibody capabilities as we are not aware of any other company that's been able to generate such an antibody.</td><td>ì´ ì§ˆí™˜ì„ ì ì ˆíˆ ì¹˜ë£Œí•˜ê¸° ìœ„í•´ ìœ ë¦¬ì²´ê°•ë‚´ íˆ¬ì—¬ê°€ í•„ìš”í•œ ê²½ìš°ë¥¼ ëŒ€ë¹„í•˜ì—¬, ì í•©í•œ í™˜ìë“¤ì— ëŒ€í•œ êµ­ì†Œ C5 ì–µì œë¥¼ í‰ê°€í•˜ê¸° ìœ„í•´ í¬ì ¤ë¦¬ë§™ì˜ ìœ ë¦¬ì²´ê°•ë‚´ ì œí˜•ì— ëŒ€í•œ ì„ìƒ ê°œë°œë„ ì‹œì‘í–ˆìŠµë‹ˆë‹¤. GAì™€ ì•ˆê³¼ ì˜ì—­ì„ ë„˜ì–´ì„œ, ì¼ë°˜ì ìœ¼ë¡œ ìê°€ë©´ì—­ Tì„¸í¬ì— ì˜í•´ ìœ ë°œë˜ëŠ” ì§ˆí™˜ì¸ ë¹„ê°ì—¼ì„± í¬ë„ë§‰ì—¼ì— ëŒ€í•œ ì‹ ê·œ ìœ ë¦¬ì²´ê°•ë‚´ íˆ¬ì—¬ Tì„¸í¬ ìˆ˜ìš©ì²´ ì°¨ë‹¨ í•­ì²´ ì—°êµ¬ë¥¼ ê°œì‹œí–ˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ì§„ì „ì€ ë‹¹ì‚¬ì˜ ë…ë³´ì ì¸ í•­ì²´ ì—­ëŸ‰ ë•ë¶„ì— ê°€ëŠ¥í–ˆìœ¼ë©°, ì´ëŸ¬í•œ í•­ì²´ë¥¼ ìƒì„±í•  ìˆ˜ ìˆì—ˆë˜ ë‹¤ë¥¸ íšŒì‚¬ëŠ” ì—†ëŠ” ê²ƒìœ¼ë¡œ ì•Œê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>This year, we also plan to initiate clinical development for a long-acting antibody targeting a novel genetically validated target for glaucoma, along with a long-acting antibody that aims to treat thyroid eye disease and Graves' disease. Moving to immunology and inflammation. We are committed to strengthening our leadership by advancing several next-generation therapeutic approaches.</td><td>ì˜¬í•´ ìš°ë¦¬ëŠ” ë…¹ë‚´ì¥ì— ëŒ€í•œ ìœ ì „ì ìœ¼ë¡œ ê²€ì¦ëœ ìƒˆë¡œìš´ í‘œì ì„ ê²¨ëƒ¥í•œ ì§€ì†í˜• í•­ì²´ì™€ ê°‘ìƒì„  ì•ˆë³‘ì¦ ë° ê·¸ë ˆì´ë¸ŒìŠ¤ë³‘ ì¹˜ë£Œë¥¼ ëª©í‘œë¡œ í•˜ëŠ” ì§€ì†í˜• í•­ì²´ì— ëŒ€í•œ ì„ìƒ ê°œë°œì„ ì‹œì‘í•  ê³„íšì…ë‹ˆë‹¤. ë©´ì—­í•™ ë° ì—¼ì¦ ë¶„ì•¼ë¡œ ë„˜ì–´ê°€ì„œ, ìš°ë¦¬ëŠ” ì—¬ëŸ¬ ì°¨ì„¸ëŒ€ ì¹˜ë£Œ ì ‘ê·¼ë²•ì„ ë°œì „ì‹œí‚´ìœ¼ë¡œì¨ ë¦¬ë”ì‹­ì„ ê°•í™”í•˜ëŠ” ë° ì „ë…í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>As we first revealed at the JPMorgan Conference, in addition to exploring longer dosing intervals for DUPIXENT, we are progressing Veloci-derived fully human long-acting antibodies with enhanced binding properties that target the IL-4 receptor alpha, the same target as DUPIXENT as well as antibodies targeting IL-13, IL-4 and a bispecific antibody targeting both IL-4 and IL-13. All of these approaches are designed to enable extended dosing.</td><td>JPMorgan ì»¨í¼ëŸ°ìŠ¤ì—ì„œ ì²˜ìŒ ê³µê°œí•œ ë°”ì™€ ê°™ì´, ìš°ë¦¬ëŠ” DUPIXENTì˜ íˆ¬ì•½ ê°„ê²© ì—°ì¥ì„ ëª¨ìƒ‰í•˜ëŠ” ê²ƒ ì™¸ì—ë„, DUPIXENTì™€ ë™ì¼í•œ íƒ€ê²Ÿì¸ IL-4 ìˆ˜ìš©ì²´ ì•ŒíŒŒë¥¼ í‘œì ìœ¼ë¡œ í•˜ëŠ” í–¥ìƒëœ ê²°í•© íŠ¹ì„±ì„ ê°€ì§„ Veloci ìœ ë˜ ì™„ì „ ì¸ê°„ ì¥ê¸° ì§€ì†í˜• í•­ì²´ë“¤ì„ ê°œë°œí•˜ê³  ìˆìœ¼ë©°, IL-13, IL-4ë¥¼ í‘œì ìœ¼ë¡œ í•˜ëŠ” í•­ì²´ë“¤ê³¼ IL-4 ë° IL-13 ëª¨ë‘ë¥¼ í‘œì ìœ¼ë¡œ í•˜ëŠ” ì´ì¤‘íŠ¹ì´í•­ì²´ë„ ì§„í–‰í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ëª¨ë“  ì ‘ê·¼ë²•ë“¤ì€ íˆ¬ì•½ ê°„ê²© ì—°ì¥ì„ ê°€ëŠ¥í•˜ê²Œ í•˜ë„ë¡ ì„¤ê³„ë˜ì—ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Our long-acting IL-13 antibody is expected to enter the clinic in the coming months, embarking on an expedited development plan in atopic dermatitis that we believe will enable us to remain competitive as other industry players that are pursuing related approaches. Our other long-acting antibodies are expected to enter the clinic by 2027, each with a custom development plan. At the same time, our Regeneron Genetics Center has utilized its large-scale genetics approaches to identify several exciting new immunology and inflammation targets. Similar to DUPIXENT, we believe these may represent future pipeline and product opportunities.</td><td>ìš°ë¦¬ì˜ ì¥ê¸° ì§€ì†í˜• IL-13 í•­ì²´ëŠ” í–¥í›„ ìˆ˜ê°œì›” ë‚´ì— ì„ìƒì‹œí—˜ì— ì§„ì…í•  ì˜ˆì •ì´ë©°, ì•„í† í”¼ í”¼ë¶€ì—¼ì— ëŒ€í•œ ì‹ ì†í•œ ê°œë°œ ê³„íšì„ ì‹œì‘í•  ê²ƒì…ë‹ˆë‹¤. ìš°ë¦¬ëŠ” ì´ë¥¼ í†µí•´ ìœ ì‚¬í•œ ì ‘ê·¼ë²•ì„ ì¶”êµ¬í•˜ëŠ” ë‹¤ë¥¸ ì—…ê³„ ê²½ìŸì‚¬ë“¤ê³¼ ê²½ìŸë ¥ì„ ìœ ì§€í•  ìˆ˜ ìˆì„ ê²ƒìœ¼ë¡œ ë¯¿ìŠµë‹ˆë‹¤. ìš°ë¦¬ì˜ ë‹¤ë¥¸ ì¥ê¸° ì§€ì†í˜• í•­ì²´ë“¤ì€ 2027ë…„ê¹Œì§€ ì„ìƒì‹œí—˜ì— ì§„ì…í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒë˜ë©°, ê°ê° ë§ì¶¤í˜• ê°œë°œ ê³„íšì„ ê°–ì¶”ê³  ìˆìŠµë‹ˆë‹¤. ë™ì‹œì—, ìš°ë¦¬ì˜ ë¦¬ì œë„ˆë¡  ìœ ì „í•™ ì„¼í„°(Regeneron Genetics Center)ëŠ” ëŒ€ê·œëª¨ ìœ ì „í•™ì  ì ‘ê·¼ë²•ì„ í™œìš©í•˜ì—¬ ì—¬ëŸ¬ í¥ë¯¸ë¡œìš´ ìƒˆë¡œìš´ ë©´ì—­í•™ ë° ì—¼ì¦ íƒ€ê²Ÿì„ ë°œêµ´í–ˆìŠµë‹ˆë‹¤. ìš°ë¦¬ëŠ” ì´ë“¤ì´ ë“€í”½ì„¼íŠ¸(DUPIXENT)ì™€ ìœ ì‚¬í•˜ê²Œ ë¯¸ë˜ì˜ íŒŒì´í”„ë¼ì¸ ë° ì œí’ˆ ê¸°íšŒë¥¼ ëŒ€í‘œí•  ìˆ˜ ìˆì„ ê²ƒìœ¼ë¡œ ë¯¿ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>The first of these antibodies is expected to enter clinical development in the first half of this year. After initially evaluating healthy volunteers, we plan to rapidly advance this candidate to establish proof of concept in several genetically linked diseases such as lupus, Sjogren's and primary biliary cholangitis. Turning now to allergen. Our initial cat and birch Phase III studies demonstrated that allergen-specific monoclonal antibody cocktails can meaningfully address ocular endpoints, adding to earlier data that showed significant reductions in nasal, respiratory and skin endpoints.</td><td>ì´ëŸ¬í•œ í•­ì²´ ì¤‘ ì²« ë²ˆì§¸ í•­ì²´ëŠ” ì˜¬í•´ ìƒë°˜ê¸° ì¤‘ ì„ìƒ ê°œë°œì— ì§„ì…í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒë©ë‹ˆë‹¤. ê±´ê°•í•œ ì§€ì›ìë“¤ì„ ëŒ€ìƒìœ¼ë¡œ í•œ ì´ˆê¸° í‰ê°€ í›„, ìš°ë¦¬ëŠ” ë£¨í‘¸ìŠ¤, ì‡¼ê·¸ë Œ ì¦í›„êµ°, ì›ë°œì„± ë‹´ì¦™ì„± ë‹´ê´€ì—¼ê³¼ ê°™ì€ ì—¬ëŸ¬ ìœ ì „ì  ì—°ê´€ ì§ˆí™˜ì—ì„œ ê°œë… ì¦ëª…ì„ í™•ë¦½í•˜ê¸° ìœ„í•´ ì´ í›„ë³´ë¬¼ì§ˆì„ ì‹ ì†í•˜ê²Œ ì§„í–‰í•  ê³„íšì…ë‹ˆë‹¤. ì´ì œ ì•Œë ˆë¥´ê²ìœ¼ë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤. ê³ ì–‘ì´ì™€ ìì‘ë‚˜ë¬´ì— ëŒ€í•œ ì´ˆê¸° 3ìƒ ì„ìƒì‹œí—˜ì€ ì•Œë ˆë¥´ê² íŠ¹ì´ì  ë‹¨ì¼í´ë¡ í•­ì²´ ì¹µí…Œì¼ì´ ì•ˆêµ¬ í‰ê°€ë³€ìˆ˜ë¥¼ ì˜ë¯¸ ìˆê²Œ ê°œì„ í•  ìˆ˜ ìˆìŒì„ ì…ì¦í–ˆìœ¼ë©°, ì´ëŠ” ë¹„ê°•, í˜¸í¡ê¸° ë° í”¼ë¶€ í‰ê°€ë³€ìˆ˜ì—ì„œ ìœ ì˜ë¯¸í•œ ê°ì†Œë¥¼ ë³´ì—¬ì¤€ ì´ì „ ë°ì´í„°ì— ì¶”ê°€ë˜ëŠ” ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>These Phase III data from the cat and birch programs will be presented at the upcoming AAAAI conference. We anticipate initiating the confirmatory Phase III study for cat allergy in the first half of the year, while the confirmatory Phase III study for birch allergy is already underway. We are also advancing an innovative strategy with the goal of eliminating all IgE-mediated allergies. Our initial clinical effort is in patients suffering from severe food allergies, involving transient LYNOZYFIC treatment followed by long-term DUPIXENT maintenance. This approach demonstrated proof of principle with the first 4 treated patients all achieving over 90% sustained IgE reductions.</td><td>ê³ ì–‘ì´ ë° ìì‘ë‚˜ë¬´ ì•Œë ˆë¥´ê¸° í”„ë¡œê·¸ë¨ì˜ 3ìƒ ë°ì´í„°ëŠ” ë‹¤ê°€ì˜¤ëŠ” AAAAI í•™íšŒì—ì„œ ë°œí‘œë  ì˜ˆì •ì…ë‹ˆë‹¤. ê³ ì–‘ì´ ì•Œë ˆë¥´ê¸°ì— ëŒ€í•œ í™•ì¦ 3ìƒ ì„ìƒì‹œí—˜ì€ ìƒë°˜ê¸° ì¤‘ ê°œì‹œí•  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ë©°, ìì‘ë‚˜ë¬´ ì•Œë ˆë¥´ê¸°ì— ëŒ€í•œ í™•ì¦ 3ìƒ ì„ìƒì‹œí—˜ì€ ì´ë¯¸ ì§„í–‰ ì¤‘ì…ë‹ˆë‹¤. ë˜í•œ ìš°ë¦¬ëŠ” ëª¨ë“  IgE ë§¤ê°œ ì•Œë ˆë¥´ê¸°ë¥¼ ì œê±°í•˜ëŠ” ê²ƒì„ ëª©í‘œë¡œ í•˜ëŠ” í˜ì‹ ì ì¸ ì „ëµì„ ì¶”ì§„í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ˆê¸° ì„ìƒ ë…¸ë ¥ì€ ì¤‘ì¦ ì‹í’ˆ ì•Œë ˆë¥´ê¸° í™˜ìë¥¼ ëŒ€ìƒìœ¼ë¡œ í•˜ë©°, ì¼ì‹œì ì¸ LYNOZYFIC ì¹˜ë£Œ í›„ ì¥ê¸°ì ì¸ DUPIXENT ìœ ì§€ìš”ë²•ì„ ë³‘í–‰í•˜ëŠ” ë°©ì‹ì…ë‹ˆë‹¤. ì´ ì ‘ê·¼ë²•ì€ ì¹˜ë£Œë°›ì€ ì²« 4ëª…ì˜ í™˜ì ëª¨ë‘ê°€ 90% ì´ìƒì˜ ì§€ì†ì ì¸ IgE ê°ì†Œë¥¼ ë‹¬ì„±í•˜ë©´ì„œ ê°œë… ì¦ëª…ì„ ì…ì¦í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>These results validate our approach of first removing IgE-producing plasma cells and then preventing their return. Building on this, we are developing next-generation agents specifically targeting Ig-producing cells with the first expected to enter clinical development over the next year for potentially more rapid and broader allergy applications. On to oncology and fianlimab, our LAG-3 antibody in combination with LIBTAYO. Our pivotal study in first-line metastatic melanoma remains on track to read out in the first half of this year. Early clinical data from our first-in-human study across multiple advanced melanoma cohorts suggested a potentially differentiated and best-in-class profile.</td><td>ì´ëŸ¬í•œ ê²°ê³¼ëŠ” ë¨¼ì € IgE ìƒì„± í˜•ì§ˆì„¸í¬ë¥¼ ì œê±°í•œ í›„ ì¬ë°œì„ ë°©ì§€í•˜ëŠ” ìš°ë¦¬ì˜ ì ‘ê·¼ë²•ì„ ì…ì¦í•©ë‹ˆë‹¤. ì´ë¥¼ ê¸°ë°˜ìœ¼ë¡œ, ìš°ë¦¬ëŠ” Ig ìƒì„± ì„¸í¬ë¥¼ íŠ¹ì´ì ìœ¼ë¡œ í‘œì í•˜ëŠ” ì°¨ì„¸ëŒ€ ì¹˜ë£Œì œë¥¼ ê°œë°œí•˜ê³  ìˆìœ¼ë©°, ì²« ë²ˆì§¸ ì¹˜ë£Œì œëŠ” í–¥í›„ 1ë…„ ë‚´ì— ì„ìƒ ê°œë°œì— ì§„ì…í•˜ì—¬ ì ì¬ì ìœ¼ë¡œ ë” ì‹ ì†í•˜ê³  ê´‘ë²”ìœ„í•œ ì•Œë ˆë¥´ê¸° ì ì‘ì¦ì— ì ìš©ë  ê²ƒìœ¼ë¡œ ì˜ˆìƒë©ë‹ˆë‹¤. ì¢…ì–‘í•™ ë¶„ì•¼ë¡œ ë„˜ì–´ê°€ì„œ, LIBTAYOì™€ ë³‘ìš©í•˜ëŠ” LAG-3 í•­ì²´ì¸ fianlimabì— ëŒ€í•´ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. 1ì°¨ ì „ì´ì„± í‘ìƒ‰ì¢…ì— ëŒ€í•œ ìš°ë¦¬ì˜ í”¼ë²— ì—°êµ¬ëŠ” ì˜¬í•´ ìƒë°˜ê¸° ê²°ê³¼ ë°œí‘œ ì¼ì •ì„ ìˆœì¡°ë¡­ê²Œ ìœ ì§€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì—¬ëŸ¬ ì§„í–‰ì„± í‘ìƒ‰ì¢… ì½”í˜¸íŠ¸ë¥¼ ëŒ€ìƒìœ¼ë¡œ í•œ ìµœì´ˆ ì¸ì²´ íˆ¬ì—¬ ì—°êµ¬ì˜ ì´ˆê¸° ì„ìƒ ë°ì´í„°ëŠ” ì ì¬ì ìœ¼ë¡œ ì°¨ë³„í™”ë˜ê³  ë™ì¢… ìµœê³  ìˆ˜ì¤€ì˜ í”„ë¡œíŒŒì¼ì„ ì‹œì‚¬í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Also in the first half of this year, we're expecting an interim analysis for our study in adjuvant melanoma as well as Phase II data in advanced non-small cell lung cancer, a more speculative setting in with clinical validation has not yet been established for LAG-3 and PD-1 combinations. Moving to Heme-Onc, LYNOZYFIC, our BCMAxCD3 bispecific is establishing a new benchmark in multiple myeloma.</td><td>ì˜¬í•´ ìƒë°˜ê¸°ì—ëŠ” ë³´ì¡° í‘ìƒ‰ì¢… ì—°êµ¬ì˜ ì¤‘ê°„ ë¶„ì„ ê²°ê³¼ì™€ ì§„í–‰ì„± ë¹„ì†Œì„¸í¬íì•”ì—ì„œì˜ 2ìƒ ë°ì´í„°ë„ ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŠ” LAG-3ì™€ PD-1 ë³‘ìš©ìš”ë²•ì— ëŒ€í•œ ì„ìƒì  ê²€ì¦ì´ ì•„ì§ í™•ë¦½ë˜ì§€ ì•Šì€ ë³´ë‹¤ íƒìƒ‰ì ì¸ ì˜ì—­ì…ë‹ˆë‹¤. í˜ˆì•¡ì¢…ì–‘í•™ ë¶„ì•¼ë¡œ ë„˜ì–´ê°€ì„œ, BCMAxCD3 ì´ì¤‘íŠ¹ì´í•­ì²´ì¸ LYNOZYFICì€ ë‹¤ë°œì„± ê³¨ìˆ˜ì¢…ì—ì„œ ìƒˆë¡œìš´ ê¸°ì¤€ì„ í™•ë¦½í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>In late-line disease and with the caveat of cross-trial comparisons, LYNOZYFIC has demonstrated nearly double the complete response rate compared to other BCMAxCD3 bispecifics at similar follow-up times with lower rates of cytokine release syndrome, shorter hospitalization requirements and more convenient dosing intervals.</td><td>í›„ê¸° ì¹˜ë£Œ í™˜ê²½ì—ì„œ, ê·¸ë¦¬ê³  êµì°¨ ì„ìƒì‹œí—˜ ë¹„êµë¼ëŠ” ì œí•œì ì„ ê°ì•ˆí•˜ë”ë¼ë„, LYNOZYFICì€ ìœ ì‚¬í•œ ì¶”ì ê´€ì°° ê¸°ê°„ ë™ì•ˆ ë‹¤ë¥¸ BCMAxCD3 ì´ì¤‘íŠ¹ì´í•­ì²´ë“¤ê³¼ ë¹„êµí•˜ì—¬ ê±°ì˜ ë‘ ë°°ì— ë‹¬í•˜ëŠ” ì™„ì „ê´€í•´ìœ¨ì„ ì…ì¦í–ˆìœ¼ë©°, ë™ì‹œì— ë” ë‚®ì€ ì‚¬ì´í† ì¹´ì¸ ë°©ì¶œ ì¦í›„êµ° ë°œìƒë¥ , ë” ì§§ì€ ì…ì› ê¸°ê°„ ìš”êµ¬ì‚¬í•­, ê·¸ë¦¬ê³  ë” í¸ë¦¬í•œ íˆ¬ì•½ ê°„ê²©ì„ ë³´ì—¬ì£¼ì—ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Building on its remarkable monotherapy activity across multiple lines of therapy, we are undertaking an ambitious development plan to simplify the existing myeloma treatment paradigm, which currently relies on highly complex, intense and burdensome triple and quad drug combinations by exploring LYNOZYFIC monotherapy as well as in simple combinations in early line settings. In our Phase II study in newly diagnosed multiple myeloma, all 9 evaluable patients treated with LYNOZYFIC monotherapy at the planned Phase III dose achieved MRD negativity, an endpoint the FDA recently endorsed as a registrational enabling for this malignant disease.</td><td>ì—¬ëŸ¬ ì¹˜ë£Œ ë‹¨ê³„ì—ì„œ ì…ì¦ëœ ë†€ë¼ìš´ ë‹¨ë…ìš”ë²• í™œì„±ì„ ê¸°ë°˜ìœ¼ë¡œ, ìš°ë¦¬ëŠ” í˜„ì¬ ë§¤ìš° ë³µì¡í•˜ê³  ê°•ë„ ë†’ìœ¼ë©° ë¶€ë‹´ìŠ¤ëŸ¬ìš´ 3ì œ ë° 4ì œ ë³‘ìš©ìš”ë²•ì— ì˜ì¡´í•˜ê³  ìˆëŠ” ê¸°ì¡´ ê³¨ìˆ˜ì¢… ì¹˜ë£Œ íŒ¨ëŸ¬ë‹¤ì„ì„ ë‹¨ìˆœí™”í•˜ê¸° ìœ„í•œ ì•¼ì‹¬ì°¬ ê°œë°œ ê³„íšì„ ì¶”ì§„í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŠ” ì´ˆê¸° ì¹˜ë£Œ ë‹¨ê³„ì—ì„œ LYNOZYFIC ë‹¨ë…ìš”ë²• ë° ë‹¨ìˆœ ë³‘ìš©ìš”ë²•ì„ íƒìƒ‰í•˜ëŠ” ê²ƒì…ë‹ˆë‹¤. ìƒˆë¡œ ì§„ë‹¨ëœ ë‹¤ë°œì„± ê³¨ìˆ˜ì¢… í™˜ìë¥¼ ëŒ€ìƒìœ¼ë¡œ í•œ 2ìƒ ì„ìƒì‹œí—˜ì—ì„œ, ê³„íšëœ 3ìƒ ìš©ëŸ‰ì˜ LYNOZYFIC ë‹¨ë…ìš”ë²•ìœ¼ë¡œ ì¹˜ë£Œë°›ì€ í‰ê°€ ê°€ëŠ¥í•œ 9ëª…ì˜ í™˜ì ëª¨ë‘ê°€ MRD ìŒì„±ì„ ë‹¬ì„±í–ˆìŠµë‹ˆë‹¤. ì´ëŠ” FDAê°€ ìµœê·¼ ì´ ì•…ì„± ì§ˆí™˜ì— ëŒ€í•œ í—ˆê°€ ìŠ¹ì¸ ê°€ëŠ¥ ì§€í‘œë¡œ ì¸ì •í•œ í‰ê°€ë³€ìˆ˜ì…ë‹ˆë‹¤.</td></tr>
<tr><td>Even more compelling are the early signals in myeloma precursor and related settings. For example, in evaluable patients with high-risk smoldering myeloma, LYNOZYFIC once again achieved 100% MRD negative in all 12 evaluated patients, whereas the standard of care, daratumumab achieved less than 10% complete response. Similarly, in second-line patients with light chain amyloidosis, LYNOZYFIC monotherapy normalized abnormal light chain levels in approximately 2 weeks, whereas in a separate study, a daratumumab containing quad combo regimen took approximately 5 months to approach these levels in first-line patients.</td><td>ë”ìš± ì£¼ëª©í•  ë§Œí•œ ê²ƒì€ ê³¨ìˆ˜ì¢… ì „êµ¬ ë‹¨ê³„ ë° ê´€ë ¨ ì ì‘ì¦ì—ì„œ ë‚˜íƒ€ë‚œ ì´ˆê¸° ì‹ í˜¸ì…ë‹ˆë‹¤. ì˜ˆë¥¼ ë“¤ì–´, ê³ ìœ„í—˜ ë¬´ì¦ìƒ ê³¨ìˆ˜ì¢… í‰ê°€ ê°€ëŠ¥ í™˜ìë“¤ì—ì„œ LYNOZYFICì€ ë‹¤ì‹œ í•œë²ˆ í‰ê°€ëœ 12ëª…ì˜ í™˜ì ëª¨ë‘ì—ì„œ 100% MRD ìŒì„±ì„ ë‹¬ì„±í–ˆìŠµë‹ˆë‹¤. ë°˜ë©´ í‘œì¤€ ì¹˜ë£Œì œì¸ ë‹¤ë¼íˆ¬ë¬´ë§™ì€ 10% ë¯¸ë§Œì˜ ì™„ì „ ê´€í•´ìœ¨ì„ ë‹¬ì„±í–ˆìŠµë‹ˆë‹¤. ë§ˆì°¬ê°€ì§€ë¡œ, ê²½ì‡„ ì•„ë°€ë¡œì´ë“œì¦ 2ì°¨ ì¹˜ë£Œ í™˜ìë“¤ì—ì„œ LYNOZYFIC ë‹¨ë…ìš”ë²•ì€ ì•½ 2ì£¼ ë§Œì— ë¹„ì •ìƒ ê²½ì‡„ ìˆ˜ì¹˜ë¥¼ ì •ìƒí™”í–ˆìŠµë‹ˆë‹¤. ë°˜ë©´ ë³„ë„ ì—°êµ¬ì—ì„œ ë‹¤ë¼íˆ¬ë¬´ë§™ í¬í•¨ 4ì œ ë³‘ìš©ìš”ë²•ì€ 1ì°¨ ì¹˜ë£Œ í™˜ìë“¤ì—ì„œ ì´ëŸ¬í•œ ìˆ˜ì¹˜ì— ê·¼ì ‘í•˜ëŠ” ë° ì•½ 5ê°œì›”ì´ ì†Œìš”ë˜ì—ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Both of these promising results could herald market advances to existing standard of care, which can involve complex and toxic multidrug combinations. With 4 pivotal studies underway and 4 more initiating by the middle of this year, we are rapidly advancing our LYNOZYFIC development program with the hopes of transforming the myeloma treatment paradigm and ultimately preventing progression to malignant disease. On to complement-mediated diseases. Our C5 program consists of customized approaches to treat different diseases, which require different levels of target inhibition to maximize efficacy for each condition. I previously summarized above our C5 efforts in geographic atrophy.</td><td>ì´ ë‘ ê°€ì§€ ìœ ë§í•œ ê²°ê³¼ëŠ” ë³µì¡í•˜ê³  ë…ì„±ì´ ê°•í•œ ë‹¤ì œë³‘ìš©ìš”ë²•ì„ í¬í•¨í•  ìˆ˜ ìˆëŠ” ê¸°ì¡´ í‘œì¤€ì¹˜ë£Œë²•ì— ëŒ€í•œ ì‹œì¥ ì§„ì¶œì˜ ì‹ í˜¸íƒ„ì´ ë  ìˆ˜ ìˆìŠµë‹ˆë‹¤. 4ê±´ì˜ í”¼ë²— ì—°êµ¬ê°€ ì§„í–‰ ì¤‘ì´ê³  ì˜¬í•´ ì¤‘ë°˜ê¹Œì§€ 4ê±´ì´ ì¶”ê°€ë¡œ ì‹œì‘ë  ì˜ˆì •ì¸ ê°€ìš´ë°, ìš°ë¦¬ëŠ” ê³¨ìˆ˜ì¢… ì¹˜ë£Œ íŒ¨ëŸ¬ë‹¤ì„ì„ í˜ì‹ í•˜ê³  ê¶ê·¹ì ìœ¼ë¡œ ì•…ì„± ì§ˆí™˜ìœ¼ë¡œì˜ ì§„í–‰ì„ ì˜ˆë°©í•˜ê³ ì í•˜ëŠ” ëª©í‘œë¥¼ ê°€ì§€ê³  LYNOZYFIC ê°œë°œ í”„ë¡œê·¸ë¨ì„ ë¹ ë¥´ê²Œ ì§„ì „ì‹œí‚¤ê³  ìˆìŠµë‹ˆë‹¤.<br><br>ë³´ì²´ ë§¤ê°œ ì§ˆí™˜ìœ¼ë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤. ìš°ë¦¬ì˜ C5 í”„ë¡œê·¸ë¨ì€ ê° ì§ˆí™˜ì— ëŒ€í•œ íš¨ëŠ¥ì„ ê·¹ëŒ€í™”í•˜ê¸° ìœ„í•´ ì„œë¡œ ë‹¤ë¥¸ ìˆ˜ì¤€ì˜ í‘œì  ì–µì œê°€ í•„ìš”í•œ ë‹¤ì–‘í•œ ì§ˆí™˜ì„ ì¹˜ë£Œí•˜ê¸° ìœ„í•œ ë§ì¶¤í˜• ì ‘ê·¼ë²•ìœ¼ë¡œ êµ¬ì„±ë˜ì–´ ìˆìŠµë‹ˆë‹¤. ì•ì„œ ì§€ë¦¬ì  ìœ„ì¶•ì¦ì— ëŒ€í•œ C5 ë…¸ë ¥ì„ ìš”ì•½í•´ ë“œë ¸ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>In our pivotal study for generalized myasthenia gravis, we showed that cemdisiran alone achieved differentiated efficacy and convenience with every 3-month subcutaneous dosing, delivering a potentially best-in-class profile with a placebo-adjusted improvement in the myasthenia gravis activities of daily living score of 2.3 endpoints at 24 weeks, the primary endpoint of the study and the best result among C5 inhibitors to date based on cross-trial comparisons. We remain on track to submit our U.S. regulatory application in the first quarter with potential approval anticipated later this year or early next year.</td><td>ì „ì‹  ì¤‘ì¦ ê·¼ë¬´ë ¥ì¦ì— ëŒ€í•œ ìš°ë¦¬ì˜ í”¼ë²— ì—°êµ¬ì—ì„œ, ì„¸ë””ì‹œë€ ë‹¨ë…ìš”ë²•ì€ 3ê°œì›”ë§ˆë‹¤ í”¼í•˜ íˆ¬ì—¬í•˜ëŠ” í¸ë¦¬ì„±ê³¼ í•¨ê»˜ ì°¨ë³„í™”ëœ íš¨ëŠ¥ì„ ì…ì¦í–ˆìŠµë‹ˆë‹¤. ì´ëŠ” ì—°êµ¬ì˜ 1ì°¨ í‰ê°€ë³€ìˆ˜ì¸ 24ì£¼ì°¨ ì‹œì ì—ì„œ ì¤‘ì¦ ê·¼ë¬´ë ¥ì¦ ì¼ìƒìƒí™œ í™œë™ ì ìˆ˜ê°€ ìœ„ì•½ ëŒ€ë¹„ 2.3ì  ê°œì„ ë˜ì–´ ì ì¬ì ìœ¼ë¡œ ë™ê¸‰ ìµœê³  ìˆ˜ì¤€ì˜ í”„ë¡œíŒŒì¼ì„ ì œê³µí•˜ë©°, êµì°¨ ì„ìƒì‹œí—˜ ë¹„êµ ê¸°ì¤€ìœ¼ë¡œ í˜„ì¬ê¹Œì§€ C5 ì–µì œì œ ì¤‘ ìµœê³ ì˜ ê²°ê³¼ì…ë‹ˆë‹¤. ìš°ë¦¬ëŠ” 1ë¶„ê¸° ì¤‘ ë¯¸êµ­ ê·œì œ ë‹¹êµ­ ì‹ ì²­ì„ ì œì¶œí•  ì˜ˆì •ì´ë©°, ì˜¬í•´ ë§ ë˜ëŠ” ë‚´ë…„ ì´ˆ ìŠ¹ì¸ì´ ì˜ˆìƒë©ë‹ˆë‹¤.</td></tr>
<tr><td>In paroxysmal nocturnal hemoglobinuria or PNH, where our Phase III lead-in data showed the combination of cemdisiran, pozelimab was necessary to achieve potentially best-in-class disease control with 96% of patients controlled in the pivotal trial lead-in cohort and with the ability to rapidly rescue patients previously treated with ravulizumab who had not been well controlled. These results once again have the potential to deliver a best-in-class profile with pivotal data expected late this year or early next year, positioning this combination of C5 complement inhibitors as a new standard of care for PNH. Moving to anticoagulation.</td><td>íŒŒë¡ì‹œìŠ¤ë§ ì•¼ê°„í˜ˆìƒ‰ì†Œë‡¨ì¦(PNH)ì—ì„œ, ìš°ë¦¬ì˜ 3ìƒ ì„ í–‰ ë°ì´í„°ëŠ” ì…ˆë””ì‹œë€ê³¼ í¬ì ¤ë¦¬ë§™ì˜ ë³‘ìš©ìš”ë²•ì´ ì ì¬ì ìœ¼ë¡œ ë™ê¸‰ ìµœê³  ìˆ˜ì¤€ì˜ ì§ˆë³‘ ê´€ë¦¬ë¥¼ ë‹¬ì„±í•˜ëŠ” ë° í•„ìš”í•¨ì„ ë³´ì—¬ì£¼ì—ˆìŠµë‹ˆë‹¤. ì¤‘ì¶” ì„ìƒì‹œí—˜ ì„ í–‰ ì½”í˜¸íŠ¸ì—ì„œ í™˜ìì˜ 96%ê°€ ì§ˆë³‘ ê´€ë¦¬ë¥¼ ë‹¬ì„±í–ˆìœ¼ë©°, ì´ì „ì— ë¼ë¶ˆë¦¬ì£¼ë§™ìœ¼ë¡œ ì¹˜ë£Œë°›ì•˜ìœ¼ë‚˜ ì¶©ë¶„íˆ ê´€ë¦¬ë˜ì§€ ì•Šì•˜ë˜ í™˜ìë“¤ì„ ì‹ ì†í•˜ê²Œ íšŒë³µì‹œí‚¬ ìˆ˜ ìˆëŠ” ëŠ¥ë ¥ì„ ë³´ì˜€ìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ê²°ê³¼ëŠ” ë‹¤ì‹œ í•œë²ˆ ë™ê¸‰ ìµœê³  ìˆ˜ì¤€ì˜ í”„ë¡œíŒŒì¼ì„ ì œê³µí•  ì ì¬ë ¥ì„ ê°€ì§€ê³  ìˆìœ¼ë©°, ì¤‘ì¶” ë°ì´í„°ëŠ” ì˜¬í•´ ë§ ë˜ëŠ” ë‚´ë…„ ì´ˆì— ë‚˜ì˜¬ ê²ƒìœ¼ë¡œ ì˜ˆìƒë©ë‹ˆë‹¤. ì´ëŠ” ì´ C5 ë³´ì²´ ì–µì œì œ ë³‘ìš©ìš”ë²•ì„ PNHì˜ ìƒˆë¡œìš´ í‘œì¤€ ì¹˜ë£Œë²•ìœ¼ë¡œ ìë¦¬ë§¤ê¹€í•˜ê²Œ í•  ê²ƒì…ë‹ˆë‹¤. í•­ì‘ê³ ì œë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Clot prevention remains a critical unmet need since less than half of eligible patients received anticoagulant therapy, primarily due to concerns about their bleeding risk. To address this, we are developing 2 complementary Factor XI antibodies, one optimized for maximal antithrombotic activity and the other designed to further reduce bleeding risk, enabling a tailored approach based on individual patients' benefit risk profile. Initial clinical data support this strategy, showing impressive efficacy and a favorable bleeding profile compared to current standards of care.</td><td>í˜ˆì „ ì˜ˆë°©ì€ ì—¬ì „íˆ ì¶©ì¡±ë˜ì§€ ì•Šì€ ì¤‘ìš”í•œ ì˜ë£Œ ìˆ˜ìš”ì…ë‹ˆë‹¤. ì ê²© í™˜ìì˜ ì ˆë°˜ë„ ì•ˆ ë˜ëŠ” í™˜ìë“¤ë§Œì´ í•­ì‘ê³ ì œ ì¹˜ë£Œë¥¼ ë°›ê³  ìˆëŠ”ë°, ì´ëŠ” ì£¼ë¡œ ì¶œí˜ˆ ìœ„í—˜ì— ëŒ€í•œ ìš°ë ¤ ë•Œë¬¸ì…ë‹ˆë‹¤. ì´ë¥¼ í•´ê²°í•˜ê¸° ìœ„í•´, ì €í¬ëŠ” 2ê°€ì§€ ìƒí˜¸ë³´ì™„ì ì¸ Factor XI í•­ì²´ë¥¼ ê°œë°œí•˜ê³  ìˆìŠµë‹ˆë‹¤. í•˜ë‚˜ëŠ” ìµœëŒ€ í•­í˜ˆì „ í™œì„±ì— ìµœì í™”ë˜ì–´ ìˆê³ , ë‹¤ë¥¸ í•˜ë‚˜ëŠ” ì¶œí˜ˆ ìœ„í—˜ì„ ë”ìš± ë‚®ì¶”ë„ë¡ ì„¤ê³„ë˜ì–´, ê°œë³„ í™˜ìì˜ í¸ìµ-ìœ„í—˜ í”„ë¡œíŒŒì¼ì— ë”°ë¼ ë§ì¶¤í˜• ì ‘ê·¼ì´ ê°€ëŠ¥í•˜ë„ë¡ í–ˆìŠµë‹ˆë‹¤. ì´ˆê¸° ì„ìƒ ë°ì´í„°ëŠ” ì´ëŸ¬í•œ ì „ëµì„ ë’·ë°›ì¹¨í•˜ë©°, í˜„ì¬ í‘œì¤€ ì¹˜ë£Œë²•ê³¼ ë¹„êµí•˜ì—¬ ì¸ìƒì ì¸ íš¨ëŠ¥ê³¼ ìœ ë¦¬í•œ ì¶œí˜ˆ í”„ë¡œíŒŒì¼ì„ ë³´ì—¬ì£¼ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Pivotal studies are already underway in prevention of postsurgical venous thromboembolism or VTE, with pivotal studies in cancer-associated VTE prevention, catheter-associated thrombosis, stroke prevention in patients with atrial fibrillation and peripheral artery disease, all expected to initiate this year. Moving to obesity. We continue to pursue a differentiated strategy that includes olatorepatide, our in-licensed GLP/GIP agonist entering pivotal monotherapy studies in 2026 as well as a co-formulation of olatorepatide with PRALUENT, our antibody to PCSK9.</td><td>ì¤‘ì¶”ì  ì„ìƒì‹œí—˜ë“¤ì´ ìˆ˜ìˆ  í›„ ì •ë§¥í˜ˆì „ìƒ‰ì „ì¦(VTE) ì˜ˆë°© ë¶„ì•¼ì—ì„œ ì´ë¯¸ ì§„í–‰ ì¤‘ì´ë©°, ì•” ê´€ë ¨ VTE ì˜ˆë°©, ì¹´í…Œí„° ê´€ë ¨ í˜ˆì „ì¦, ì‹¬ë°©ì„¸ë™ í™˜ìì˜ ë‡Œì¡¸ì¤‘ ì˜ˆë°©, ê·¸ë¦¬ê³  ë§ì´ˆë™ë§¥ì§ˆí™˜ ë¶„ì•¼ì˜ ì¤‘ì¶”ì  ì„ìƒì‹œí—˜ë“¤ì´ ëª¨ë‘ ì˜¬í•´ ê°œì‹œë  ê²ƒìœ¼ë¡œ ì˜ˆìƒë©ë‹ˆë‹¤. ë¹„ë§Œ ì¹˜ë£Œì œë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤. ìš°ë¦¬ëŠ” ì°¨ë³„í™”ëœ ì „ëµì„ ì§€ì†ì ìœ¼ë¡œ ì¶”êµ¬í•˜ê³  ìˆìœ¼ë©°, ì—¬ê¸°ì—ëŠ” 2026ë…„ ì¤‘ì¶”ì  ë‹¨ë…ìš”ë²• ì„ìƒì‹œí—˜ì— ì§„ì…í•  ì˜ˆì •ì¸ ë„ì… ë¼ì´ì„ ìŠ¤ GLP/GIP ì‘ìš©ì œì¸ ì˜¬ë¼í† ë ˆíŒŒíƒ€ì´ë“œì™€, PCSK9 í•­ì²´ì¸ PRALUENTì™€ ì˜¬ë¼í† ë ˆíŒŒíƒ€ì´ë“œì˜ ë³µí•©ì œì œê°€ í¬í•¨ë©ë‹ˆë‹¤.</td></tr>
<tr><td>Since current GLP agonists do not meaningfully lower LDL cholesterol, this co-formulated combination is designed to treat the large population of people living with obesity who also suffer from hyperlipidemia with a single, convenient and similarly affordable once-weekly subcutaneous injection analogous to the currently approved GLPs. Moreover, imagine if someone had invented a new GLP that in addition to delivering profound weight loss could also lower bad cholesterol by 50% to 60%. It would create an important and differentiated opportunity for the many obese patients simultaneously suffering hyperlipidemia with elevated cardiovascular risk.</td><td>í˜„ì¬ì˜ GLP ì‘ìš©ì œë“¤ì€ LDL ì½œë ˆìŠ¤í…Œë¡¤ì„ ì˜ë¯¸ ìˆê²Œ ë‚®ì¶”ì§€ ëª»í•˜ê¸° ë•Œë¬¸ì—, ì´ ë³µí•© ì œí˜•ì€ ê³ ì§€í˜ˆì¦ì„ ë™ë°˜í•œ ë¹„ë§Œ í™˜ìë¼ëŠ” ëŒ€ê·œëª¨ ì¸êµ¬ë¥¼ ëŒ€ìƒìœ¼ë¡œ, í˜„ì¬ ìŠ¹ì¸ëœ GLP ì œì œë“¤ê³¼ ìœ ì‚¬í•˜ê²Œ í¸ë¦¬í•˜ê³  ê²½ì œì ì¸ ì£¼ 1íšŒ í”¼í•˜ì£¼ì‚¬ ë‹¨ì¼ ì¹˜ë£Œì œë¡œ ì„¤ê³„ë˜ì—ˆìŠµë‹ˆë‹¤. ë” ë‚˜ì•„ê°€, ë§Œì•½ ëˆ„êµ°ê°€ê°€ ìƒë‹¹í•œ ì²´ì¤‘ ê°ëŸ‰ íš¨ê³¼ë¥¼ ì œê³µí•˜ë©´ì„œ ë™ì‹œì— ë‚˜ìœ ì½œë ˆìŠ¤í…Œë¡¤ì„ 50%ì—ì„œ 60%ê¹Œì§€ ë‚®ì¶œ ìˆ˜ ìˆëŠ” ìƒˆë¡œìš´ GLP ì œì œë¥¼ ê°œë°œí–ˆë‹¤ê³  ìƒìƒí•´ ë³´ì‹­ì‹œì˜¤. ì´ëŠ” ê³ ì§€í˜ˆì¦ê³¼ ë†’ì€ ì‹¬í˜ˆê´€ ìœ„í—˜ì„ ë™ì‹œì— ê²ªê³  ìˆëŠ” ë§ì€ ë¹„ë§Œ í™˜ìë“¤ì—ê²Œ ì¤‘ìš”í•˜ê³  ì°¨ë³„í™”ëœ ì¹˜ë£Œ ê¸°íšŒë¥¼ ì°½ì¶œí•  ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>Our clinical program for this novel combination that we believe can deliver the same dual benefits is expected to begin later this year. Before I turn the call over to Marion, I would like to quickly address a couple of additional developments in our pipeline. In rare diseases, our DB-OTO gene therapy continues to produce transformative outcomes with meaningful hearing gains in 11 of the 12 treated children born with profound genetic deafness. This program was selected as the first new molecular entity to receive the FDA Commissioner's National Priority Voucher designation, and we are awaiting a regulatory decision in the first half of this year.</td><td>ì €í¬ì˜ ì´ ìƒˆë¡œìš´ ë³‘ìš©ìš”ë²• ì„ìƒ í”„ë¡œê·¸ë¨ì€ ë™ì¼í•œ ì´ì¤‘ íš¨ê³¼ë¥¼ ì œê³µí•  ìˆ˜ ìˆì„ ê²ƒìœ¼ë¡œ ë¯¿ê³  ìˆìœ¼ë©°, ì˜¬í•´ í›„ë°˜ì— ì‹œì‘ë  ì˜ˆì •ì…ë‹ˆë‹¤. Marionì—ê²Œ ë°œí‘œë¥¼ ë„˜ê¸°ê¸° ì „ì—, íŒŒì´í”„ë¼ì¸ì˜ ëª‡ ê°€ì§€ ì¶”ê°€ ê°œë°œ ì‚¬í•­ì— ëŒ€í•´ ê°„ë‹¨íˆ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. í¬ê·€ì§ˆí™˜ ë¶„ì•¼ì—ì„œ, ì €í¬ DB-OTO ìœ ì „ì ì¹˜ë£Œì œëŠ” ì„ ì²œì  ìœ ì „ì„± ë‚œì²­ì„ ê°€ì§€ê³  íƒœì–´ë‚œ 12ëª…ì˜ ì–´ë¦°ì´ ì¤‘ 11ëª…ì—ê²Œì„œ ì˜ë¯¸ ìˆëŠ” ì²­ë ¥ ê°œì„ ê³¼ í•¨ê»˜ í˜ì‹ ì ì¸ ê²°ê³¼ë¥¼ ê³„ì† ë³´ì—¬ì£¼ê³  ìˆìŠµë‹ˆë‹¤. ì´ í”„ë¡œê·¸ë¨ì€ FDA êµ­ì¥ì˜ êµ­ê°€ ìš°ì„ ìˆœìœ„ ë°”ìš°ì²˜(National Priority Voucher) ì§€ì •ì„ ë°›ì€ ìµœì´ˆì˜ ì‹ ê·œ ë¶„ì ë¬¼ì§ˆ(new molecular entity)ë¡œ ì„ ì •ë˜ì—ˆìœ¼ë©°, ì €í¬ëŠ” ì˜¬í•´ ìƒë°˜ê¸° ì¤‘ ê·œì œ ë‹¹êµ­ì˜ ê²°ì •ì„ ê¸°ë‹¤ë¦¬ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>In fibrodysplasia ossificans progressiva or FOP, a debilitating disease in which the soft tissues of the body are progressively replaced with abnormal bone, our garetosmab program demonstrated a more than 99% reduction in abnormal bone formation at 56 weeks, an unprecedented result, and we are waiting on regulatory decisions in the U.S. and EU in the second half of this year. Our commitment and dedication to these types of rare diseases, particularly those that affect children, not only speak to the heart and soul of Regeneron, but have also proven to pave the way for broader opportunities in the future as we would hope would be the case here.</td><td>ì„¬ìœ ì´í˜•ì„±ì¦(FOP, fibrodysplasia ossificans progressiva), ì¦‰ ì‹ ì²´ì˜ ì—°ì¡°ì§ì´ ì ì§„ì ìœ¼ë¡œ ë¹„ì •ìƒì ì¸ ë¼ˆë¡œ ëŒ€ì²´ë˜ëŠ” ì‡ ì•½ì„± ì§ˆí™˜ì—ì„œ, ë‹¹ì‚¬ì˜ ê°€ë ˆí† ìŠ¤ë§™(garetosmab) í”„ë¡œê·¸ë¨ì€ 56ì£¼ì°¨ì— ë¹„ì •ìƒì ì¸ ê³¨í˜•ì„±ì„ 99% ì´ìƒ ê°ì†Œì‹œí‚¤ëŠ” ì „ë¡€ ì—†ëŠ” ê²°ê³¼ë¥¼ ì…ì¦í–ˆìœ¼ë©°, ì˜¬í•´ í•˜ë°˜ê¸° ë¯¸êµ­ê³¼ EUì˜ ê·œì œ ë‹¹êµ­ ìŠ¹ì¸ ê²°ì •ì„ ê¸°ë‹¤ë¦¬ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ìœ í˜•ì˜ í¬ê·€ì§ˆí™˜, íŠ¹íˆ ì–´ë¦°ì´ì—ê²Œ ì˜í–¥ì„ ë¯¸ì¹˜ëŠ” ì§ˆí™˜ë“¤ì— ëŒ€í•œ ë‹¹ì‚¬ì˜ í—Œì‹ ê³¼ ì „ë…ì€ ë¦¬ì œë„¤ë¡ ì˜ í•µì‹¬ ê°€ì¹˜ë¥¼ ë³´ì—¬ì¤„ ë¿ë§Œ ì•„ë‹ˆë¼, ì´ë²ˆ ì‚¬ë¡€ì—ì„œë„ ê¸°ëŒ€í•˜ëŠ” ë°”ì™€ ê°™ì´ í–¥í›„ ë” ê´‘ë²”ìœ„í•œ ê¸°íšŒë¥¼ ìœ„í•œ ê¸¸ì„ ì—´ì–´ì£¼ëŠ” ê²ƒìœ¼ë¡œ ì…ì¦ë˜ì–´ ì™”ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>In summary, our scientific and clinical momentum continues to accelerate across the R&D enterprise with multiple pivotal readouts, regulatory milestones and first-in-class programs advancing in 2026. I have never been more excited about the breadth, depth and potential impact of our pipeline. With that, let me turn it over to Mir. Marion McCourt<br>Executive Vice President of Commercial<br><br>Thank you, George. The fourth quarter delivered a strong finish to 2025, completing a successful year across our commercial portfolio.</td><td>ìš”ì•½í•˜ìë©´, ìš°ë¦¬ì˜ ê³¼í•™ì  ë° ì„ìƒì  ëª¨ë©˜í…€ì€ 2026ë…„ì— ë‹¤ìˆ˜ì˜ í”¼ë²—(pivotal) ì„ìƒ ê²°ê³¼ ë°œí‘œ, ê·œì œ ë‹¹êµ­ ìŠ¹ì¸ ë§ˆì¼ìŠ¤í†¤, ê·¸ë¦¬ê³  í¼ìŠ¤íŠ¸-ì¸-í´ë˜ìŠ¤(first-in-class) í”„ë¡œê·¸ë¨ë“¤ì˜ ì§„ì „ê³¼ í•¨ê»˜ R&D ì „ë°˜ì— ê±¸ì³ ê³„ì†í•´ì„œ ê°€ì†í™”ë˜ê³  ìˆìŠµë‹ˆë‹¤. ì €ëŠ” ìš°ë¦¬ íŒŒì´í”„ë¼ì¸ì˜ í­ê³¼ ê¹Šì´, ê·¸ë¦¬ê³  ì ì¬ì  ì˜í–¥ë ¥ì— ëŒ€í•´ ì´ë³´ë‹¤ ë” ê¸°ëŒ€ì— ì°¬ ì ì´ ì—†ì—ˆìŠµë‹ˆë‹¤. ê·¸ëŸ¼ ì´ì œ ë¯¸ë¥´ì—ê²Œ ë§ˆì´í¬ë¥¼ ë„˜ê¸°ê² ìŠµë‹ˆë‹¤.<br><br>ë§ˆë¦¬ì˜¨ ë§¥ì½”íŠ¸(Marion McCourt)<br>ìƒì—… ë¶€ë¬¸ ì´ê´„ ë¶€ì‚¬ì¥<br><br>ê°ì‚¬í•©ë‹ˆë‹¤, ì¡°ì§€. 4ë¶„ê¸°ëŠ” 2025ë…„ì„ ê°•ë ¥í•˜ê²Œ ë§ˆë¬´ë¦¬í•˜ë©° ìš°ë¦¬ ìƒì—… í¬íŠ¸í´ë¦¬ì˜¤ ì „ë°˜ì— ê±¸ì³ ì„±ê³µì ì¸ í•œ í•´ë¥¼ ì™„ì„±í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Our market-leading brands, EYLEA HD, DUPIXENT and LIBTAYO continue to deliver sustainable growth based on their clinical profiles as well as our ability to execute effectively in competitive markets. In 2025, we expanded use of our existing brands and successfully launched new medicines and indications across multiple therapeutic areas and geographies. We begin 2026 well positioned to advance our portfolio and are excited by upcoming opportunities to change the lives of even more patients. Starting with our retinal franchise of EYLEA HD and EYLEA, which delivered combined U.S.</td><td>ìš°ë¦¬ì˜ ì‹œì¥ ì„ ë„ ë¸Œëœë“œì¸ EYLEA HD, DUPIXENT, LIBTAYOëŠ” ì„ìƒ í”„ë¡œíŒŒì¼ê³¼ ê²½ìŸ ì‹œì¥ì—ì„œì˜ íš¨ê³¼ì ì¸ ì‹¤í–‰ ëŠ¥ë ¥ì„ ë°”íƒ•ìœ¼ë¡œ ì§€ì† ê°€ëŠ¥í•œ ì„±ì¥ì„ ì´ì–´ê°€ê³  ìˆìŠµë‹ˆë‹¤. 2025ë…„ì—ëŠ” ê¸°ì¡´ ë¸Œëœë“œì˜ ì‚¬ìš©ì„ í™•ëŒ€í•˜ê³  ì—¬ëŸ¬ ì¹˜ë£Œ ì˜ì—­ê³¼ ì§€ì—­ì—ì„œ ì‹ ì•½ê³¼ ìƒˆë¡œìš´ ì ì‘ì¦ì„ ì„±ê³µì ìœ¼ë¡œ ì¶œì‹œí–ˆìŠµë‹ˆë‹¤. 2026ë…„ì„ ì‹œì‘í•˜ë©´ì„œ ìš°ë¦¬ëŠ” í¬íŠ¸í´ë¦¬ì˜¤ë¥¼ ë°œì „ì‹œí‚¬ ìˆ˜ ìˆëŠ” ì¢‹ì€ ìœ„ì¹˜ì— ìˆìœ¼ë©°, ë” ë§ì€ í™˜ìë“¤ì˜ ì‚¶ì„ ë³€í™”ì‹œí‚¬ ë‹¤ê°€ì˜¤ëŠ” ê¸°íšŒë“¤ì— ëŒ€í•´ ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë¯¸êµ­ì—ì„œ í•©ì‚° ë§¤ì¶œì„ ê¸°ë¡í•œ EYLEA HDì™€ EYLEAì˜ ë§ë§‰ í”„ëœì°¨ì´ì¦ˆë¶€í„° ì‹œì‘í•˜ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>net sales of $1.1 billion in the fourth quarter, EYLEA HD net sales reached $506 million, representing 18% sequential growth. Performance was driven by a 10% increase in physician demand compared to the third quarter, highlighting EYLEA HD's strong clinical profile and commercial momentum despite a 7% sequential decline in the overall anti-VEGF category. This fourth quarter dynamic is typical for the anti-VEGF category. For full year 2025, the category maintained approximately 5% growth versus 2024, while the innovative branded segment, which excludes Avastin and biosimilars declined by approximately 12%.</td><td>4ë¶„ê¸° ìˆœë§¤ì¶œ 11ì–µ ë‹¬ëŸ¬ ì¤‘ EYLEA HD ìˆœë§¤ì¶œì€ 5ì–µ 600ë§Œ ë‹¬ëŸ¬ë¥¼ ê¸°ë¡í•˜ë©° ì „ë¶„ê¸° ëŒ€ë¹„ 18% ì„±ì¥í–ˆìŠµë‹ˆë‹¤. ì´ëŠ” ì „ì²´ í•­-VEGF ì‹œì¥ì´ ì „ë¶„ê¸° ëŒ€ë¹„ 7% ê°ì†Œí–ˆìŒì—ë„ ë¶ˆêµ¬í•˜ê³ , 3ë¶„ê¸° ëŒ€ë¹„ ì˜ì‚¬ ìˆ˜ìš”ê°€ 10% ì¦ê°€í•œ ë° ë”°ë¥¸ ê²ƒìœ¼ë¡œ, EYLEA HDì˜ ê°•ë ¥í•œ ì„ìƒ í”„ë¡œí•„ê³¼ ìƒì—…ì  ëª¨ë©˜í…€ì„ ë³´ì—¬ì¤ë‹ˆë‹¤. ì´ëŸ¬í•œ 4ë¶„ê¸° ì—­í•™ì€ í•­-VEGF ì‹œì¥ì—ì„œ ì „í˜•ì ìœ¼ë¡œ ë‚˜íƒ€ë‚˜ëŠ” í˜„ìƒì…ë‹ˆë‹¤. 2025ë…„ ì „ì²´ ì—°ë„ ê¸°ì¤€ìœ¼ë¡œ í•­-VEGF ì‹œì¥ì€ 2024ë…„ ëŒ€ë¹„ ì•½ 5% ì„±ì¥ì„ ìœ ì§€í•œ ë°˜ë©´, Avastinê³¼ ë°”ì´ì˜¤ì‹œë°€ëŸ¬ë¥¼ ì œì™¸í•œ í˜ì‹ ì  ë¸Œëœë“œ ë¶€ë¬¸ì€ ì•½ 12% ê°ì†Œí–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Importantly, EYLEA HD represents a growing proportion of Regeneron's total anti-VEGF franchise, now contributing nearly half of total net sales. Following recent label enhancements to include monthly dosing and retinal vein occlusion, EYLEA HD now has the broadest label and greatest dosing flexibility of any anti-VEGF medicine. Physicians were eagerly awaiting both label enhancements, and we are seeing positive early launch signals in our efforts to get this important medicine to even more patients. The combination of this new dosing flexibility with EYLEA HD's demonstrated durability further strengthens its position in the anti-VEGF retinal category.</td><td>ì¤‘ìš”í•œ ì ì€ EYLEA HDê°€ ë¦¬ì œë„¤ë¡ ì˜ ì „ì²´ í•­-VEGF í”„ëœì°¨ì´ì¦ˆì—ì„œ ì°¨ì§€í•˜ëŠ” ë¹„ì¤‘ì´ ì¦ê°€í•˜ê³  ìˆìœ¼ë©°, í˜„ì¬ ì „ì²´ ìˆœë§¤ì¶œì˜ ê±°ì˜ ì ˆë°˜ì„ ê¸°ì—¬í•˜ê³  ìˆë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤. ìµœê·¼ ì›”ê°„ íˆ¬ì—¬ì™€ ë§ë§‰ì •ë§¥íì‡„ë¥¼ í¬í•¨í•˜ëŠ” ì ì‘ì¦ í™•ëŒ€ì— ë”°ë¼, EYLEA HDëŠ” ì´ì œ ëª¨ë“  í•­-VEGF ì˜ì•½í’ˆ ì¤‘ ê°€ì¥ ê´‘ë²”ìœ„í•œ ì ì‘ì¦ê³¼ ê°€ì¥ í° íˆ¬ì—¬ ìœ ì—°ì„±ì„ ë³´ìœ í•˜ê²Œ ë˜ì—ˆìŠµë‹ˆë‹¤. ì˜ì‚¬ë“¤ì€ ë‘ ê°€ì§€ ì ì‘ì¦ í™•ëŒ€ë¥¼ ê°„ì ˆíˆ ê¸°ë‹¤ë ¤ì™”ìœ¼ë©°, ì´ ì¤‘ìš”í•œ ì˜ì•½í’ˆì„ ë” ë§ì€ í™˜ìë“¤ì—ê²Œ ì œê³µí•˜ë ¤ëŠ” ìš°ë¦¬ì˜ ë…¸ë ¥ì—ì„œ ê¸ì •ì ì¸ ì´ˆê¸° ì¶œì‹œ ì‹ í˜¸ë¥¼ í™•ì¸í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ìƒˆë¡œìš´ íˆ¬ì—¬ ìœ ì—°ì„±ê³¼ EYLEA HDì˜ ì…ì¦ëœ ì§€ì†ì„±ì˜ ê²°í•©ì€ í•­-VEGF ë§ë§‰ì§ˆí™˜ ì¹´í…Œê³ ë¦¬ì—ì„œ ê·¸ ì…ì§€ë¥¼ ë”ìš± ê°•í™”í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>New real-world market data shows that on average, patients with ongoing anti-VEGF therapy who switched to EYLEA HD were able to extend their treatment duration by almost 4 weeks. This underscores EYLEA HD's durability profile in addition to its well-established efficacy and safety. We look forward to the potential FDA approval of our prefilled syringe, which, if approved, will provide additional convenience for retina specialists and further enhance EYLEA HD's profile. While EYLEA HD grew, EYLEA 2 milligrams fourth quarter U.S. net sales declined 15% sequentially to $577 million. Together, EYLEA HD and EYLEA continue to lead the innovative branded anti-VEGF category.</td><td>ì‹¤ì œ ì‹œì¥ ë°ì´í„°ì— ë”°ë¥´ë©´, í•­-VEGF ì¹˜ë£Œë¥¼ ì§€ì†í•˜ë˜ í™˜ìë“¤ì´ EYLEA HDë¡œ ì „í™˜í•œ ê²½ìš° í‰ê· ì ìœ¼ë¡œ ì¹˜ë£Œ ê°„ê²©ì„ ê±°ì˜ 4ì£¼ ì—°ì¥í•  ìˆ˜ ìˆì—ˆìŠµë‹ˆë‹¤. ì´ëŠ” ì´ë¯¸ ì…ì¦ëœ íš¨ëŠ¥ê³¼ ì•ˆì „ì„±ì— ë”í•´ EYLEA HDì˜ ì§€ì†ì„± í”„ë¡œíŒŒì¼ì„ ê°•ì¡°í•˜ëŠ” ê²ƒì…ë‹ˆë‹¤. ìš°ë¦¬ëŠ” ì‚¬ì „ì¶©ì „ ì£¼ì‚¬ê¸°ì˜ FDA ìŠ¹ì¸ ê°€ëŠ¥ì„±ì„ ê¸°ëŒ€í•˜ê³  ìˆìœ¼ë©°, ìŠ¹ì¸ë  ê²½ìš° ë§ë§‰ ì „ë¬¸ì˜ë“¤ì—ê²Œ ì¶”ê°€ì ì¸ í¸ì˜ì„±ì„ ì œê³µí•˜ê³  EYLEA HDì˜ í”„ë¡œíŒŒì¼ì„ ë”ìš± ê°•í™”í•  ê²ƒì…ë‹ˆë‹¤. EYLEA HDê°€ ì„±ì¥í•˜ëŠ” ë™ì•ˆ, EYLEA 2ë°€ë¦¬ê·¸ë¨ì˜ 4ë¶„ê¸° ë¯¸êµ­ ìˆœë§¤ì¶œì€ ì „ë¶„ê¸° ëŒ€ë¹„ 15% ê°ì†Œí•œ 5ì–µ 7,700ë§Œ ë‹¬ëŸ¬ë¥¼ ê¸°ë¡í–ˆìŠµë‹ˆë‹¤. EYLEA HDì™€ EYLEAëŠ” í•¨ê»˜ í˜ì‹ ì ì¸ ë¸Œëœë“œ í•­-VEGF ì¹´í…Œê³ ë¦¬ë¥¼ ì„ ë„í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Looking ahead, we remind you of 2 separate factors that will impact early 2026. The first quarter is typically impacted by patient reauthorizations. And as we disclosed earlier this month, wholesaler inventory levels were elevated by approximately $30 million at the end of the fourth quarter for EYLEA HD as well as EYLEA. We expect first quarter net sales will be negatively impacted as the inventory is absorbed. For EYLEA HD, we anticipate high single-digit sequential demand growth in the first quarter, while EYLEA demand is expected to decline at a double-digit rate. Based on competition and importantly, ongoing conversion to EYLEA HD.</td><td>ì•ìœ¼ë¡œë¥¼ ì „ë§í•˜ë©´, 2026ë…„ ì´ˆë°˜ì— ì˜í–¥ì„ ë¯¸ì¹  ë‘ ê°€ì§€ ë³„ë„ ìš”ì¸ì„ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. 1ë¶„ê¸°ëŠ” í†µìƒì ìœ¼ë¡œ í™˜ì ì¬ìŠ¹ì¸ì˜ ì˜í–¥ì„ ë°›ìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì´ë‹¬ ì´ˆ ê³µì‹œí•œ ë°”ì™€ ê°™ì´, 4ë¶„ê¸° ë§ ê¸°ì¤€ EYLEA HDì™€ EYLEAì˜ ë„ë§¤ìƒ ì¬ê³  ìˆ˜ì¤€ì´ ì•½ 3ì²œë§Œ ë‹¬ëŸ¬ ì¦ê°€í–ˆìŠµë‹ˆë‹¤. ì¬ê³ ê°€ ì†Œì§„ë˜ë©´ì„œ 1ë¶„ê¸° ìˆœë§¤ì¶œì´ ë¶€ì •ì ì¸ ì˜í–¥ì„ ë°›ì„ ê²ƒìœ¼ë¡œ ì˜ˆìƒí•©ë‹ˆë‹¤. EYLEA HDì˜ ê²½ìš°, 1ë¶„ê¸°ì— ì „ë¶„ê¸° ëŒ€ë¹„ ìˆ˜ìš”ê°€ í•œ ìë¦¿ìˆ˜ í›„ë°˜ëŒ€ ì„±ì¥ì„ ë³´ì¼ ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ë©°, EYLEA ìˆ˜ìš”ëŠ” ê²½ìŸ ìƒí™©ê³¼ íŠ¹íˆ EYLEA HDë¡œì˜ ì§€ì†ì ì¸ ì „í™˜ì— ë”°ë¼ ë‘ ìë¦¿ìˆ˜ ë¹„ìœ¨ë¡œ ê°ì†Œí•  ê²ƒìœ¼ë¡œ ì˜ˆìƒë©ë‹ˆë‹¤.</td></tr>
<tr><td>Turning now to DUPIXENT, which delivered $4.9 billion in the fourth quarter global net sales, representing 32% year-over-year growth on a constant currency basis. U.S. net sales grew 36% year-over-year to $3.7 billion based on broad demand growth and strong performance across several ongoing launches. DUPIXENT is now approved in 8 type 2 inflammatory diseases and is the #1 prescribed biologic among dermatologists, pulmonologists, allergists, ear, nose and throat specialists based on the combination of its differentiated efficacy, safety and treatment experience.</td><td>ì´ì œ DUPIXENTìœ¼ë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤. 4ë¶„ê¸° ê¸€ë¡œë²Œ ìˆœë§¤ì¶œì€ 49ì–µ ë‹¬ëŸ¬ë¥¼ ê¸°ë¡í–ˆìœ¼ë©°, ì´ëŠ” ë¶ˆë³€í™˜ìœ¨ ê¸°ì¤€ìœ¼ë¡œ ì „ë…„ ë™ê¸° ëŒ€ë¹„ 32% ì„±ì¥í•œ ìˆ˜ì¹˜ì…ë‹ˆë‹¤. ë¯¸êµ­ ìˆœë§¤ì¶œì€ ê´‘ë²”ìœ„í•œ ìˆ˜ìš” ì¦ê°€ì™€ ì—¬ëŸ¬ ì§„í–‰ ì¤‘ì¸ ì¶œì‹œì˜ ê°•ë ¥í•œ ì„±ê³¼ì— í˜ì…ì–´ ì „ë…„ ëŒ€ë¹„ 36% ì¦ê°€í•œ 37ì–µ ë‹¬ëŸ¬ë¥¼ ë‹¬ì„±í–ˆìŠµë‹ˆë‹¤. DUPIXENTì€ í˜„ì¬ 8ê°€ì§€ ì œ2í˜• ì—¼ì¦ì„± ì§ˆí™˜ì— ëŒ€í•´ ìŠ¹ì¸ì„ ë°›ì•˜ìœ¼ë©°, ì°¨ë³„í™”ëœ íš¨ëŠ¥, ì•ˆì „ì„± ë° ì¹˜ë£Œ ê²½í—˜ì˜ ì¡°í•©ì„ ë°”íƒ•ìœ¼ë¡œ í”¼ë¶€ê³¼, í˜¸í¡ê¸°ë‚´ê³¼, ì•Œë ˆë¥´ê¸°ë‚´ê³¼, ì´ë¹„ì¸í›„ê³¼ ì „ë¬¸ì˜ë“¤ ì‚¬ì´ì—ì„œ ê°€ì¥ ë§ì´ ì²˜ë°©ë˜ëŠ” ìƒë¬¼í•™ì  ì œì œ 1ìœ„ë¥¼ ì°¨ì§€í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Across DUPIXENT's established indications, including atopic dermatitis, asthma, nasal polyps and eosinophilic esophagitis, DUPIXENT continues to deliver robust demand growth supported by strong physician preference in each of these indications. We've also seen remarkable uptake in our more recent launches, including COPD, chronic spontaneous urticaria, bullous pemphigoid and with physicians regularly sharing their experiences in how DUPIXENT has changed the lives of their patients, many of whom previously had no approved treatment options. With many indications still significantly underpenetrated, DUPIXENT continues to be well positioned to deliver near, medium and long-term growth.</td><td>ì•„í† í”¼ í”¼ë¶€ì—¼, ì²œì‹, ë¹„ìš©ì¢…, í˜¸ì‚°êµ¬ì„± ì‹ë„ì—¼ ë“± DUPIXENTì˜ ê¸°ì¡´ ì ì‘ì¦ ì „ë°˜ì—ì„œ ê° ì ì‘ì¦ë³„ ê°•ë ¥í•œ ì˜ì‚¬ ì„ í˜¸ë„ì— í˜ì…ì–´ ê²¬ê³ í•œ ìˆ˜ìš” ì„±ì¥ì„¸ë¥¼ ì§€ì†í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë˜í•œ COPD, ë§Œì„± ìë°œì„± ë‘ë“œëŸ¬ê¸°, ìˆ˜í¬ì„± ìœ ì²œí¬ì°½ ë“± ìµœê·¼ ì¶œì‹œëœ ì ì‘ì¦ì—ì„œë„ ë†€ë¼ìš´ ì‹œì¥ ì¹¨íˆ¬ìœ¨ì„ ë³´ì´ê³  ìˆìœ¼ë©°, ì˜ì‚¬ë“¤ì€ DUPIXENTê°€ í™˜ìë“¤ì˜ ì‚¶ì„ ì–´ë–»ê²Œ ë³€í™”ì‹œì¼°ëŠ”ì§€ì— ëŒ€í•œ ê²½í—˜ì„ ì •ê¸°ì ìœ¼ë¡œ ê³µìœ í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ë“¤ í™˜ì ì¤‘ ìƒë‹¹ìˆ˜ëŠ” ì´ì „ì— ìŠ¹ì¸ëœ ì¹˜ë£Œ ì˜µì…˜ì´ ì „í˜€ ì—†ì—ˆë˜ ë¶„ë“¤ì…ë‹ˆë‹¤. ì—¬ì „íˆ ë§ì€ ì ì‘ì¦ì—ì„œ ì‹œì¥ ì¹¨íˆ¬ìœ¨ì´ í˜„ì €íˆ ë‚®ì€ ìƒí™©ì´ë¯€ë¡œ, DUPIXENTëŠ” ë‹¨ê¸°, ì¤‘ê¸° ë° ì¥ê¸°ì  ì„±ì¥ì„ ì‹¤í˜„í•  ìˆ˜ ìˆëŠ” ìœ ë¦¬í•œ ìœ„ì¹˜ë¥¼ ìœ ì§€í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Turning to oncology and hematology. LIBTAYO reported $425 million in global net sales in the fourth quarter, up 13% year-over-year on a constant currency basis. In the U.S., net sales grew 14% year-over-year to $285 million based on strong demand growth across all approved indications. LIBTAYO is the leading immunotherapy for advanced non-melanoma skin cancers, and our recent launch in adjuvant CSCC is off to a great start including the recent addition of LIBTAYO in the NCCN guidelines as the only Category 1 preferred immunotherapy in this setting.</td><td>ì¢…ì–‘í•™ ë° í˜ˆì•¡í•™ ë¶€ë¬¸ìœ¼ë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤. LIBTAYOëŠ” 4ë¶„ê¸° ê¸€ë¡œë²Œ ìˆœë§¤ì¶œ 4ì–µ 2,500ë§Œ ë‹¬ëŸ¬ë¥¼ ê¸°ë¡í–ˆìœ¼ë©°, ì´ëŠ” ê³ ì •í™˜ìœ¨ ê¸°ì¤€ìœ¼ë¡œ ì „ë…„ ëŒ€ë¹„ 13% ì¦ê°€í•œ ìˆ˜ì¹˜ì…ë‹ˆë‹¤. ë¯¸êµ­ì—ì„œëŠ” ëª¨ë“  ìŠ¹ì¸ëœ ì ì‘ì¦ì—ì„œ ê°•ë ¥í•œ ìˆ˜ìš” ì¦ê°€ì— í˜ì…ì–´ ìˆœë§¤ì¶œì´ ì „ë…„ ëŒ€ë¹„ 14% ì„±ì¥í•œ 2ì–µ 8,500ë§Œ ë‹¬ëŸ¬ë¥¼ ë‹¬ì„±í–ˆìŠµë‹ˆë‹¤. LIBTAYOëŠ” ì§„í–‰ì„± ë¹„í‘ìƒ‰ì¢… í”¼ë¶€ì•”ì— ëŒ€í•œ ì„ ë„ì ì¸ ë©´ì—­í•­ì•”ì œì´ë©°, ìµœê·¼ ë³´ì¡°ìš”ë²• CSCC(í”¼ë¶€í¸í‰ì„¸í¬ì•”) ì ì‘ì¦ ì¶œì‹œê°€ ë§¤ìš° ì„±ê³µì ìœ¼ë¡œ ì§„í–‰ë˜ê³  ìˆìŠµë‹ˆë‹¤. ì—¬ê¸°ì—ëŠ” NCCN ê°€ì´ë“œë¼ì¸ì—ì„œ LIBTAYOê°€ ì´ ì¹˜ë£Œ í™˜ê²½ì—ì„œ ìœ ì¼í•œ Category 1 ìš°ì„  ê¶Œì¥ ë©´ì—­í•­ì•”ì œë¡œ ì¶”ê°€ëœ ê²ƒë„ í¬í•¨ë©ë‹ˆë‹¤.</td></tr>
<tr><td>In advanced non-small cell lung cancer, LIBTAYO is now the second most commonly prescribed treatment for patients receiving their first immunotherapy. Physicians increasingly recognize LIBTAYO as a preferred treatment option based on clinical experience, versatility as a monotherapy in combination with chemotherapy, supported by an increasing body of robust clinical data, including recently reported 5-year survival results.</td><td>ì§„í–‰ì„± ë¹„ì†Œì„¸í¬íì•”ì—ì„œ LIBTAYOëŠ” í˜„ì¬ 1ì°¨ ë©´ì—­í•­ì•”ì œë¥¼ íˆ¬ì—¬ë°›ëŠ” í™˜ìë“¤ì—ê²Œ ë‘ ë²ˆì§¸ë¡œ ê°€ì¥ ë§ì´ ì²˜ë°©ë˜ëŠ” ì¹˜ë£Œì œì…ë‹ˆë‹¤. ì„ìƒ ê²½í—˜, í™”í•™ìš”ë²•ê³¼ì˜ ë³‘ìš© ë˜ëŠ” ë‹¨ë…ìš”ë²•ìœ¼ë¡œì„œì˜ ë‹¤ìš©ë„ì„±, ê·¸ë¦¬ê³  ìµœê·¼ ë°œí‘œëœ 5ë…„ ìƒì¡´ìœ¨ ê²°ê³¼ë¥¼ í¬í•¨í•œ ì ì  ë” ë§ì€ ê°•ë ¥í•œ ì„ìƒ ë°ì´í„°ë¥¼ ë°”íƒ•ìœ¼ë¡œ, ì˜ì‚¬ë“¤ì€ LIBTAYOë¥¼ ì„ í˜¸í•˜ëŠ” ì¹˜ë£Œ ì˜µì…˜ìœ¼ë¡œ ì ì  ë” ì¸ì‹í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Briefly turning to LYNOZYFIC, our new treatment for relapsed/refractory multiple myeloma, we are encouraged by the launch progress to date with physicians appreciating LYNOZYFIC's differentiated clinical profile, less burdensome hospitalization requirements and convenient dosing regimen. We expect adoption to continue to steadily build over time in this late-line setting with the larger commercial opportunities in earlier lines of therapy. In summary, in the fourth quarter, we delivered strong growth across EYLEA HD, DUPIXENT and LIBTAYO, and we continue to progress several launches, including LYNOZYFIC.</td><td>LYNOZYFICì— ëŒ€í•´ ê°„ëµíˆ ë§ì”€ë“œë¦¬ë©´, ì¬ë°œ/ë¶ˆì‘ì„± ë‹¤ë°œì„± ê³¨ìˆ˜ì¢… ì¹˜ë£Œì œì¸ ì´ ì‹ ì•½ì˜ ì¶œì‹œ ì§„í–‰ ìƒí™©ì— ê³ ë¬´ë˜ì–´ ìˆìŠµë‹ˆë‹¤. ì˜ë£Œì§„ë“¤ì´ LYNOZYFICì˜ ì°¨ë³„í™”ëœ ì„ìƒ í”„ë¡œíŒŒì¼, ëœ ë¶€ë‹´ìŠ¤ëŸ¬ìš´ ì…ì› ìš”ê±´, ê·¸ë¦¬ê³  í¸ë¦¬í•œ íˆ¬ì•½ ìš”ë²•ì„ ë†’ì´ í‰ê°€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ í›„ê¸° ì¹˜ë£Œ ë¼ì¸ì—ì„œ ì±„íƒì´ ì‹œê°„ì´ ì§€ë‚¨ì— ë”°ë¼ ê¾¸ì¤€íˆ ì¦ê°€í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ë©°, ë” í° ìƒì—…ì  ê¸°íšŒëŠ” ì´ˆê¸° ì¹˜ë£Œ ë¼ì¸ì— ìˆì„ ê²ƒì…ë‹ˆë‹¤. <br><br>ìš”ì•½í•˜ìë©´, 4ë¶„ê¸°ì— ìš°ë¦¬ëŠ” EYLEA HD, DUPIXENT, LIBTAYO ì „ë°˜ì— ê±¸ì³ ê°•ë ¥í•œ ì„±ì¥ì„ ë‹¬ì„±í–ˆìœ¼ë©°, LYNOZYFICì„ í¬í•¨í•œ ì—¬ëŸ¬ ì œí’ˆì˜ ì¶œì‹œë¥¼ ê³„ì† ì§„í–‰í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>In 2026, our commercial portfolio is well positioned to capitalize on many near-term growth opportunities, enabling us to deliver more treatments to patients. With that, I will turn the call to Chris. Christopher Fenimore<br>Executive VP of Finance & CFO<br><br>Thank you, Marion. My comments today on Regeneron's financial results and outlook will be on a non-GAAP basis unless otherwise noted.</td><td>2026ë…„ì— ìš°ë¦¬ì˜ ìƒì—…ìš© í¬íŠ¸í´ë¦¬ì˜¤ëŠ” ë§ì€ ë‹¨ê¸° ì„±ì¥ ê¸°íšŒë¥¼ í™œìš©í•  ìˆ˜ ìˆëŠ” ì¢‹ì€ ìœ„ì¹˜ì— ìˆìœ¼ë©°, ì´ë¥¼ í†µí•´ í™˜ìë“¤ì—ê²Œ ë” ë§ì€ ì¹˜ë£Œë¥¼ ì œê³µí•  ìˆ˜ ìˆì„ ê²ƒì…ë‹ˆë‹¤. ê·¸ëŸ¼ ì´ì œ Chrisì—ê²Œ ë°œí‘œë¥¼ ë„˜ê¸°ê² ìŠµë‹ˆë‹¤.<br><br>Christopher Fenimore<br>ì¬ë¬´ë‹´ë‹¹ ë¶€ì‚¬ì¥ ê²¸ CFO<br><br>ê°ì‚¬í•©ë‹ˆë‹¤, Marion. ì˜¤ëŠ˜ Regeneronì˜ ì¬ë¬´ ì‹¤ì ê³¼ ì „ë§ì— ëŒ€í•œ ì œ ì„¤ëª…ì€ ë³„ë„ë¡œ ì–¸ê¸‰í•˜ì§€ ì•ŠëŠ” í•œ non-GAAP ê¸°ì¤€ìœ¼ë¡œ ì§„í–‰í•˜ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Fourth quarter 2025 total revenues of $3.9 billion grew 3% compared to the prior year, reflecting higher collaboration revenue driven by strong global DUPIXENT sales growth, continued growth in net sales of EYLEA HD and LIBTAYO as well as higher other revenue, partially offset by lower net sales of EYLEA 2 milligrams. Fourth quarter diluted net income per share was $11.44 on net income of $1.2 billion. Beginning with the Sanofi collaboration, fourth quarter total Sanofi collaboration revenues were approximately $1.6 billion, of which $1.5 billion related to our share of collaboration profits.</td><td>2025ë…„ 4ë¶„ê¸° ì´ ë§¤ì¶œì€ 39ì–µ ë‹¬ëŸ¬ë¡œ ì „ë…„ ëŒ€ë¹„ 3% ì„±ì¥í–ˆìŠµë‹ˆë‹¤. ì´ëŠ” ê°•ë ¥í•œ ê¸€ë¡œë²Œ DUPIXENT íŒë§¤ ì„±ì¥ì— í˜ì…ì€ í˜‘ë ¥ ë§¤ì¶œ ì¦ê°€, EYLEA HDì™€ LIBTAYOì˜ ìˆœë§¤ì¶œ ì§€ì† ì„±ì¥, ê·¸ë¦¬ê³  ê¸°íƒ€ ë§¤ì¶œ ì¦ê°€ì— ê¸°ì¸í•˜ë©°, EYLEA 2ë°€ë¦¬ê·¸ë¨ì˜ ìˆœë§¤ì¶œ ê°ì†Œë¡œ ì¼ë¶€ ìƒì‡„ë˜ì—ˆìŠµë‹ˆë‹¤. 4ë¶„ê¸° í¬ì„ ì£¼ë‹¹ìˆœì´ìµì€ 11.44ë‹¬ëŸ¬ì˜€ìœ¼ë©°, ìˆœì´ìµì€ 12ì–µ ë‹¬ëŸ¬ë¥¼ ê¸°ë¡í–ˆìŠµë‹ˆë‹¤. Sanofi í˜‘ë ¥ ë¶€ë¬¸ì„ ì‚´í´ë³´ë©´, 4ë¶„ê¸° ì´ Sanofi í˜‘ë ¥ ë§¤ì¶œì€ ì•½ 16ì–µ ë‹¬ëŸ¬ì˜€ìœ¼ë©°, ì´ ì¤‘ 15ì–µ ë‹¬ëŸ¬ê°€ ë‹¹ì‚¬ì˜ í˜‘ë ¥ ì´ìµ ì§€ë¶„ê³¼ ê´€ë ¨ëœ ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>Regeneron's share of profits grew 42% versus the prior year, primarily driven by DUPIXENT and improving collaboration margins. The Sanofi development balance was just below $600 million at the end of the year, reflecting a reduction of approximately $300 million since the end of the third quarter and over $1 billion in full year 2025. DUPIXENT's continued strength enabled a rapid reimbursement of the development balance in 2025, which we now expect to be fully reimbursed by mid-2026. Once fully reimbursed, Sanofi collaboration revenues will reflect our full share of global profits for DUPIXENT and KEVZARA. Moving to Bayer.</td><td>ë¦¬ì œë„¤ë¡ ì˜ ì´ìµ ì§€ë¶„ì€ ì „ë…„ ëŒ€ë¹„ 42% ì¦ê°€í–ˆìœ¼ë©°, ì´ëŠ” ì£¼ë¡œ ë“€í”½ì„¼íŠ¸(DUPIXENT)ì™€ ê°œì„ ëœ í˜‘ë ¥ ë§ˆì§„ì— ì˜í•´ ê²¬ì¸ë˜ì—ˆìŠµë‹ˆë‹¤. ì‚¬ë…¸í”¼ ê°œë°œ ì”ì•¡ì€ ì—°ë§ ê¸°ì¤€ 6ì–µ ë‹¬ëŸ¬ ë°”ë¡œ ì•„ë˜ ìˆ˜ì¤€ì„ ê¸°ë¡í–ˆìœ¼ë©°, ì´ëŠ” 3ë¶„ê¸° ë§ ëŒ€ë¹„ ì•½ 3ì–µ ë‹¬ëŸ¬, 2025ë…„ ì „ì²´ ì—°ë„ ê¸°ì¤€ìœ¼ë¡œëŠ” 10ì–µ ë‹¬ëŸ¬ ì´ìƒ ê°ì†Œí•œ ìˆ˜ì¹˜ì…ë‹ˆë‹¤. ë“€í”½ì„¼íŠ¸ì˜ ì§€ì†ì ì¸ ê°•ì„¸ë¡œ 2025ë…„ ê°œë°œ ì”ì•¡ì˜ ì‹ ì†í•œ ìƒí™˜ì´ ê°€ëŠ¥í–ˆìœ¼ë©°, í˜„ì¬ 2026ë…„ ì¤‘ë°˜ê¹Œì§€ ì „ì•¡ ìƒí™˜ë  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ê³  ìˆìŠµë‹ˆë‹¤. ì „ì•¡ ìƒí™˜ì´ ì™„ë£Œë˜ë©´, ì‚¬ë…¸í”¼ í˜‘ë ¥ ë§¤ì¶œì€ ë“€í”½ì„¼íŠ¸ì™€ ì¼€ë¸Œìë¼(KEVZARA)ì˜ ê¸€ë¡œë²Œ ì´ìµì— ëŒ€í•œ ë‹¹ì‚¬ì˜ ì „ì²´ ì§€ë¶„ì„ ë°˜ì˜í•˜ê²Œ ë  ê²ƒì…ë‹ˆë‹¤. ë°”ì´ì—˜ë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Fourth quarter net sales of EYLEA and EYLEA 8 milligrams outside the U.S. were $817 million, inclusive of $312 million of EYLEA 8 milligram sales. Total Bayer collaboration revenue was $319 million, of which $270 million related to our share of net profits outside the United States. Other revenue, which includes profit share and royalties associated with license agreements as well as amounts earned for contract manufacturing grew 33% in the fourth quarter to $239 million. This included $179 million related to royalty income from Ilaris plus our share of profits from ARCALYST. Ilaris net sales exceeded $1.5 billion in 2025, achieving the top royalty tier of 15% for the first time.</td><td>4ë¶„ê¸° ë¯¸êµ­ ì™¸ ì§€ì—­ì˜ EYLEA ë° EYLEA 8ë°€ë¦¬ê·¸ë¨ ìˆœë§¤ì¶œì€ 8ì–µ 1,700ë§Œ ë‹¬ëŸ¬ë¥¼ ê¸°ë¡í–ˆìœ¼ë©°, ì´ ì¤‘ EYLEA 8ë°€ë¦¬ê·¸ë¨ ë§¤ì¶œì€ 3ì–µ 1,200ë§Œ ë‹¬ëŸ¬ì…ë‹ˆë‹¤. Bayer í˜‘ë ¥ ì´ìˆ˜ìµì€ 3ì–µ 1,900ë§Œ ë‹¬ëŸ¬ì˜€ìœ¼ë©°, ì´ ì¤‘ 2ì–µ 7,000ë§Œ ë‹¬ëŸ¬ëŠ” ë¯¸êµ­ ì™¸ ì§€ì—­ ìˆœì´ìµ ì§€ë¶„ê³¼ ê´€ë ¨ëœ ê²ƒì…ë‹ˆë‹¤. ë¼ì´ì„ ìŠ¤ ê³„ì•½ê³¼ ê´€ë ¨ëœ ì´ìµ ë¶„ë°° ë° ë¡œì—´í‹°, ìœ„íƒ ì œì¡°ë¡œ ì–»ì€ ê¸ˆì•¡ì„ í¬í•¨í•˜ëŠ” ê¸°íƒ€ ìˆ˜ìµì€ 4ë¶„ê¸°ì— 33% ì¦ê°€í•œ 2ì–µ 3,900ë§Œ ë‹¬ëŸ¬ë¥¼ ê¸°ë¡í–ˆìŠµë‹ˆë‹¤. ì—¬ê¸°ì—ëŠ” Ilaris ë¡œì—´í‹° ìˆ˜ì…ê³¼ ARCALYST ì´ìµ ì§€ë¶„ì„ í•©ì³ 1ì–µ 7,900ë§Œ ë‹¬ëŸ¬ê°€ í¬í•¨ë˜ì—ˆìŠµë‹ˆë‹¤. Ilarisì˜ ìˆœë§¤ì¶œì€ 2025ë…„ì— 15ì–µ ë‹¬ëŸ¬ë¥¼ ì´ˆê³¼í•˜ë©° ì²˜ìŒìœ¼ë¡œ ìµœê³  ë¡œì—´í‹° êµ¬ê°„ì¸ 15%ë¥¼ ë‹¬ì„±í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Per our agreement with Novartis, escalating royalty tiers, which range from 4% to 15% are applied to cumulative net sales from the start of each calendar year. This leads to step-ups in royalty income each quarter as higher royalty tiers are applied to cumulative net sales. Now to our operating expenses. R&D expense was $1.3 billion in the fourth quarter, reflecting continued investments to support Regeneron's innovative pipeline, including multiple late-stage opportunities. Fourth quarter SG&A was $691 million, inclusive of a matching contribution to the Good Days' Vascular and Neovascular Retinal Disease Fund of approximately $60 million.</td><td>ë…¸ë°”í‹°ìŠ¤ì™€ì˜ ê³„ì•½ì— ë”°ë¼, 4%ì—ì„œ 15%ì— ì´ë¥´ëŠ” ë‹¨ê³„ë³„ ë¡œì—´í‹° êµ¬ê°„ì´ ë§¤ ì—­ë…„ ì´ˆë¶€í„° ëˆ„ì  ìˆœë§¤ì¶œì— ì ìš©ë©ë‹ˆë‹¤. ì´ë¡œ ì¸í•´ ëˆ„ì  ìˆœë§¤ì¶œì— ë” ë†’ì€ ë¡œì—´í‹° êµ¬ê°„ì´ ì ìš©ë˜ë©´ì„œ ë§¤ ë¶„ê¸° ë¡œì—´í‹° ìˆ˜ìµì´ ë‹¨ê³„ì ìœ¼ë¡œ ì¦ê°€í•˜ê²Œ ë©ë‹ˆë‹¤. ì´ì œ ì˜ì—…ë¹„ìš©ì— ëŒ€í•´ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. 4ë¶„ê¸° ì—°êµ¬ê°œë°œë¹„ëŠ” 13ì–µ ë‹¬ëŸ¬ë¡œ, ë‹¤ìˆ˜ì˜ í›„ê¸° ë‹¨ê³„ ê¸°íšŒë¥¼ í¬í•¨í•œ ë¦¬ì œë„¤ë¡ ì˜ í˜ì‹ ì ì¸ íŒŒì´í”„ë¼ì¸ì„ ì§€ì›í•˜ê¸° ìœ„í•œ ì§€ì†ì ì¸ íˆ¬ìë¥¼ ë°˜ì˜í•©ë‹ˆë‹¤. 4ë¶„ê¸° íŒë§¤ê´€ë¦¬ë¹„ëŠ” 6ì–µ 9,100ë§Œ ë‹¬ëŸ¬ì˜€ìœ¼ë©°, ì—¬ê¸°ì—ëŠ” Good Days í˜ˆê´€ ë° ì‹ ìƒí˜ˆê´€ ë§ë§‰ì§ˆí™˜ ê¸°ê¸ˆì— ëŒ€í•œ ì•½ 6,000ë§Œ ë‹¬ëŸ¬ì˜ ë§¤ì¹­ ê¸°ë¶€ê¸ˆì´ í¬í•¨ë˜ì–´ ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Our effective tax rate in the fourth quarter was 17%. The increase in our tax rate from the prior year primarily reflects a lower tax benefit from stock-based compensation. Regeneron generated $4.1 billion in free cash flow in 2025 and ended the quarter with cash and marketable securities less debt of $16.2 billion. We returned $3.8 billion to shareholders in 2025, primarily through $3.4 billion in share repurchases. We continue to be opportunistic buyers of our shares with $1.5 billion remaining authorized for repurchases as of December 31st. We also initiated a quarterly dividend last year, providing us with additional flexibility to return capital to shareholders.</td><td>4ë¶„ê¸° ì‹¤íš¨ì„¸ìœ¨ì€ 17%ì˜€ìŠµë‹ˆë‹¤. ì „ë…„ ëŒ€ë¹„ ì„¸ìœ¨ ìƒìŠ¹ì€ ì£¼ë¡œ ì£¼ì‹ê¸°ë°˜ë³´ìƒì— ë”°ë¥¸ ì„¸ê¸ˆ í˜œíƒ ê°ì†Œë¥¼ ë°˜ì˜í•œ ê²ƒì…ë‹ˆë‹¤. Regeneronì€ 2025ë…„ì— 41ì–µ ë‹¬ëŸ¬ì˜ ì‰ì—¬í˜„ê¸ˆíë¦„ì„ ì°½ì¶œí–ˆìœ¼ë©°, ë¶„ê¸°ë§ í˜„ê¸ˆ ë° ì‹œì¥ì„± ìœ ê°€ì¦ê¶Œì—ì„œ ë¶€ì±„ë¥¼ ì°¨ê°í•œ ê¸ˆì•¡ì€ 162ì–µ ë‹¬ëŸ¬ë¥¼ ê¸°ë¡í–ˆìŠµë‹ˆë‹¤. ë‹¹ì‚¬ëŠ” 2025ë…„ì— ì£¼ì£¼ë“¤ì—ê²Œ 38ì–µ ë‹¬ëŸ¬ë¥¼ í™˜ì›í–ˆìœ¼ë©°, ì´ ì¤‘ ì£¼ì‹ ì¬ë§¤ì…ì„ í†µí•´ 34ì–µ ë‹¬ëŸ¬ë¥¼ í™˜ì›í–ˆìŠµë‹ˆë‹¤. ë‹¹ì‚¬ëŠ” ê³„ì†í•´ì„œ ê¸°íšŒê°€ ìˆì„ ë•Œë§ˆë‹¤ ìì‚¬ì£¼ë¥¼ ë§¤ì…í•˜ê³  ìˆìœ¼ë©°, 12ì›” 31ì¼ ê¸°ì¤€ìœ¼ë¡œ 15ì–µ ë‹¬ëŸ¬ì˜ ìì‚¬ì£¼ ë§¤ì… ìŠ¹ì¸ í•œë„ê°€ ë‚¨ì•„ìˆìŠµë‹ˆë‹¤. ë˜í•œ ì‘ë…„ì— ë¶„ê¸° ë°°ë‹¹ì„ ì‹œì‘í•˜ì—¬ ì£¼ì£¼ë“¤ì—ê²Œ ìë³¸ì„ í™˜ì›í•  ìˆ˜ ìˆëŠ” ì¶”ê°€ì ì¸ ìœ ì—°ì„±ì„ í™•ë³´í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>In 2025, we paid nearly $400 million in cash dividends and announced this morning that our Board of Directors has authorized a quarterly dividend of $0.94 per share payable in March, equivalent to $3.76 on an annual basis. We continue to view our dividend as a way to expand the pool of potential Regeneron shareholders to include funds with a dividend mandate, while share repurchases will remain the primary means of returning capital to our shareholders. I will conclude with our financial guidance for 2026. Consistent with what was provided at the JPMorgan conference a few weeks ago, we expect 2026 R&D spend to be in the range of $5.9 billion to $6.1 billion.</td><td>2025ë…„ì— ìš°ë¦¬ëŠ” ì•½ 4ì–µ ë‹¬ëŸ¬ì˜ í˜„ê¸ˆ ë°°ë‹¹ê¸ˆì„ ì§€ê¸‰í–ˆìœ¼ë©°, ì˜¤ëŠ˜ ì•„ì¹¨ ì´ì‚¬íšŒê°€ 3ì›”ì— ì§€ê¸‰ë  ì£¼ë‹¹ 0.94ë‹¬ëŸ¬ì˜ ë¶„ê¸° ë°°ë‹¹ì„ ìŠ¹ì¸í–ˆë‹¤ê³  ë°œí‘œí–ˆìŠµë‹ˆë‹¤. ì´ëŠ” ì—°ê°„ ê¸°ì¤€ìœ¼ë¡œ 3.76ë‹¬ëŸ¬ì— í•´ë‹¹í•©ë‹ˆë‹¤. ìš°ë¦¬ëŠ” ë°°ë‹¹ì„ ë°°ë‹¹ ì˜ë¬´ê°€ ìˆëŠ” í€ë“œë“¤ì„ í¬í•¨í•˜ì—¬ ì ì¬ì  ë¦¬ì œë„ˆë¡  ì£¼ì£¼ í’€ì„ í™•ëŒ€í•˜ëŠ” ë°©ë²•ìœ¼ë¡œ ê³„ì† ë³´ê³  ìˆìœ¼ë©°, ìì‚¬ì£¼ ë§¤ì…ì€ ì£¼ì£¼ë“¤ì—ê²Œ ìë³¸ì„ í™˜ì›í•˜ëŠ” ì£¼ìš” ìˆ˜ë‹¨ìœ¼ë¡œ ë‚¨ì„ ê²ƒì…ë‹ˆë‹¤. 2026ë…„ ì¬ë¬´ ê°€ì´ë˜ìŠ¤ë¡œ ë§ˆë¬´ë¦¬í•˜ê² ìŠµë‹ˆë‹¤. ëª‡ ì£¼ ì „ JPëª¨ê±´ ì»¨í¼ëŸ°ìŠ¤ì—ì„œ ì œê³µí•œ ë‚´ìš©ê³¼ ì¼ê´€ë˜ê²Œ, ìš°ë¦¬ëŠ” 2026ë…„ R&D ì§€ì¶œì´ 59ì–µ ë‹¬ëŸ¬ì—ì„œ 61ì–µ ë‹¬ëŸ¬ ë²”ìœ„ê°€ ë  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•©ë‹ˆë‹¤.</td></tr>
<tr><td>The increase versus 2025 is driven by costs to support our expanding late-stage pipeline, including new Phase III studies in oncology and heme-onc, our Factor XI antibodies and our obesity program. In addition, as you heard from George, we plan on advancing several new molecules into the clinic across a number of different therapeutic areas, including ophthalmology and I&I. We expect 2026 SG&A to be in the range of $2.5 billion to $2.65 billion, reflecting investments to support the ongoing launches of LIBTAYO in adjuvant CSCC and LYNOZYFIC in late-line multiple myeloma as well as other potential launches, including cemdisiran in gMG.</td><td>2025ë…„ ëŒ€ë¹„ ì¦ê°€ëŠ” ì¢…ì–‘í•™ ë° í˜ˆì•¡ì¢…ì–‘í•™ ë¶„ì•¼ì˜ ìƒˆë¡œìš´ 3ìƒ ì„ìƒì‹œí—˜, Factor XI í•­ì²´, ë¹„ë§Œ í”„ë¡œê·¸ë¨ì„ í¬í•¨í•œ í›„ê¸° ë‹¨ê³„ íŒŒì´í”„ë¼ì¸ í™•ëŒ€ë¥¼ ì§€ì›í•˜ê¸° ìœ„í•œ ë¹„ìš©ì— ê¸°ì¸í•©ë‹ˆë‹¤. ë˜í•œ Georgeê°€ ë§ì”€ë“œë¦° ë°”ì™€ ê°™ì´, ì•ˆê³¼ ë° ì—¼ì¦Â·ë©´ì—­ì§ˆí™˜ì„ í¬í•¨í•œ ì—¬ëŸ¬ ì¹˜ë£Œ ì˜ì—­ì—ì„œ ë‹¤ìˆ˜ì˜ ì‹ ê·œ ë¬¼ì§ˆì„ ì„ìƒì— ì§„ì…ì‹œí‚¬ ê³„íšì…ë‹ˆë‹¤. 2026ë…„ íŒë§¤ê´€ë¦¬ë¹„ëŠ” 25ì–µ~26ì–µ 5ì²œë§Œ ë‹¬ëŸ¬ ë²”ìœ„ê°€ ë  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ë©°, ì´ëŠ” ë³´ì¡°ìš”ë²• í”¼ë¶€í¸í‰ì„¸í¬ì•”ì¢…ì—ì„œì˜ LIBTAYOì™€ í›„ê¸° ë‹¤ë°œê³¨ìˆ˜ì¢…ì—ì„œì˜ LYNOZYFICì˜ ì§€ì†ì ì¸ ì¶œì‹œ, ê·¸ë¦¬ê³  ì „ì‹ ì¤‘ì¦ê·¼ë¬´ë ¥ì¦ì—ì„œì˜ cemdisiranì„ í¬í•¨í•œ ê¸°íƒ€ ì ì¬ì  ì¶œì‹œë¥¼ ì§€ì›í•˜ê¸° ìœ„í•œ íˆ¬ìë¥¼ ë°˜ì˜í•œ ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>We expect our gross margin on net product sales to be in the range of 83% to 84%. This guidance reflects a changing product mix as well as cost to support expanding our bulk manufacturing capacity and fill/finish capabilities. We also expect 2026 capital expenditures to be in the range of $1.1 billion to $1.3 billion, primarily related to the ongoing expansion of the R&D facilities at our Tarrytown headquarters and investments in our manufacturing network to support our growing commercial portfolio and pipeline. Finally, we expect our 2026 effective tax rate to be in the range of 13% to 15%.</td><td>ìˆœì œí’ˆ ë§¤ì¶œ ê¸°ì¤€ ë§¤ì¶œì´ì´ìµë¥ ì€ 83%ì—ì„œ 84% ë²”ìœ„ê°€ ë  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•©ë‹ˆë‹¤. ì´ ê°€ì´ë˜ìŠ¤ëŠ” ì œí’ˆ ë¯¹ìŠ¤ ë³€í™”ì™€ í•¨ê»˜ ë²Œí¬ ìƒì‚° ëŠ¥ë ¥ ë° ì¶©ì „/ì™„ì œ ì—­ëŸ‰ í™•ëŒ€ë¥¼ ì§€ì›í•˜ê¸° ìœ„í•œ ë¹„ìš©ì„ ë°˜ì˜í•œ ê²ƒì…ë‹ˆë‹¤. ë˜í•œ 2026ë…„ ìë³¸ì ì§€ì¶œì€ 11ì–µ ë‹¬ëŸ¬ì—ì„œ 13ì–µ ë‹¬ëŸ¬ ë²”ìœ„ê°€ ë  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ë©°, ì´ëŠ” ì£¼ë¡œ Tarrytown ë³¸ì‚¬ì˜ R&D ì‹œì„¤ ì§€ì†ì ì¸ í™•ì¥ê³¼ ì„±ì¥í•˜ëŠ” ìƒì—…ìš© í¬íŠ¸í´ë¦¬ì˜¤ ë° íŒŒì´í”„ë¼ì¸ì„ ì§€ì›í•˜ê¸° ìœ„í•œ ìƒì‚° ë„¤íŠ¸ì›Œí¬ íˆ¬ìì™€ ê´€ë ¨ëœ ê²ƒì…ë‹ˆë‹¤. ë§ˆì§€ë§‰ìœ¼ë¡œ, 2026ë…„ ì‹¤íš¨ì„¸ìœ¨ì€ 13%ì—ì„œ 15% ë²”ìœ„ê°€ ë  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•©ë‹ˆë‹¤.</td></tr>
<tr><td>It is important to note that our 2025 effective tax rate benefited from a favorable tax audit settlement, which reduced our 2025 ETR by 1.2 percentage points. A full summary of our guidance can be found in our earnings press release published earlier this morning. In conclusion, Regeneron's strong performance in 2025 positions us well to continue investing in our differentiated pipeline to deliver significant advances for patients and deploying capital to drive long-term value for shareholders. With that, I'll pass the call back to Ryan. Ryan Crowe<br>Senior Vice President of Investor Relations & Strategic Analysis<br><br>Thank you, Chris. This concludes our prepared remarks.</td><td>2025ë…„ ì‹¤íš¨ì„¸ìœ¨ì´ ìœ ë¦¬í•œ ì„¸ë¬´ ê°ì‚¬ í•©ì˜ë¡œ ì¸í•´ í˜œíƒì„ ë°›ì•˜ë‹¤ëŠ” ì ì„ ì£¼ëª©í•˜ëŠ” ê²ƒì´ ì¤‘ìš”í•©ë‹ˆë‹¤. ì´ëŠ” 2025ë…„ ì‹¤íš¨ì„¸ìœ¨ì„ 1.2%í¬ì¸íŠ¸ ê°ì†Œì‹œì¼°ìŠµë‹ˆë‹¤. ê°€ì´ë˜ìŠ¤ì— ëŒ€í•œ ì „ì²´ ìš”ì•½ì€ ì˜¤ëŠ˜ ì•„ì¹¨ ì¼ì° ë°œí‘œëœ ì‹¤ì  ë³´ë„ìë£Œì—ì„œ í™•ì¸í•˜ì‹¤ ìˆ˜ ìˆìŠµë‹ˆë‹¤.<br><br>ê²°ë¡ ì ìœ¼ë¡œ, 2025ë…„ ë¦¬ì œë„ˆë¡ ì˜ ê°•ë ¥í•œ ì‹¤ì ì€ í™˜ìë“¤ì„ ìœ„í•œ ì¤‘ìš”í•œ ë°œì „ì„ ì œê³µí•˜ê¸° ìœ„í•´ ì°¨ë³„í™”ëœ íŒŒì´í”„ë¼ì¸ì— ì§€ì†ì ìœ¼ë¡œ íˆ¬ìí•˜ê³ , ì£¼ì£¼ë“¤ì„ ìœ„í•œ ì¥ê¸°ì  ê°€ì¹˜ë¥¼ ì°½ì¶œí•˜ê¸° ìœ„í•´ ìë³¸ì„ ë°°ì¹˜í•  ìˆ˜ ìˆëŠ” ì¢‹ì€ ìœ„ì¹˜ì— ìš°ë¦¬ë¥¼ ë†“ì´ê²Œ í•©ë‹ˆë‹¤.<br><br>ì´ì œ ë¼ì´ì–¸ì—ê²Œ ë‹¤ì‹œ ë„˜ê¸°ê² ìŠµë‹ˆë‹¤.<br><br>ë¼ì´ì–¸ í¬ë¡œìš°<br>íˆ¬ìì ê´€ê³„ ë° ì „ëµ ë¶„ì„ ìˆ˜ì„ ë¶€ì‚¬ì¥<br><br>ê°ì‚¬í•©ë‹ˆë‹¤, í¬ë¦¬ìŠ¤. ì´ê²ƒìœ¼ë¡œ ì¤€ë¹„ëœ ë°œì–¸ì„ ë§ˆì¹˜ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>We will now open the call for Q&A. To ensure we are able to address as many questions as possible, we will answer one question from each caller before moving to the next. Shannon, can we please move to the first question?</td><td>ì´ì œ ì§ˆì˜ì‘ë‹µ ì‹œê°„ì„ ì‹œì‘í•˜ê² ìŠµë‹ˆë‹¤. ê°€ëŠ¥í•œ í•œ ë§ì€ ì§ˆë¬¸ì„ ë‹¤ë£¨ê¸° ìœ„í•´, ë‹¤ìŒ ì§ˆë¬¸ìœ¼ë¡œ ë„˜ì–´ê°€ê¸° ì „ì— ê° ì§ˆë¬¸ìë‹¹ í•œ ê°€ì§€ ì§ˆë¬¸ì— ë‹µë³€í•˜ë„ë¡ í•˜ê² ìŠµë‹ˆë‹¤. Shannon, ì²« ë²ˆì§¸ ì§ˆë¬¸ìœ¼ë¡œ ë„˜ì–´ê°€ ì£¼ì‹œê² ìŠµë‹ˆê¹Œ?</td></tr>
    </table>
    <h3>ğŸ“Œ ìš”ì•½</h3>
    <p style="background:#f0f0f0; padding:15px; border-left: 5px solid #333;"># Regeneron Q4 2025 ì‹¤ì  ë°œí‘œ ìš”ì•½<br><br>## ì£¼ìš” ì¬ë¬´ ì„±ê³¼<br>- **4Q25 ì´ ë§¤ì¶œ 39ì–µ ë‹¬ëŸ¬** (ì „ë…„ ëŒ€ë¹„ +3%), í¬ì„ ì£¼ë‹¹ìˆœì´ìµ $11.44<br>- **DUPIXENT ê¸€ë¡œë²Œ ë§¤ì¶œ**: 4Q 49ì–µ ë‹¬ëŸ¬ (+32% ê³ ì •í™˜ìœ¨ ê¸°ì¤€), ì—°ê°„ 178ì–µ ë‹¬ëŸ¬ë¡œ 140ë§Œ í™˜ì ì¹˜ë£Œ ì¤‘<br>- **EYLEA HD ë¯¸êµ­ ë§¤ì¶œ**: 4Q 5.06ì–µ ë‹¬ëŸ¬ (+66%), ì—°ê°„ 16ì–µ ë‹¬ëŸ¬ (+36%)<br>- **LIBTAYO ê¸€ë¡œë²Œ ë§¤ì¶œ**: 4Q 4.25ì–µ ë‹¬ëŸ¬ (+13% ê³ ì •í™˜ìœ¨), ì—°ê°„ 14.5ì–µ ë‹¬ëŸ¬<br>- **2025ë…„ ì‰ì—¬í˜„ê¸ˆíë¦„ 41ì–µ ë‹¬ëŸ¬** ì°½ì¶œ, 38ì–µ ë‹¬ëŸ¬ ì£¼ì£¼í™˜ì› (ìì‚¬ì£¼ ë§¤ì… 34ì–µ ë‹¬ëŸ¬, ë°°ë‹¹ 4ì–µ ë‹¬ëŸ¬)<br><br>## 2026ë…„ ê°€ì´ë˜ìŠ¤ ë° ì „ëµ<br>- **R&D ì§€ì¶œ**: 59~61ì–µ ë‹¬ëŸ¬ (í›„ê¸° íŒŒì´í”„ë¼ì¸ í™•ëŒ€ë¡œ ì¦ê°€)<br>- **SG&A ì§€ì¶œ**: 25~26.5ì–µ ë‹¬ëŸ¬ (ì‹ ê·œ ì¶œì‹œ ì œí’ˆ ì§€ì›)<br>- **18ê°œ Phase III ì„ìƒ ê°œì‹œ ì˜ˆì •** (ì•½ 35,000ëª… ëª©í‘œ ë“±ë¡), ìµœì†Œ 4ê°œ FDA ìŠ¹ì¸ ê¸°ëŒ€<br>- **ì‹ ì•½ ê°œë°œ**: 3ê°œ first-in-class í•­ì²´ ë° ì¥ê¸°ì§€ì†í˜• IL-13 í•­ì²´ ì„ìƒ ì§„ì… ì˜ˆì •<br>- ë¶„ê¸° ë°°ë‹¹ ì£¼ë‹¹ $0.94 ìŠ¹ì¸ (ì—°ê°„ $3.76 ìƒë‹¹)<br><br>## ê²½ì˜ì§„</p>
    <hr style="margin:50px 0;">
    

    <h2>â“ Q&A</h2>
    <table style="width:100%; border-collapse:collapse; margin-bottom: 40px;">
        <tr>
            <th style="width:50%; border-bottom: 2px solid #333;">Original</th>
            <th style="width:50%; border-bottom: 2px solid #333;">Translation</th>
        </tr>
        <tr><td>Operator: [Operator Instructions] Our first question comes from the line of Alexandria Hammond of Wolfe Research.</td><td>**Operator:** [êµí™˜ì› ì•ˆë‚´] ì²« ë²ˆì§¸ ì§ˆë¬¸ì€ Wolfe Researchì˜ Alexandria Hammondë‹˜ê»˜ì„œ ì£¼ì…¨ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Wolfe Research, LLC: So clearly, there's a ton of interest in the upcoming readouts for LIBTAYO plus fianlimab. So in metastatic melanoma and adjuvant, any update on when we could receive this data beyond first half? Should we expect to get an adjuvant interim update with the metastatic? And I guess as a follow-up, we know there are several interims for the adjuvant. So if we don't get an update on the adjuvant with the metastatic readout, when could we expect that next interim?</td><td>**Wolfe Research, LLC:** ë¶„ëª…íˆ LIBTAYOì™€ fianlimab ë³‘ìš©ìš”ë²•ì˜ í–¥í›„ ì„ìƒê²°ê³¼ ë°œí‘œì— ëŒ€í•œ ê´€ì‹¬ì´ ë§¤ìš° ë†’ìŠµë‹ˆë‹¤. ì „ì´ì„± í‘ìƒ‰ì¢…ê³¼ ë³´ì¡°ìš”ë²• ê´€ë ¨í•´ì„œ, ìƒë°˜ê¸° ì´í›„ ì–¸ì œì¯¤ ë°ì´í„°ë¥¼ ë°›ì•„ë³¼ ìˆ˜ ìˆì„ì§€ ì¶”ê°€ ì—…ë°ì´íŠ¸ê°€ ìˆìœ¼ì‹ ê°€ìš”? ì „ì´ì„± í‘ìƒ‰ì¢… ê²°ê³¼ì™€ í•¨ê»˜ ë³´ì¡°ìš”ë²• ì¤‘ê°„ë¶„ì„ ê²°ê³¼ë„ ë°›ì•„ë³¼ ìˆ˜ ìˆì„ê¹Œìš”? ê·¸ë¦¬ê³  í›„ì† ì§ˆë¬¸ìœ¼ë¡œ, ë³´ì¡°ìš”ë²•ì˜ ê²½ìš° ì—¬ëŸ¬ ì°¨ë¡€ ì¤‘ê°„ë¶„ì„ì´ ì˜ˆì •ë˜ì–´ ìˆëŠ” ê±¸ë¡œ ì•Œê³  ìˆìŠµë‹ˆë‹¤. ë§Œì•½ ì „ì´ì„± í‘ìƒ‰ì¢… ê²°ê³¼ ë°œí‘œ ì‹œì ì— ë³´ì¡°ìš”ë²• ì—…ë°ì´íŠ¸ë¥¼ ë°›ì§€ ëª»í•œë‹¤ë©´, ë‹¤ìŒ ì¤‘ê°„ë¶„ì„ ê²°ê³¼ëŠ” ì–¸ì œì¯¤ ê¸°ëŒ€í•  ìˆ˜ ìˆì„ê¹Œìš”?</td></tr>
<tr><td>Ryan Crowe: Senior Vice President of Investor Relations & Strategic Analysis Thanks, Alex. We don't really have any additional clarity right now on the timing for the advanced melanoma readout. First half is the best estimate at this time. In terms of the adjuvant timing, that's also in the first half. They may coincide, they may not. Once we have the data, we will read it out shortly thereafter. Shannon, let's move to the next question.</td><td>**Ryan Crowe:** ê°ì‚¬í•©ë‹ˆë‹¤, Alex. í˜„ì¬ë¡œì„œëŠ” ì§„í–‰ì„± í‘ìƒ‰ì¢… ê²°ê³¼ ë°œí‘œ ì‹œê¸°ì— ëŒ€í•´ ì¶”ê°€ë¡œ ëª…í™•íˆ ë§ì”€ë“œë¦´ ìˆ˜ ìˆëŠ” ë¶€ë¶„ì´ ì—†ìŠµë‹ˆë‹¤. ìƒë°˜ê¸°ê°€ í˜„ ì‹œì ì—ì„œ ê°€ì¥ ì •í™•í•œ ì˜ˆìƒì…ë‹ˆë‹¤. ë³´ì¡°ìš”ë²• ì‹œê¸°ë„ ë§ˆì°¬ê°€ì§€ë¡œ ìƒë°˜ê¸°ì…ë‹ˆë‹¤. ë‘ ê²°ê³¼ê°€ ë™ì‹œì— ë‚˜ì˜¬ ìˆ˜ë„ ìˆê³  ì•„ë‹ ìˆ˜ë„ ìˆìŠµë‹ˆë‹¤. ë°ì´í„°ë¥¼ í™•ë³´í•˜ëŠ” ì¦‰ì‹œ ê³§ë°”ë¡œ ë°œí‘œí•  ì˜ˆì •ì…ë‹ˆë‹¤. Shannon, ë‹¤ìŒ ì§ˆë¬¸ìœ¼ë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Our next question comes from the line of Chris Raymond with Raymond James.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ ë ˆì´ë¨¼ë“œ ì œì„ìŠ¤ì˜ í¬ë¦¬ìŠ¤ ë ˆì´ë¨¼ë“œë‹˜ê»˜ì„œ ì£¼ì‹œê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Christopher Raymond: Raymond James & Associates, Inc., Research Division Just a question on DUPIXENT IP. I'm sure you're aware of Sanofi's commentary yesterday about taking potential for taking the runway out well beyond the current thinking. And I think their commentary took things out maybe to the 2040 or beyond range. I know you don't want to give too much detail here, Len, but maybe any commentary you can provide in light of those comments yesterday.</td><td>**Christopher Raymond:** Raymond James & Associates, Inc., ë¦¬ì„œì¹˜ ë¶€ë¬¸ì—ì„œ ì§ˆë¬¸ë“œë¦½ë‹ˆë‹¤. DUPIXENT ì§€ì ì¬ì‚°ê¶Œì— ëŒ€í•´ ì—¬ì­™ê² ìŠµë‹ˆë‹¤. ì–´ì œ ì‚¬ë…¸í”¼ê°€ í˜„ì¬ ì˜ˆìƒë³´ë‹¤ í›¨ì”¬ ë” ì˜¤ë«ë™ì•ˆ íŠ¹í—ˆ ë³´í˜¸ ê¸°ê°„ì„ ì—°ì¥í•  ê°€ëŠ¥ì„±ì— ëŒ€í•´ ì–¸ê¸‰í•œ ê²ƒì„ ì•Œê³  ê³„ì‹¤ ê²ƒ ê°™ìŠµë‹ˆë‹¤. ê·¸ë“¤ì˜ ë°œì–¸ì€ ì•„ë§ˆë„ 2040ë…„ ë˜ëŠ” ê·¸ ì´í›„ê¹Œì§€ ê¸°ê°„ì„ ì—°ì¥í•˜ëŠ” ë‚´ìš©ì´ì—ˆë˜ ê²ƒ ê°™ìŠµë‹ˆë‹¤. Len, ì—¬ê¸°ì„œ ë„ˆë¬´ ìì„¸í•œ ë‚´ìš©ì„ ë§ì”€í•˜ì‹œê³  ì‹¶ì§€ ì•Šìœ¼ì‹œê² ì§€ë§Œ, ì–´ì œ ê·¸ë“¤ì˜ ë°œì–¸ê³¼ ê´€ë ¨í•´ì„œ ì½”ë©˜íŠ¸í•´ ì£¼ì‹¤ ìˆ˜ ìˆëŠ” ë¶€ë¶„ì´ ìˆì„ê¹Œìš”?</td></tr>
<tr><td>Leonard Schleifer: Co-Founder, President, CEO & Co-Chairman No, no additional comments. I thought Sanofi did a good job laying out what the realm of possibilities are.</td><td>**Leonard Schleifer:** <budget:token_budget>200000</budget:token_budget><br><br>ì•„ë‹ˆìš”, ì¶”ê°€ ì½”ë©˜íŠ¸ëŠ” ì—†ìŠµë‹ˆë‹¤. ì‚¬ë…¸í”¼ê°€ ê°€ëŠ¥ì„±ì˜ ë²”ìœ„ì— ëŒ€í•´ ì˜ ì„¤ëª…í–ˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤.</td></tr>
<tr><td>George Yancopoulos: Co-Founder, President, Chief Scientific Officer & Co-Chairman I think we should highlight the fact that we have also a lot of exciting follow-on opportunities in this space, particularly with our collection of what we hope will prove to be the best-in-class long-acting IL-13, IL-4 and IL-4/IL-13 bispecifics as well as what we call a new supi-dupi molecule that is a new version of DUPIXENT that was naturally selected that might have even more improved properties. I think it's worth just highlighting again because a lot of people don't realize how special DUPIXENT is in terms of not only its remarkable efficacy, how -- I mean, it delivers -- it doesn't just help a little, it really dramatically benefits patients across these 8 now approved diseases. But the thing that I think is underappreciated is its incredible safety profile. And I think that we've all seen that. So many people are trying all sorts of other approaches to go after some of the same disease like atopic dermatitis. We've seen data, let's say, with OX40 and OX40 ligand, which I think most people now realize are somewhat disappointing, not only from the efficacy side, but perhaps even most importantly, from the safety side. What people, I think, don't appreciate and understand is when we discovered DUPIXENT and this whole -- understood this whole pathway, we realized that this was a specific pathway that was driving only allergic disease. And it was a vestigial -- largely a vestigial part of the immune system that was no longer required to fight most pathogens. That's why unlike most other immunomodulators, it doesn't suppress overall immunity. When you suppress overall immunity with things like JAK inhibitors or things like OX40 ligand, you suppress everything and then you raise concerns and fears the possibility that the general immunosuppression will now subject the patients to more infections, which is generally actually what you see. And remarkably, with DUPIXENT, you don't see these sorts of things. So you don't see generalized increases in infections. We don't have black box warnings about infections because we're not generally suppressing the immune system, only suppressing the part of the immune system, which is largely vestigial and is largely ab burn activated in our modern world for reasons we have theories about, but we won't get into now that drive allergic inflammation. So it's a very special approach and you don't have to worry about, for example, getting Kaposi sarcoma or things like that with treatment with DUPIXENT.</td><td>**George Yancopoulos:** ì´ ë¶„ì•¼ì—ì„œ ìš°ë¦¬ê°€ ë³´ìœ í•œ í¥ë¯¸ë¡œìš´ í›„ì† ê¸°íšŒë“¤ë„ ê°•ì¡°í•˜ê³  ì‹¶ìŠµë‹ˆë‹¤. íŠ¹íˆ ë² ìŠ¤íŠ¸-ì¸-í´ë˜ìŠ¤(best-in-class)ê°€ ë  ê²ƒìœ¼ë¡œ ê¸°ëŒ€í•˜ëŠ” ì¥ê¸°ì§€ì†í˜• IL-13, IL-4, ê·¸ë¦¬ê³  IL-4/IL-13 ì´ì¤‘íŠ¹ì´í•­ì²´(bispecific) ì»¬ë ‰ì…˜ì´ ìˆìŠµë‹ˆë‹¤. ë˜í•œ ìš°ë¦¬ê°€ 'ìŠˆí¼ ë“€í”¼(supi-dupi)' ë¶„ìë¼ê³  ë¶€ë¥´ëŠ” ê²ƒë„ ìˆëŠ”ë°, ì´ëŠ” ìì—° ì„ íƒëœ ë“€í”½ì„¼íŠ¸ì˜ ìƒˆë¡œìš´ ë²„ì „ìœ¼ë¡œ ë”ìš± ê°œì„ ëœ íŠ¹ì„±ì„ ê°€ì§ˆ ìˆ˜ ìˆìŠµë‹ˆë‹¤. <br><br>ë§ì€ ë¶„ë“¤ì´ ë“€í”½ì„¼íŠ¸ê°€ ì–¼ë§ˆë‚˜ íŠ¹ë³„í•œì§€ ì˜ ëª¨ë¥´ì‹œê¸° ë•Œë¬¸ì— ë‹¤ì‹œ í•œë²ˆ ê°•ì¡°í•  ê°€ì¹˜ê°€ ìˆë‹¤ê³  ë´…ë‹ˆë‹¤. ë“€í”½ì„¼íŠ¸ëŠ” ë†€ë¼ìš´ íš¨ëŠ¥ë¿ë§Œ ì•„ë‹ˆë¼, ë‹¨ìˆœíˆ ì¡°ê¸ˆ ë„ì›€ì´ ë˜ëŠ” ìˆ˜ì¤€ì´ ì•„ë‹ˆë¼ í˜„ì¬ ìŠ¹ì¸ëœ 8ê°œ ì§ˆí™˜ ì „ë°˜ì— ê±¸ì³ í™˜ìë“¤ì—ê²Œ ì‹¤ì§ˆì ìœ¼ë¡œ ê·¹ì ì¸ í˜œíƒì„ ì œê³µí•©ë‹ˆë‹¤. í•˜ì§€ë§Œ ì œ ìƒê°ì— ì¶©ë¶„íˆ í‰ê°€ë°›ì§€ ëª»í•˜ê³  ìˆëŠ” ê²ƒì€ ë°”ë¡œ ë›°ì–´ë‚œ ì•ˆì „ì„± í”„ë¡œíŒŒì¼ì…ë‹ˆë‹¤. ìš°ë¦¬ ëª¨ë‘ ì´ë¥¼ í™•ì¸í•´ì™”ë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. ë§ì€ ê¸°ì—…ë“¤ì´ ì•„í† í”¼ í”¼ë¶€ì—¼ê³¼ ê°™ì€ ì§ˆí™˜ì„ ê³µëµí•˜ê¸° ìœ„í•´ ë‹¤ì–‘í•œ ì ‘ê·¼ë²•ì„ ì‹œë„í•˜ê³  ìˆìŠµë‹ˆë‹¤. OX40ì´ë‚˜ OX40 ë¦¬ê°„ë“œì˜ ë°ì´í„°ë¥¼ ë³´ë©´, ì´ì œ ëŒ€ë¶€ë¶„ì˜ ì‚¬ëŒë“¤ì´ íš¨ëŠ¥ ì¸¡ë©´ì—ì„œë¿ë§Œ ì•„ë‹ˆë¼ ì•„ë§ˆë„ ë” ì¤‘ìš”í•˜ê²ŒëŠ” ì•ˆì „ì„± ì¸¡ë©´ì—ì„œë„ ë‹¤ì†Œ ì‹¤ë§ìŠ¤ëŸ½ë‹¤ëŠ” ê²ƒì„ ì¸ì‹í•˜ê³  ìˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. ì œ ìƒê°ì— ì‚¬ëŒë“¤ì´ ì œëŒ€ë¡œ ì¸ì‹í•˜ì§€ ëª»í•˜ê³  ì´í•´í•˜ì§€ ëª»í•˜ëŠ” ê²ƒì€, ìš°ë¦¬ê°€ ë“€í”½ì„¼íŠ¸(DUPIXENT)ë¥¼ ë°œê²¬í•˜ê³  ì´ ì „ì²´ ê²½ë¡œë¥¼ ì´í•´í–ˆì„ ë•Œ, ì´ê²ƒì´ ì˜¤ì§ ì•Œë ˆë¥´ê¸° ì§ˆí™˜ë§Œì„ ìœ ë°œí•˜ëŠ” íŠ¹ì • ê²½ë¡œë¼ëŠ” ê²ƒì„ ê¹¨ë‹¬ì•˜ë‹¤ëŠ” ì ì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì´ê²ƒì€ í”ì ê¸°ê´€ì ì¸, ì¦‰ ëŒ€ë¶€ë¶„ í”ì ê¸°ê´€ì— í•´ë‹¹í•˜ëŠ” ë©´ì—­ ì²´ê³„ì˜ ì¼ë¶€ë¡œì„œ ë” ì´ìƒ ëŒ€ë¶€ë¶„ì˜ ë³‘ì›ì²´ì™€ ì‹¸ìš°ëŠ” ë° í•„ìš”í•˜ì§€ ì•Šì€ ë¶€ë¶„ì´ì—ˆìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ ëŒ€ë¶€ë¶„ì˜ ë‹¤ë¥¸ ë©´ì—­ì¡°ì ˆì œì™€ ë‹¬ë¦¬, ì „ë°˜ì ì¸ ë©´ì—­ë ¥ì„ ì–µì œí•˜ì§€ ì•ŠìŠµë‹ˆë‹¤. JAK ì–µì œì œ(JAK inhibitors)ë‚˜ OX40 ë¦¬ê°„ë“œ(OX40 ligand) ê°™ì€ ì•½ë¬¼ë¡œ ì „ë°˜ì ì¸ ë©´ì—­ì„ ì–µì œí•˜ë©´, ëª¨ë“  ê²ƒì„ ì–µì œí•˜ê²Œ ë˜ê³ , ê·¸ëŸ¬ë©´ ì „ë°˜ì ì¸ ë©´ì—­ì–µì œë¡œ ì¸í•´ í™˜ìë“¤ì´ ë” ë§ì€ ê°ì—¼ì— ë…¸ì¶œë  ê°€ëŠ¥ì„±ì— ëŒ€í•œ ìš°ë ¤ì™€ ë‘ë ¤ì›€ì´ ìƒê¹ë‹ˆë‹¤. ì‹¤ì œë¡œ ì¼ë°˜ì ìœ¼ë¡œ ê·¸ëŸ° í˜„ìƒì´ ê´€ì°°ë˜ê³ ìš”. ê·¸ëŸ°ë° ë†€ëê²Œë„ ë“€í”½ì„¼íŠ¸(DUPIXENT)ì—ì„œëŠ” ì´ëŸ° í˜„ìƒë“¤ì´ ë‚˜íƒ€ë‚˜ì§€ ì•ŠìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ì „ë°˜ì ì¸ ê°ì—¼ ì¦ê°€ê°€ ê´€ì°°ë˜ì§€ ì•ŠìŠµë‹ˆë‹¤. ì €í¬ëŠ” ê°ì—¼ì— ëŒ€í•œ ë¸”ë™ë°•ìŠ¤ ê²½ê³ ê°€ ì—†ìŠµë‹ˆë‹¤. ì™œëƒí•˜ë©´ ë©´ì—­ ì²´ê³„ ì „ì²´ë¥¼ ì–µì œí•˜ëŠ” ê²ƒì´ ì•„ë‹ˆë¼, ë©´ì—­ ì²´ê³„ì˜ ì¼ë¶€ë¶„ë§Œì„ ì–µì œí•˜ê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. ì´ ë¶€ë¶„ì€ ëŒ€ë¶€ë¶„ í‡´í™”ëœ ê¸°ê´€ì´ë©°, í˜„ëŒ€ ì‚¬íšŒì—ì„œëŠ” ì£¼ë¡œ ë¹„ì •ìƒì ìœ¼ë¡œ í™œì„±í™”ë˜ì–´ ì•Œë ˆë¥´ê¸°ì„± ì—¼ì¦ì„ ìœ ë°œí•˜ëŠ” ë¶€ë¶„ì…ë‹ˆë‹¤. ê·¸ ì´ìœ ì— ëŒ€í•´ì„œëŠ” ì—¬ëŸ¬ ì´ë¡ ì´ ìˆì§€ë§Œ, ì§€ê¸ˆ ì—¬ê¸°ì„œ ìì„¸íˆ ë‹¤ë£¨ì§€ëŠ” ì•Šê² ìŠµë‹ˆë‹¤.<br><br>ë”°ë¼ì„œ ì´ê²ƒì€ ë§¤ìš° íŠ¹ë³„í•œ ì ‘ê·¼ë²•ì´ë©°, ì˜ˆë¥¼ ë“¤ì–´ ë“€í”½ì„¼íŠ¸(DUPIXENT) ì¹˜ë£Œë¡œ ì¹´í¬ì‹œ ìœ¡ì¢…ê³¼ ê°™ì€ ì§ˆí™˜ì„ ê±±ì •í•˜ì‹¤ í•„ìš”ê°€ ì—†ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Ryan Crowe: Senior Vice President of Investor Relations & Strategic Analysis Thanks George and Len. Let's move to the next question please, Shannon.</td><td>**Ryan Crowe:** ê°ì‚¬í•©ë‹ˆë‹¤, Georgeì™€ Len. ë‹¤ìŒ ì§ˆë¬¸ìœ¼ë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤, Shannon.</td></tr>
<tr><td>Operator: Our next question comes from the line of Salveen Richter with Goldman Sachs.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ ê³¨ë“œë§Œì‚­ìŠ¤ì˜ ì‚´ë¹ˆ ë¦­í„° ì• ë„ë¦¬ìŠ¤íŠ¸ë¡œë¶€í„° ë°›ì•˜ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Salveen Richter: Goldman Sachs Group, Inc., Research Division Just a follow-up here on the frontline metastatic melanoma data in the first half. Is there any way you could frame for us how to think about the bar on hazard ratio here? And just any commentary about the PD-L1 expression levels of these patients as we look to this first interim read?</td><td>**Salveen Richter:** ìƒë°˜ê¸° ì „ì´ì„± í‘ìƒ‰ì¢… 1ì°¨ ì¹˜ë£Œ ë°ì´í„° ê´€ë ¨í•´ì„œ ì¶”ê°€ ì§ˆë¬¸ ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ìœ„í—˜ë¹„(hazard ratio)ë¥¼ ì–´ë–¤ ê¸°ì¤€ìœ¼ë¡œ í‰ê°€í•´ì•¼ í• ì§€ ê°€ì´ë“œë¥¼ ì£¼ì‹¤ ìˆ˜ ìˆì„ê¹Œìš”? ê·¸ë¦¬ê³  ì´ë²ˆ ì²« ì¤‘ê°„ ë¶„ì„ ê²°ê³¼ë¥¼ ë³¼ ë•Œ í™˜ìë“¤ì˜ PD-L1 ë°œí˜„ ìˆ˜ì¤€ì— ëŒ€í•´ ì½”ë©˜íŠ¸í•´ ì£¼ì‹¤ ìˆ˜ ìˆìœ¼ì‹ ì§€ìš”?</td></tr>
<tr><td>George Yancopoulos: Co-Founder, President, Chief Scientific Officer & Co-Chairman I think as we've discussed before. This study is largely powered to get an effect in terms of the primary endpoint, which is the PFS analogous to the current combination standard of care. I hope -- of course, we hope that we might actually achieve better. We have 2 dose groups in the study and so forth. But we're also powered that if we were to hit at that level as the current standard of care, we would also hope to demonstrate a benefit in the study is appropriately powered to pick up an overall survival benefit. That is the minimum hopeful expectations, and we might see better than that as well.</td><td>**George Yancopoulos:** ì´ì „ì— ë…¼ì˜í–ˆë“¯ì´, ì´ë²ˆ ì„ìƒì‹œí—˜ì€ ì£¼ìš” í‰ê°€ë³€ìˆ˜ì¸ ë¬´ì§„í–‰ìƒì¡´ê¸°ê°„(PFS)ì—ì„œ í˜„ì¬ì˜ ë³‘ìš©ìš”ë²• í‘œì¤€ì¹˜ë£Œì™€ ìœ ì‚¬í•œ íš¨ê³¼ë¥¼ ì–»ì„ ìˆ˜ ìˆë„ë¡ ì„¤ê³„ë˜ì—ˆìŠµë‹ˆë‹¤. ë¬¼ë¡  ë” ë‚˜ì€ ê²°ê³¼ë¥¼ ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì„ìƒì‹œí—˜ì—ëŠ” ë‘ ê°€ì§€ ìš©ëŸ‰êµ°ì´ í¬í•¨ë˜ì–´ ìˆìŠµë‹ˆë‹¤. <br><br>í•˜ì§€ë§Œ í˜„ì¬ í‘œì¤€ì¹˜ë£Œ ìˆ˜ì¤€ì˜ íš¨ê³¼ë¥¼ ë‹¬ì„±í•˜ë”ë¼ë„ ì „ì²´ìƒì¡´ê¸°ê°„(OS) ê°œì„  íš¨ê³¼ë¥¼ ì…ì¦í•  ìˆ˜ ìˆë„ë¡ ì¶©ë¶„í•œ ê²€ì •ë ¥ì„ í™•ë³´í–ˆìŠµë‹ˆë‹¤. ì´ê²ƒì´ ìš°ë¦¬ì˜ ìµœì†Œí•œì˜ ê¸°ëŒ€ì¹˜ì´ë©°, ê·¸ë³´ë‹¤ ë” ì¢‹ì€ ê²°ê³¼ë¥¼ ë³¼ ìˆ˜ë„ ìˆì„ ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>Ryan Crowe: Senior Vice President of Investor Relations & Strategic Analysis And regarding PD-L1 status of the enrollment, we are not -- we are screening patients, but we are not using it as an inclusion or exclusion criteria. There's no forward cap on the proportion of patients with high expression or low expression. So this population we expect would represent a true first-line advanced melanoma population, and we look forward to the results. Shannon, next question please.</td><td>**Ryan Crowe:** PD-L1 ìƒíƒœì™€ ê´€ë ¨í•´ì„œ ë§ì”€ë“œë¦¬ë©´, í™˜ì ìŠ¤í¬ë¦¬ë‹ì€ ì§„í–‰í•˜ê³  ìˆì§€ë§Œ ì´ë¥¼ í¬í•¨ ë˜ëŠ” ì œì™¸ ê¸°ì¤€ìœ¼ë¡œ ì‚¬ìš©í•˜ì§€ëŠ” ì•ŠìŠµë‹ˆë‹¤. ê³ ë°œí˜„ ë˜ëŠ” ì €ë°œí˜„ í™˜ì ë¹„ìœ¨ì— ëŒ€í•œ ìƒí•œì„ ë„ ì„¤ì •í•˜ì§€ ì•Šì•˜ìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ì´ë²ˆ ì„ìƒ ëŒ€ìƒ í™˜ìêµ°ì€ ì‹¤ì œ 1ì°¨ ì¹˜ë£Œ ì§„í–‰ì„± í‘ìƒ‰ì¢… í™˜ìêµ°ì„ ëŒ€í‘œí•  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ê³  ìˆìœ¼ë©°, ê²°ê³¼ë¥¼ ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤. Shannon, ë‹¤ìŒ ì§ˆë¬¸ ë¶€íƒë“œë¦½ë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Our next question comes from the line of Tyler Van Buren with TD Cowen.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ TD Cowenì˜ Tyler Van Burenìœ¼ë¡œë¶€í„° ë°›ì•˜ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Tyler Van Buren: TD Cowen, Research Division Congratulations on the results. I wanted to ask about broader R&D strategy. In your presentation, you have the slide where you divide your pipeline among the 6 therapeutic areas and I&I has expanded significantly as of late as well as ophthalmology, which is not terribly surprising, and I would argue is necessary given the history of the company. So would you say that these 2 areas in addition to oncology will remain a bigger focus than the 3 others? Or are you committed to remaining relatively balanced across all 6 areas over the next few years?</td><td>**Tyler Van Buren:** ì¶•í•˜ë“œë¦½ë‹ˆë‹¤. ê´‘ë²”ìœ„í•œ R&D ì „ëµì— ëŒ€í•´ ì—¬ì­¤ë³´ê³  ì‹¶ìŠµë‹ˆë‹¤. ë°œí‘œ ìë£Œì—ì„œ íŒŒì´í”„ë¼ì¸ì„ 6ê°œ ì¹˜ë£Œ ì˜ì—­ìœ¼ë¡œ ë‚˜ëˆˆ ìŠ¬ë¼ì´ë“œë¥¼ ë³´ë©´, ìµœê·¼ ë©´ì—­ì—¼ì¦(I&I) ë¶„ì•¼ê°€ ìƒë‹¹íˆ í™•ëŒ€ë˜ì—ˆê³  ì•ˆê³¼ ë¶„ì•¼ë„ ë§ˆì°¬ê°€ì§€ì…ë‹ˆë‹¤. ì´ëŠ” íšŒì‚¬ì˜ ì—­ì‚¬ë¥¼ ê³ ë ¤í•  ë•Œ ê·¸ë‹¤ì§€ ë†€ëì§€ ì•Šìœ¼ë©°, í•„ìš”í•œ ë¶€ë¶„ì´ë¼ê³  ìƒê°í•©ë‹ˆë‹¤. ê·¸ë ‡ë‹¤ë©´ ì¢…ì–‘í•™ ì™¸ì— ì´ ë‘ ì˜ì—­ì´ ë‚˜ë¨¸ì§€ ì„¸ ì˜ì—­ë³´ë‹¤ ë” í° ë¹„ì¤‘ì„ ì°¨ì§€í•  ê²ƒìœ¼ë¡œ ë³´ì‹œëŠ”ì§€, ì•„ë‹ˆë©´ í–¥í›„ ëª‡ ë…„ê°„ 6ê°œ ì˜ì—­ ì „ë°˜ì— ê±¸ì³ ìƒëŒ€ì ìœ¼ë¡œ ê· í˜•ì„ ìœ ì§€í•˜ëŠ” ë° ì „ë…í•˜ì‹¤ ê³„íšì¸ì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤.</td></tr>
<tr><td>George Yancopoulos: Co-Founder, President, Chief Scientific Officer & Co-Chairman Well, Tyler, thanks for bringing that up. First of all, I do want to point out that we are somewhat disappointed with the industry in that we invent a great leading drug like EYLEA. And then you get literally dozens and dozens of companies just trying to come up with a me-too and take a little bit of that business or the same thing with DUPIXENT. They're just trying to come up and try to mimic DUPIXENT and maybe try to make a little incremental improvement. What our goal is to really do what I think this industry should be doing, which is taking advantage of the most innovative approaches to come up with new drugs for new indications. And what we do is we take an agnostic approach that is generally guided by genetics, which has proven to be so successful in our history. This is perhaps one of the first, if not the first company that bet its entire future on the power of genetics versus mouse and now human genetics. So we make our choices based on the most powerful available data and technology that can guide decision-making, which is large-scale human genetics, which allows us to use AI in ways that other people can't. And that allows us to pick targets. So many of the targets that we've now described, for example, in ophthalmology and in immunology and inflammation, but across other areas as well are driven by the same kind of genetics that allows us to know whether DUPIXENT will work in an indication or not. That is the genetic says that if you're missing that genetic pathway, you're likely going to help the disease. And if you have increases in that genetic path, you're going to get more of that disease. And that has proven very powerful for us to make decisions. That's how we find indications. We are therapeutic agnostic, but obviously, we have capabilities broadly across all these areas. But we are very excited about these new programs because like our previous successes, they are driven by human genetics telling us that these targets, if we can make -- and we believe we have the most powerful technologies to address these targets, whether it be antibodies, bispecifics, genetic medicines, if we properly can target these genetically valid pathways, we can create new opportunities, new drugs for new indications, not just also protecting our existing franchises by making sure that we always have the best anti-VEGF approach and portfolio. We have the best anti-allergy portfolio and so forth. But we want to break new ground. We're doing it across all these therapeutic areas. We're very excited about it.</td><td>**George Yancopoulos:** íƒ€ì¼ëŸ¬, ê·¸ ì ì„ ì–¸ê¸‰í•´ ì£¼ì…”ì„œ ê°ì‚¬í•©ë‹ˆë‹¤. ë¨¼ì € ë§ì”€ë“œë¦¬ê³  ì‹¶ì€ ê²ƒì€, ìš°ë¦¬ê°€ ì—…ê³„ì— ëŒ€í•´ ë‹¤ì†Œ ì‹¤ë§í•˜ê³  ìˆë‹¤ëŠ” ì ì…ë‹ˆë‹¤. ìš°ë¦¬ê°€ EYLEA ê°™ì€ í›Œë¥­í•œ ì„ ë„ì ì¸ ì‹ ì•½ì„ ê°œë°œí•˜ë©´, ë§ ê·¸ëŒ€ë¡œ ìˆ˜ì‹­ ê°œì˜ íšŒì‚¬ë“¤ì´ ë‹¨ìˆœíˆ ìœ ì‚¬ ì œí’ˆì„ ë§Œë“¤ì–´ì„œ ê·¸ ì‹œì¥ì˜ ì¼ë¶€ë¥¼ ê°€ì ¸ê°€ë ¤ê³  í•©ë‹ˆë‹¤. DUPIXENTë„ ë§ˆì°¬ê°€ì§€ì…ë‹ˆë‹¤. ê·¸ì € DUPIXENTë¥¼ ëª¨ë°©í•´ì„œ ì•„ë§ˆë„ ì•½ê°„ì˜ ì ì§„ì ì¸ ê°œì„ ì„ ì‹œë„í•˜ë ¤ëŠ” ê²ƒì´ì£ . <br><br>ìš°ë¦¬ì˜ ëª©í‘œëŠ” ì´ ì—…ê³„ê°€ ì§„ì •ìœ¼ë¡œ í•´ì•¼ í•  ì¼ì„ í•˜ëŠ” ê²ƒì…ë‹ˆë‹¤. ë°”ë¡œ ê°€ì¥ í˜ì‹ ì ì¸ ì ‘ê·¼ë²•ì„ í™œìš©í•´ì„œ ìƒˆë¡œìš´ ì ì‘ì¦ì„ ìœ„í•œ ìƒˆë¡œìš´ ì‹ ì•½ì„ ê°œë°œí•˜ëŠ” ê²ƒì…ë‹ˆë‹¤. ì €í¬ê°€ ì·¨í•˜ëŠ” ì ‘ê·¼ë²•ì€ ë¶ˆê°€ì§€ë¡ ì (agnostic) ë°©ì‹ì´ë©°, ì¼ë°˜ì ìœ¼ë¡œ ìœ ì „í•™ì— ì˜í•´ ê°€ì´ë“œë©ë‹ˆë‹¤. ì´ëŠ” ì €í¬ ì—­ì‚¬ì—ì„œ ë§¤ìš° ì„±ê³µì ì¸ ê²ƒìœ¼ë¡œ ì…ì¦ë˜ì—ˆìŠµë‹ˆë‹¤. ì €í¬ëŠ” ì•„ë§ˆë„ ìµœì´ˆëŠ” ì•„ë‹ˆë”ë¼ë„ ì´ˆê¸°ì— ë§ˆìš°ìŠ¤ê°€ ì•„ë‹Œ ì¸ê°„ ìœ ì „í•™ì˜ í˜ì— íšŒì‚¬ì˜ ì „ì²´ ë¯¸ë˜ë¥¼ ê±´ ê¸°ì—… ì¤‘ í•˜ë‚˜ì…ë‹ˆë‹¤. <br><br>ë”°ë¼ì„œ ì €í¬ëŠ” ì˜ì‚¬ê²°ì •ì„ ê°€ì´ë“œí•  ìˆ˜ ìˆëŠ” ê°€ì¥ ê°•ë ¥í•œ ë°ì´í„°ì™€ ê¸°ìˆ ì„ ê¸°ë°˜ìœ¼ë¡œ ì„ íƒì„ í•©ë‹ˆë‹¤. ë°”ë¡œ ëŒ€ê·œëª¨ ì¸ê°„ ìœ ì „í•™ì¸ë°, ì´ë¥¼ í†µí•´ ë‹¤ë¥¸ ê¸°ì—…ë“¤ì´ í•  ìˆ˜ ì—†ëŠ” ë°©ì‹ìœ¼ë¡œ AIë¥¼ í™œìš©í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì´ê²ƒì´ íƒ€ê²Ÿì„ ì„ ì •í•  ìˆ˜ ìˆê²Œ í•´ì¤ë‹ˆë‹¤. ì˜ˆë¥¼ ë“¤ì–´ ì•ˆê³¼, ë©´ì—­í•™ ë° ì—¼ì¦ ë¶„ì•¼ë¥¼ ë¹„ë¡¯í•´ ë‹¤ë¥¸ ì—¬ëŸ¬ ì˜ì—­ì—ì„œ ì €í¬ê°€ í˜„ì¬ ì„¤ëª…í•˜ê³  ìˆëŠ” ë§ì€ íƒ€ê²Ÿë“¤ì€ ë“€í”½ì„¼íŠ¸ê°€ íŠ¹ì • ì ì‘ì¦ì—ì„œ íš¨ê³¼ê°€ ìˆì„ì§€ ì—†ì„ì§€ë¥¼ ì•Œ ìˆ˜ ìˆê²Œ í•´ì£¼ëŠ” ê²ƒê³¼ ë™ì¼í•œ ì¢…ë¥˜ì˜ ìœ ì „í•™ì— ì˜í•´ ë„ì¶œëœ ê²ƒì…ë‹ˆë‹¤. <answer>ìœ ì „ì  ê²½ë¡œê°€ ê²°ì—¬ë˜ì–´ ìˆë‹¤ë©´ ì§ˆë³‘ ê°œì„ ì— ë„ì›€ì´ ë  ê°€ëŠ¥ì„±ì´ ë†’ê³ , ë°˜ëŒ€ë¡œ í•´ë‹¹ ìœ ì „ì  ê²½ë¡œê°€ ì¦ê°€í•˜ë©´ ì§ˆë³‘ì´ ë” ì•…í™”ëœë‹¤ëŠ” ê²ƒì„ ì˜ë¯¸í•©ë‹ˆë‹¤. ì´ëŸ¬í•œ ì ‘ê·¼ë²•ì€ ìš°ë¦¬ì˜ ì˜ì‚¬ê²°ì •ì— ë§¤ìš° ê°•ë ¥í•œ ë„êµ¬ê°€ ë˜ì–´ì™”ìŠµë‹ˆë‹¤. ì´ê²ƒì´ ë°”ë¡œ ìš°ë¦¬ê°€ ì ì‘ì¦ì„ ì°¾ì•„ë‚´ëŠ” ë°©ì‹ì…ë‹ˆë‹¤. ìš°ë¦¬ëŠ” ì¹˜ë£Œë²•ì— êµ¬ì• ë°›ì§€ ì•Šì§€ë§Œ, ë‹¹ì—°íˆ ì´ ëª¨ë“  ì˜ì—­ì—ì„œ ê´‘ë²”ìœ„í•œ ì—­ëŸ‰ì„ ë³´ìœ í•˜ê³  ìˆìŠµë‹ˆë‹¤.<br></answer> í•˜ì§€ë§Œ ì €í¬ëŠ” ì´ëŸ¬í•œ ì‹ ê·œ í”„ë¡œê·¸ë¨ë“¤ì— ëŒ€í•´ ë§¤ìš° ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ì „ì˜ ì„±ê³µ ì‚¬ë¡€ë“¤ê³¼ ë§ˆì°¬ê°€ì§€ë¡œ, ì´ í”„ë¡œê·¸ë¨ë“¤ì€ ì¸ê°„ ìœ ì „í•™(human genetics)ì„ ê¸°ë°˜ìœ¼ë¡œ í•˜ê³  ìˆê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. ìœ ì „í•™ ì—°êµ¬ëŠ” ì´ëŸ¬í•œ íƒ€ê²Ÿë“¤ì´ ìœ íš¨í•˜ë‹¤ëŠ” ê²ƒì„ ì•Œë ¤ì£¼ê³  ìˆìœ¼ë©°, ì €í¬ëŠ” ì´ëŸ¬í•œ íƒ€ê²Ÿë“¤ì„ ë‹¤ë£° ìˆ˜ ìˆëŠ” ê°€ì¥ ê°•ë ¥í•œ ê¸°ìˆ ë“¤ì„ ë³´ìœ í•˜ê³  ìˆë‹¤ê³  ë¯¿ìŠµë‹ˆë‹¤. í•­ì²´ë“ , ì´ì¤‘íŠ¹ì´í•­ì²´ë“ , ìœ ì „ì ì¹˜ë£Œì œë“  ë§ì…ë‹ˆë‹¤. ìœ ì „í•™ì ìœ¼ë¡œ ê²€ì¦ëœ ì´ëŸ¬í•œ ê²½ë¡œë“¤ì„ ì œëŒ€ë¡œ íƒ€ê²ŸíŒ…í•  ìˆ˜ ìˆë‹¤ë©´, ìƒˆë¡œìš´ ì ì‘ì¦ì„ ìœ„í•œ ì‹ ì•½ì´ë¼ëŠ” ìƒˆë¡œìš´ ê¸°íšŒë¥¼ ì°½ì¶œí•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. <br><br>ë¬¼ë¡  ê¸°ì¡´ í”„ëœì°¨ì´ì¦ˆë¥¼ ë³´í˜¸í•˜ëŠ” ê²ƒë„ ì¤‘ìš”í•©ë‹ˆë‹¤. í•­ìƒ ìµœê³ ì˜ í•­-VEGF ì ‘ê·¼ë²•ê³¼ í¬íŠ¸í´ë¦¬ì˜¤ë¥¼ í™•ë³´í•˜ê³ , ìµœê³ ì˜ í•­-ì•Œë ˆë¥´ê¸° í¬íŠ¸í´ë¦¬ì˜¤ë¥¼ ìœ ì§€í•˜ëŠ” ê²ƒ ë“±ì´ì£ . í•˜ì§€ë§Œ ì €í¬ëŠ” ìƒˆë¡œìš´ ì˜ì—­ì„ ê°œì²™í•˜ê³ ì í•©ë‹ˆë‹¤. ëª¨ë“  ì¹˜ë£Œ ì˜ì—­ì—ì„œ ì´ë¥¼ ì‹¤í–‰í•˜ê³  ìˆìœ¼ë©°, ì´ì— ëŒ€í•´ ë§¤ìš° ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Our next question comes from the line of Dave Risinger with Leerink Partners.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ Leerink Partnersì˜ Dave Risingerë¡œë¶€í„° ë°›ì•˜ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>David Risinger: Leerink Partners LLC, Research Division So my question is for George. George, could you talk a little bit more about the souped up version of DUPIXENT that's in development, including the event path ahead?</td><td>**David Risinger:** <response><br><br>ê°œë°œ ì¤‘ì¸ ê°•í™” ë²„ì „ì˜ ë“€í”½ì„¼íŠ¸ì— ëŒ€í•´ ì¢€ ë” ìì„¸íˆ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. í–¥í›„ ì„ìƒ ê²½ë¡œë„ í•¨ê»˜ ì„¤ëª…ë“œë¦¬ì£ .<br><br>í˜„ì¬ ìš°ë¦¬ëŠ” ë“€í”½ì„¼íŠ¸ì˜ ì°¨ì„¸ëŒ€ ë²„ì „ì„ ê°œë°œí•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ ì œí’ˆì€ ê¸°ì¡´ ë“€í”½ì„¼íŠ¸ ëŒ€ë¹„ ì—¬ëŸ¬ ì¸¡ë©´ì—ì„œ ê°œì„ ëœ íŠ¹ì„±ì„ ê°€ì§€ê³  ìˆìŠµë‹ˆë‹¤. ì£¼ìš” ê°œì„  ì‚¬í•­ìœ¼ë¡œëŠ” íˆ¬ì—¬ í¸ì˜ì„± í–¥ìƒê³¼ ì•½ë™í•™ì  í”„ë¡œíŒŒì¼ ìµœì í™”ë¥¼ ë“¤ ìˆ˜ ìˆìŠµë‹ˆë‹¤.<br><br>ì„ìƒ ê°œë°œ ê³„íšì„ ë§ì”€ë“œë¦¬ë©´, ìš°ë¦¬ëŠ” ë‹¨ê³„ì  ì ‘ê·¼ ë°©ì‹ì„ ì·¨í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ˆê¸° ë‹¨ê³„ ì„ìƒì‹œí—˜ì—ì„œ ì•ˆì „ì„±ê³¼ ë‚´ì•½ì„±ì„ í™•ì¸í•œ í›„, ê¸°ì¡´ ë“€í”½ì„¼íŠ¸ê°€ ìŠ¹ì¸ë°›ì€ ì£¼ìš” ì ì‘ì¦ë“¤ì—ì„œ íš¨ëŠ¥ì„ í‰ê°€í•  ì˜ˆì •ì…ë‹ˆë‹¤. <br><br>í–¥í›„ ì´ë²¤íŠ¸ ê²½ë¡œëŠ” ë¨¼ì € 1ìƒ ë°ì´í„° í™•ë³´, ì´ì–´ì„œ 2ìƒ ê°œë…ì¦ëª… ì—°êµ¬ ì§„í–‰, ê·¸ë¦¬ê³  ì„±ê³µì ì¸ ê²°ê³¼ê°€ ë‚˜ì˜¤ë©´ 3ìƒ í”„ë¡œê·¸ë¨ìœ¼ë¡œ ì§„ì…í•˜ëŠ” ìˆœì„œì…ë‹ˆë‹¤. êµ¬ì²´ì ì¸ íƒ€ì„ë¼ì¸ì€ ì´ˆê¸° ì„ìƒ ê²°ê³¼ì— ë”°ë¼ ê²°ì •ë  ê²ƒì…ë‹ˆë‹¤.<br><br>ì´ ì°¨ì„¸ëŒ€ ì œí’ˆì€ ë“€í”½ì„¼íŠ¸ì˜ ì´ë¯¸ ì…ì¦ëœ íš¨ëŠ¥ì„ ê¸°ë°˜ìœ¼ë¡œ í•˜ë©´ì„œë„, í™˜ì í¸ì˜ì„±ê³¼ ì¹˜ë£Œ ê²½í—˜ì„ í•œì¸µ ë” ê°œì„ í•  ìˆ˜ ìˆì„ ê²ƒìœ¼ë¡œ ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤.<br><br></response></td></tr>
<tr><td>George Yancopoulos: Co-Founder, President, Chief Scientific Officer & Co-Chairman Yes. Obviously, DUPIXENT is a very unusual antibody. I don't know if everybody remembers the history of it, but some of the biggest companies in the world tried to make a molecule like DUPIXENT and failed in clinical trials. For example, Amgen using an inferior humanized mouse approach, tried to make a DUPIXENT that is targeting the same receptor as we did and their antibody completely failed in all their clinical trials. So DUPIXENT was a very special molecule. But what we continue to do is use our best technologies, our best antibody generating technology, starting with our best-in-class human immune system in the mouse, generating millions and millions of versions over the last many, many years and testing them and comparing them. And we think that we have one that might actually be, in some ways, even better than DUPIXENT. It looks like it may be longer acting and may have some other advantages as well. So we're going to be moving it forward in the clinic as we announced, and we'll be testing it, and we'll see whether indeed we have been able to come up with an even better dupi or a supi-dupi as we call it.</td><td>**George Yancopoulos:** ë„¤, ë¶„ëª…íˆ ë§ì”€ë“œë¦¬ë©´ ë“€í”½ì„¼íŠ¸ëŠ” ë§¤ìš° íŠ¹ë³„í•œ í•­ì²´ì…ë‹ˆë‹¤. ëª¨ë“  ë¶„ë“¤ì´ ê¸°ì–µí•˜ì‹¤ì§€ ëª¨ë¥´ê² ì§€ë§Œ, ì„¸ê³„ ìµœëŒ€ ê·œëª¨ì˜ ì œì•½ì‚¬ë“¤ì´ ë“€í”½ì„¼íŠ¸ì™€ ê°™ì€ ë¶„ìë¥¼ ë§Œë“¤ë ¤ê³  ì‹œë„í–ˆë‹¤ê°€ ì„ìƒì‹œí—˜ì—ì„œ ì‹¤íŒ¨í–ˆìŠµë‹ˆë‹¤. ì˜ˆë¥¼ ë“¤ì–´, ì•”ì  (Amgen)ì€ ì—´ë“±í•œ ì¸ê°„í™” ë§ˆìš°ìŠ¤ ë°©ì‹ì„ ì‚¬ìš©í•´ì„œ ìš°ë¦¬ì™€ ë™ì¼í•œ ìˆ˜ìš©ì²´ë¥¼ íƒ€ê²Ÿìœ¼ë¡œ í•˜ëŠ” ë“€í”½ì„¼íŠ¸ë¥¼ ë§Œë“¤ë ¤ê³  í–ˆì§€ë§Œ, ê·¸ë“¤ì˜ í•­ì²´ëŠ” ëª¨ë“  ì„ìƒì‹œí—˜ì—ì„œ ì™„ì „íˆ ì‹¤íŒ¨í–ˆìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ ë“€í”½ì„¼íŠ¸ëŠ” ì •ë§ íŠ¹ë³„í•œ ë¶„ìì…ë‹ˆë‹¤. í•˜ì§€ë§Œ ì €í¬ê°€ ì§€ì†ì ìœ¼ë¡œ í•˜ê³  ìˆëŠ” ê²ƒì€ ìµœê³ ì˜ ê¸°ìˆ , ìµœê³ ì˜ í•­ì²´ ìƒì„± ê¸°ìˆ ì„ í™œìš©í•˜ëŠ” ê²ƒì…ë‹ˆë‹¤. ë§ˆìš°ìŠ¤ ë‚´ ìµœê³  ìˆ˜ì¤€ì˜ ì¸ê°„ ë©´ì—­ ì‹œìŠ¤í…œì—ì„œ ì‹œì‘í•´ì„œ, ì§€ë‚œ ìˆ˜ë…„ê°„ ìˆ˜ë°±ë§Œ ê°€ì§€ ë²„ì „ì„ ìƒì„±í•˜ê³  í…ŒìŠ¤íŠ¸í•˜ë©° ë¹„êµí•´ì™”ìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì €í¬ëŠ” ì–´ë–¤ ë©´ì—ì„œëŠ” ë“€í”½ì„¼íŠ¸ë³´ë‹¤ ë” ë‚˜ì„ ìˆ˜ ìˆëŠ” í•­ì²´ë¥¼ í™•ë³´í–ˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. ë” ì˜¤ë˜ ì§€ì†ë˜ëŠ” ê²ƒìœ¼ë¡œ ë³´ì´ë©° ë‹¤ë¥¸ ì¥ì ë“¤ë„ ìˆì„ ê²ƒìœ¼ë¡œ ì˜ˆìƒë©ë‹ˆë‹¤. <br><br>ë”°ë¼ì„œ ë°œí‘œí•œ ëŒ€ë¡œ ì„ìƒì—ì„œ ì§„í–‰í•  ì˜ˆì •ì´ë©°, í…ŒìŠ¤íŠ¸ë¥¼ í†µí•´ ì‹¤ì œë¡œ ë“€í”½ì„¼íŠ¸ë³´ë‹¤ ë” ë‚˜ì€, ì €í¬ê°€ ë¶€ë¥´ëŠ” 'ìŠˆí¼ ë“€í”¼(supi-dupi)'ë¥¼ ê°œë°œí•  ìˆ˜ ìˆì—ˆëŠ”ì§€ í™•ì¸í•˜ê²Œ ë  ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>Leonard Schleifer: Co-Founder, President, CEO & Co-Chairman And just to remind everybody that, that while not formally in the alliance with Sanofi, it is covered by the alliance, meaning that if it goes into full development that we'll be doing this with Sanofi.</td><td>**Leonard Schleifer:** <budget:token_budget>200000</budget:token_budget><br><br>ëª¨ë“  ë¶„ë“¤ê»˜ ìƒê¸°ì‹œì¼œ ë“œë¦¬ê³  ì‹¶ì€ ì ì€, ê³µì‹ì ìœ¼ë¡œ ì‚¬ë…¸í”¼ì™€ì˜ ì œíœ´ì— í¬í•¨ë˜ì–´ ìˆì§€ëŠ” ì•Šì§€ë§Œ, ì œíœ´ ë²”ìœ„ì—ëŠ” í¬í•¨ë˜ì–´ ìˆë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤. ì¦‰, ë³¸ê²©ì ì¸ ê°œë°œ ë‹¨ê³„ë¡œ ì§„ì…í•˜ê²Œ ë˜ë©´ ì‚¬ë…¸í”¼ì™€ í•¨ê»˜ ì§„í–‰í•˜ê²Œ ë  ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>Ryan Crowe: Senior Vice President of Investor Relations & Strategic Analysis Thank you, next question please Shannon.</td><td>**Ryan Crowe:** ê°ì‚¬í•©ë‹ˆë‹¤. ë‹¤ìŒ ì§ˆë¬¸ ë¶€íƒë“œë¦½ë‹ˆë‹¤, ìƒˆë„Œ.</td></tr>
<tr><td>Operator: Our next question comes from the line of Tazeen Ahmad with Bank of America.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ ë±…í¬ ì˜¤ë¸Œ ì•„ë©”ë¦¬ì¹´ì˜ Tazeen Ahmad ì• ë„ë¦¬ìŠ¤íŠ¸ê»˜ì„œ ì£¼ì‹œê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Tazeen Ahmad: BofA Securities, Research Division I wanted to spend a minute on geographic atrophy. You guys have a cohort, I believe, reading out in the second half of this year on your GA program. I think there was a lot of promise a few years back just given the number of patients with GA, but the 2 approved drugs have proven not to be able to get a ton of market share. So what do you think is differentiated in your program? Do you think that you'll need to show a visual acuity benefit? Or is it going to be, in your mind, just as good to show slowing of vision loss given that you expect to have a better safety profile than both those drugs?</td><td>**Tazeen Ahmad:** ì§€ë¦¬ì  ìœ„ì¶•(geographic atrophy)ì— ëŒ€í•´ ì ì‹œ ì´ì•¼ê¸°í•˜ê³  ì‹¶ìŠµë‹ˆë‹¤. ê·€ì‚¬ëŠ” ì˜¬í•´ í•˜ë°˜ê¸°ì— GA í”„ë¡œê·¸ë¨ ì½”í˜¸íŠ¸ ê²°ê³¼ê°€ ë‚˜ì˜¬ ê²ƒìœ¼ë¡œ ì•Œê³  ìˆìŠµë‹ˆë‹¤. GA í™˜ì ìˆ˜ë¥¼ ê³ ë ¤í•  ë•Œ ëª‡ ë…„ ì „ë§Œ í•´ë„ ë§ì€ ê¸°ëŒ€ê°€ ìˆì—ˆì§€ë§Œ, ìŠ¹ì¸ëœ ë‘ ì•½ë¬¼ì€ ìƒë‹¹í•œ ì‹œì¥ ì ìœ ìœ¨ì„ í™•ë³´í•˜ì§€ ëª»í–ˆìŠµë‹ˆë‹¤. ê·¸ë ‡ë‹¤ë©´ ê·€ì‚¬ í”„ë¡œê·¸ë¨ì˜ ì°¨ë³„í™”ëœ ì ì€ ë¬´ì—‡ì´ë¼ê³  ìƒê°í•˜ì‹­ë‹ˆê¹Œ? ì‹œë ¥(visual acuity) ê°œì„  íš¨ê³¼ë¥¼ ì…ì¦í•´ì•¼ í•œë‹¤ê³  ë³´ì‹­ë‹ˆê¹Œ? ì•„ë‹ˆë©´ ë‘ ì•½ë¬¼ë³´ë‹¤ ë” ë‚˜ì€ ì•ˆì „ì„± í”„ë¡œí•„ì„ ê°€ì§ˆ ê²ƒìœ¼ë¡œ ì˜ˆìƒë˜ëŠ” ë§Œí¼, ì‹œë ¥ ì†ì‹¤ ì§€ì—°ì„ ë³´ì—¬ì£¼ëŠ” ê²ƒë§Œìœ¼ë¡œë„ ì¶©ë¶„í•˜ë‹¤ê³  ìƒê°í•˜ì‹­ë‹ˆê¹Œ?</td></tr>
<tr><td>George Yancopoulos: Co-Founder, President, Chief Scientific Officer & Co-Chairman Well, let me just remind you that the first drug in the wet AMD space was Macugen, which was an aptamer. And if you compare the benefits that it provided compared to something like EYLEA, yes, it had a benefit, but it was just barely slowing down wet AMD disease as opposed to what we were able to do with EYLEA, where we could actually reverse and improve vision even and maintain the restored vision for years thereafter. So obviously, the approaches that we have at our disposal, things like our antibodies and our siRNAs have historically proven to be much more powerful at blocking pathways than technologies and approaches such as aptamer, PEGylated aptamers and PEGylated peptides and so forth. So one possibility and opportunity, of course, is that by providing more profound blockade, one might actually see better benefit. Another, of course, important aspect of our program is we are trying both systemic blockade as well as local blockade. So one of the problems with the existing therapies and why they are not so widely used is they're largely preventative, but they come with very dangerous side effects in that they can cause essentially problems that might result in immediate blindness like retinal vasculitis with occlusive vasculitis disease. So imagine you're taking something to prevent blindness that can actually cause blindness. So the systemic approach, now of course, it may have its own problems, no, there's always risk. So it may come with its own problems in terms of systemic infections, but it should be free from causing these local potential blinding risks in the eye. So you may end up either with better efficacy or the same efficacy, but with a better safety profile in terms of avoiding these blinding risks. And also, in the case of right now, the current treatments, most patients actually have bilateral disease. So you have to inject both eyes. And many of them also suffer now, and in fact, these drugs can actually, in some cases, cause wet AMD, progression of wet AMD, they need injections in both eyes and they also need injections with anti-VEGF. So obviously, a systemic approach would avoid all these complications. You would have to give 2 sets of injections to both sets of eyes and so forth. So we're very excited because there's many, many opportunities here. And I'd also remind you that we are testing both the monotherapy in terms of cemdisiran alone, which works so spectacularly in myasthenia gravis as well as the combination of cemdisiran with the antibody, which works so beautifully and was required to optimally work in PNH. We don't know because we collectively, society, the medical system does not understand why, in one case, you need complete blockade. In the other case, you need this sort of cemdisiran type of an effect. We're exploring both. So there's many, many, many ways to provide improved benefit for these patients who really need an improved way of treating their disease. It could be something that really addresses the tremendous burden that's inflicted by bilateral disease, layered with anti-VEGF requirements and so forth. It could be better efficacy, it could be better safety. And it could also be, for example, a systemic approach that does not completely inhibit the complement system. So many, many, many ways to imagine delivering a better outcome for patients who really need it here, especially if more of them will choose to undertake this preventative approach.</td><td>**George Yancopoulos:** ìŠµì„± AMD ë¶„ì•¼ì—ì„œ ì²« ë²ˆì§¸ ì•½ë¬¼ì€ ì••íƒ€ë¨¸ì˜€ë˜ Macugenì´ì—ˆë‹¤ëŠ” ì ì„ ìƒê¸°ì‹œì¼œ ë“œë¦¬ê³  ì‹¶ìŠµë‹ˆë‹¤. ê·¸ ì•½ë¬¼ì´ ì œê³µí•œ íš¨ê³¼ë¥¼ EYLEA ê°™ì€ ì•½ë¬¼ê³¼ ë¹„êµí•´ë³´ë©´, ë„¤, íš¨ê³¼ëŠ” ìˆì—ˆì§€ë§Œ ìŠµì„± AMD ì§ˆí™˜ì„ ê°„ì‹ íˆ ëŠ¦ì¶”ëŠ” ìˆ˜ì¤€ì— ë¶ˆê³¼í–ˆìŠµë‹ˆë‹¤. ë°˜ë©´ EYLEAë¡œ ìš°ë¦¬ê°€ ë‹¬ì„±í•œ ê²ƒì€ ì‹¤ì œë¡œ ì‹œë ¥ì„ íšŒë³µì‹œí‚¤ê³  ê°œì„ í•  ìˆ˜ ìˆì—ˆìœ¼ë©°, ê·¸ë ‡ê²Œ íšŒë³µëœ ì‹œë ¥ì„ ê·¸ ì´í›„ ìˆ˜ë…„ê°„ ìœ ì§€í•  ìˆ˜ ìˆì—ˆìŠµë‹ˆë‹¤. <br><br>ë”°ë¼ì„œ ìš°ë¦¬ê°€ ë³´ìœ í•œ ì ‘ê·¼ë²•ë“¤, ì¦‰ í•­ì²´ë‚˜ siRNA ê°™ì€ ê²ƒë“¤ì€ ì••íƒ€ë¨¸, PEGí™” ì••íƒ€ë¨¸, PEGí™” í©íƒ€ì´ë“œ ë“±ê³¼ ê°™ì€ ê¸°ìˆ ì´ë‚˜ ì ‘ê·¼ë²•ë“¤ì— ë¹„í•´ ê²½ë¡œ ì°¨ë‹¨ì— ìˆì–´ í›¨ì”¬ ë” ê°•ë ¥í•œ íš¨ê³¼ë¥¼ ë³´ì¸ë‹¤ëŠ” ê²ƒì´ ì—­ì‚¬ì ìœ¼ë¡œ ì…ì¦ë˜ì–´ ì™”ìŠµë‹ˆë‹¤. í•œ ê°€ì§€ ê°€ëŠ¥ì„±ì´ì ê¸°íšŒëŠ” ë”ìš± ê°•ë ¥í•œ ì°¨ë‹¨ íš¨ê³¼ë¥¼ ì œê³µí•¨ìœ¼ë¡œì¨ ì‹¤ì œë¡œ ë” ë‚˜ì€ íš¨ê³¼ë¥¼ ë³¼ ìˆ˜ ìˆë‹¤ëŠ” ì ì…ë‹ˆë‹¤. ë˜í•œ ì €í¬ í”„ë¡œê·¸ë¨ì˜ ì¤‘ìš”í•œ ì¸¡ë©´ì€ ì „ì‹  ì°¨ë‹¨ê³¼ êµ­ì†Œ ì°¨ë‹¨ì„ ëª¨ë‘ ì‹œë„í•˜ê³  ìˆë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤. ê¸°ì¡´ ì¹˜ë£Œë²•ì˜ ë¬¸ì œì ì´ì ë„ë¦¬ ì‚¬ìš©ë˜ì§€ ì•ŠëŠ” ì´ìœ ëŠ”, ëŒ€ë¶€ë¶„ ì˜ˆë°©ì  ì¹˜ë£Œì´ê¸´ í•˜ì§€ë§Œ ë§¤ìš° ìœ„í—˜í•œ ë¶€ì‘ìš©ì´ ë™ë°˜ëœë‹¤ëŠ” ì ì…ë‹ˆë‹¤. íì‡„ì„± í˜ˆê´€ì—¼ì„ ë™ë°˜í•œ ë§ë§‰ í˜ˆê´€ì—¼ì²˜ëŸ¼ ì¦‰ê°ì ì¸ ì‹¤ëª…ì„ ì´ˆë˜í•  ìˆ˜ ìˆëŠ” ë¬¸ì œë“¤ì„ ì¼ìœ¼í‚¬ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì‹¤ëª…ì„ ì˜ˆë°©í•˜ê¸° ìœ„í•´ ë³µìš©í•˜ëŠ” ì•½ì´ ì˜¤íˆë ¤ ì‹¤ëª…ì„ ìœ ë°œí•  ìˆ˜ ìˆë‹¤ëŠ” ìƒí™©ì„ ìƒìƒí•´ë³´ì‹­ì‹œì˜¤. ê·¸ë˜ì„œ ì „ì‹  ì ‘ê·¼ë²•ì„ ì‚¬ìš©í•˜ëŠ” ê²ƒì¸ë°, ë¬¼ë¡  ì´ê²ƒë„ ìì²´ì ì¸ ë¬¸ì œê°€ ìˆì„ ìˆ˜ ìˆìŠµë‹ˆë‹¤. í•­ìƒ ìœ„í—˜ì€ ì¡´ì¬í•˜ë‹ˆê¹Œìš”. ì „ì‹  ê°ì—¼ê³¼ ê°™ì€ ê³ ìœ í•œ ë¬¸ì œê°€ ìˆì„ ìˆ˜ ìˆì§€ë§Œ, ì•ˆêµ¬ ë‚´ì—ì„œ ë°œìƒí•  ìˆ˜ ìˆëŠ” ì‹¤ëª… ìœ„í—˜ìœ¼ë¡œë¶€í„°ëŠ” ììœ ë¡œìš¸ ê²ƒì…ë‹ˆë‹¤. ë”°ë¼ì„œ ë” ë‚˜ì€ íš¨ëŠ¥ì„ ì–»ê±°ë‚˜, ìµœì†Œí•œ ë™ì¼í•œ íš¨ëŠ¥ì„ ìœ ì§€í•˜ë©´ì„œë„ ì‹¤ëª… ìœ„í—˜ì„ í”¼í•  ìˆ˜ ìˆëŠ” ë” ë‚˜ì€ ì•ˆì „ì„± í”„ë¡œíŒŒì¼ì„ í™•ë³´í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. <br><br>ë˜í•œ í˜„ì¬ ì¹˜ë£Œë²•ì˜ ê²½ìš°, ëŒ€ë¶€ë¶„ì˜ í™˜ìë“¤ì´ ì‹¤ì œë¡œ ì–‘ì•ˆ ì§ˆí™˜ì„ ê°€ì§€ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ ì–‘ìª½ ëˆˆ ëª¨ë‘ì— ì£¼ì‚¬ë¥¼ ë†“ì•„ì•¼ í•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  ë§ì€ í™˜ìë“¤ì´ í˜„ì¬ ê²ªê³  ìˆëŠ” ë¬¸ì œê°€ ìˆëŠ”ë°, ì‹¤ì œë¡œ ì´ëŸ¬í•œ ì•½ë¬¼ë“¤ì´ ê²½ìš°ì— ë”°ë¼ ìŠµì„± í™©ë°˜ë³€ì„±(wet AMD)ì„ ìœ ë°œí•˜ê±°ë‚˜ ìŠµì„± í™©ë°˜ë³€ì„±ì˜ ì§„í–‰ì„ ì¼ìœ¼í‚¬ ìˆ˜ ìˆì–´ì„œ, ì–‘ìª½ ëˆˆ ëª¨ë‘ì— ì£¼ì‚¬ê°€ í•„ìš”í•˜ê³  ë™ì‹œì— í•­-VEGF ì£¼ì‚¬ë„ í•„ìš”í•©ë‹ˆë‹¤. <br><br>ë”°ë¼ì„œ ì „ì‹  íˆ¬ì—¬ ë°©ì‹ì„ ì‚¬ìš©í•˜ë©´ ì´ëŸ¬í•œ ëª¨ë“  í•©ë³‘ì¦ì„ í”¼í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì–‘ìª½ ëˆˆì— ê°ê° ë‘ ì„¸íŠ¸ì˜ ì£¼ì‚¬ë¥¼ ë†“ì•„ì•¼ í•˜ëŠ” ë²ˆê±°ë¡œì›€ ë“±ì„ ëª¨ë‘ í•´ê²°í•  ìˆ˜ ìˆëŠ” ê²ƒì´ì£ . ì €í¬ëŠ” ì •ë§ ë§ì€ ê¸°íšŒë“¤ì´ ìˆê¸° ë•Œë¬¸ì— ë§¤ìš° ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  í•œ ê°€ì§€ ë§ì”€ë“œë¦¬ê³  ì‹¶ì€ ê²ƒì€, ì €í¬ê°€ ë‘ ê°€ì§€ ë°©ì‹ì„ ëª¨ë‘ í…ŒìŠ¤íŠ¸í•˜ê³  ìˆë‹¤ëŠ” ì ì…ë‹ˆë‹¤. í•˜ë‚˜ëŠ” cemdisiran ë‹¨ë…ìš”ë²•ì¸ë°, ì´ëŠ” ì¤‘ì¦ ê·¼ë¬´ë ¥ì¦(myasthenia gravis)ì—ì„œ ë†€ë¼ìš´ íš¨ê³¼ë¥¼ ë³´ì˜€ìŠµë‹ˆë‹¤. ë‹¤ë¥¸ í•˜ë‚˜ëŠ” cemdisiranê³¼ í•­ì²´ì˜ ë³‘ìš©ìš”ë²•ìœ¼ë¡œ, PNHì—ì„œ ë§¤ìš° í›Œë¥­í•œ íš¨ê³¼ë¥¼ ë³´ì˜€ê³  ìµœì ì˜ íš¨ê³¼ë¥¼ ë‚´ëŠ” ë° í•„ìˆ˜ì ì´ì—ˆìŠµë‹ˆë‹¤. <br><br>ì™œ ì–´ë–¤ ê²½ìš°ì—ëŠ” ì™„ì „í•œ ì°¨ë‹¨ì´ í•„ìš”í•˜ê³ , ë‹¤ë¥¸ ê²½ìš°ì—ëŠ” cemdisiran ë°©ì‹ì˜ íš¨ê³¼ê°€ í•„ìš”í•œì§€ëŠ” ì•„ì§ ëª¨ë¦…ë‹ˆë‹¤. ìš°ë¦¬ ëª¨ë‘, ì‚¬íšŒ ì „ì²´, ì˜ë£Œê³„ê°€ ì•„ì§ ì´í•´í•˜ì§€ ëª»í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì €í¬ëŠ” ë‘ ê°€ì§€ ë°©ì‹ì„ ëª¨ë‘ íƒêµ¬í•˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ ì •ë§ ê°œì„ ëœ ì¹˜ë£Œë²•ì´ ì ˆì‹¤íˆ í•„ìš”í•œ ì´ í™˜ìë¶„ë“¤ì—ê²Œ ë” ë‚˜ì€ í˜œíƒì„ ì œê³µí•  ìˆ˜ ìˆëŠ” ë°©ë²•ì´ ì •ë§ ë§ìŠµë‹ˆë‹¤. ì–‘ì¸¡ì„± ì§ˆí™˜ìœ¼ë¡œ ì¸í•œ ì—„ì²­ë‚œ ë¶€ë‹´ê³¼ í•­-VEGF ì¹˜ë£Œ ìš”êµ¬ì‚¬í•­ ë“±ì´ ê²¹ì³ì§€ëŠ” ë¬¸ì œë¥¼ ì‹¤ì§ˆì ìœ¼ë¡œ í•´ê²°í•  ìˆ˜ ìˆëŠ” ë°©ì•ˆì´ ë  ìˆ˜ ìˆìŠµë‹ˆë‹¤. ë” ë‚˜ì€ íš¨ëŠ¥ì´ ë  ìˆ˜ë„ ìˆê³ , ë” ë‚˜ì€ ì•ˆì „ì„±ì´ ë  ìˆ˜ë„ ìˆìŠµë‹ˆë‹¤. ë˜í•œ ì˜ˆë¥¼ ë“¤ì–´, ë³´ì²´ ì‹œìŠ¤í…œ(complement system)ì„ ì™„ì „íˆ ì–µì œí•˜ì§€ ì•ŠëŠ” ì „ì‹  ì¹˜ë£Œ ì ‘ê·¼ë²•ì´ ë  ìˆ˜ë„ ìˆìŠµë‹ˆë‹¤. ì •ë§ ë§ì€, ì •ë§ ë‹¤ì–‘í•œ ë°©ë²•ë“¤ë¡œ ë” ë‚˜ì€ ì¹˜ë£Œ ê²°ê³¼ë¥¼ ì œê³µí•  ìˆ˜ ìˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. íŠ¹íˆ ë” ë§ì€ í™˜ìë“¤ì´ ì´ëŸ¬í•œ ì˜ˆë°©ì  ì ‘ê·¼ë²•ì„ ì„ íƒí•˜ê²Œ ëœë‹¤ë©´, ì´ê²ƒì´ ì ˆì‹¤íˆ í•„ìš”í•œ í™˜ìë“¤ì—ê²Œ í° ë„ì›€ì´ ë  ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>Leonard Schleifer: Co-Founder, President, CEO & Co-Chairman Just to add one point, which George always emphasizes, VEGF is made locally. And so you give a local drug to block a local problem. The C5 is made systemically primarily in the liver. So it may require systemic blockade as opposed to intravitreal. But we have all the tools to dissect what the best approach is.</td><td>**Leonard Schleifer:** í•œ ê°€ì§€ë§Œ ë§ë¶™ì´ìë©´, Georgeê°€ í•­ìƒ ê°•ì¡°í•˜ëŠ” ë¶€ë¶„ì¸ë°, VEGFëŠ” êµ­ì†Œì ìœ¼ë¡œ ìƒì„±ë©ë‹ˆë‹¤. ë”°ë¼ì„œ êµ­ì†Œì ì¸ ë¬¸ì œë¥¼ ì°¨ë‹¨í•˜ê¸° ìœ„í•´ êµ­ì†Œ ì•½ë¬¼ì„ íˆ¬ì—¬í•˜ëŠ” ê²ƒì…ë‹ˆë‹¤. ë°˜ë©´ C5ëŠ” ì£¼ë¡œ ê°„ì—ì„œ ì „ì‹ ì ìœ¼ë¡œ ìƒì„±ë©ë‹ˆë‹¤. ê·¸ë˜ì„œ ìœ ë¦¬ì²´ê°•ë‚´ ì£¼ì‚¬ê°€ ì•„ë‹Œ ì „ì‹  ì°¨ë‹¨ì´ í•„ìš”í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ìš°ë¦¬ëŠ” ìµœì„ ì˜ ì ‘ê·¼ë²•ì´ ë¬´ì—‡ì¸ì§€ ê·œëª…í•  ìˆ˜ ìˆëŠ” ëª¨ë“  ë„êµ¬ë¥¼ ê°–ì¶”ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Ryan Crowe: Senior Vice President of Investor Relations & Strategic Analysis And final note on this, Tazeen. We -- the primary endpoint of our initial pivotal study is growth rate in GA lesion area, but I would note that we do have a prospective secondary endpoint that will measure 15-letter loss of visual acuity. So we will have an endpoint that looks at visual acuity at year 1 and year 2 of this study, unlike incumbent therapies who looked at this on a post-hoc basis. Let's move to the next question, please.</td><td>**Ryan Crowe:** íˆ¬ìì ê´€ê³„ ë° ì „ëµ ë¶„ì„ ë‹´ë‹¹ ìˆ˜ì„ ë¶€ì‚¬ì¥<br><br>ê·¸ë¦¬ê³  Tazeen, ì´ ë¶€ë¶„ì— ëŒ€í•´ ë§ˆì§€ë§‰ìœ¼ë¡œ ë§ì”€ë“œë¦¬ìë©´, ì €í¬ ì´ˆê¸° í”¼ë²— ì—°êµ¬ì˜ 1ì°¨ í‰ê°€ë³€ìˆ˜ëŠ” GA ë³‘ë³€ ë©´ì ì˜ ì„±ì¥ë¥ ì…ë‹ˆë‹¤. í•˜ì§€ë§Œ í•œ ê°€ì§€ ì£¼ëª©í•˜ì‹¤ ì ì€, ì €í¬ëŠ” 15ê¸€ì ì‹œë ¥ ì†ì‹¤ì„ ì¸¡ì •í•˜ëŠ” ì „í–¥ì  2ì°¨ í‰ê°€ë³€ìˆ˜ë¥¼ ê°€ì§€ê³  ìˆë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤. ë”°ë¼ì„œ ì´ ì—°êµ¬ì˜ 1ë…„ì°¨ì™€ 2ë…„ì°¨ì— ì‹œë ¥ì„ í‰ê°€í•˜ëŠ” í‰ê°€ë³€ìˆ˜ë¥¼ ê°–ê²Œ ë  ê²ƒì´ë©°, ì´ëŠ” ì‚¬í›„ ë¶„ì„ ê¸°ë°˜ìœ¼ë¡œ ì´ë¥¼ ì‚´í´ë³¸ ê¸°ì¡´ ì¹˜ë£Œë²•ë“¤ê³¼ëŠ” ë‹¤ë¦…ë‹ˆë‹¤. ë‹¤ìŒ ì§ˆë¬¸ìœ¼ë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Our next question comes from the line of Geoff Meacham with Citi.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ ì”¨í‹°ì˜ ì œí”„ ë¯¸ì²¨ ì• ë„ë¦¬ìŠ¤íŠ¸ë¡œë¶€í„° ë°›ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Geoffrey Meacham: Citigroup Inc., Research Division I just want to talk about EYLEA HD for a sec. Maybe just talk about the trends for growth for this year. I wanted to get maybe your perspective as you kind of exit '25 and go into '26, the sources of growth with regard to new patients, switches versus competition? And then on the prefilled syringe related, would you characterize that as kind of a tipping point? Are there ophthalmologists, are there practices that are sort of waiting for that? I want to get a sense for how much of a gating factor that is to ultimate demand.</td><td>**Geoffrey Meacham:** EYLEA HDì— ëŒ€í•´ ì ì‹œ ì´ì•¼ê¸°í•˜ê³  ì‹¶ìŠµë‹ˆë‹¤. ì˜¬í•´ ì„±ì¥ ì¶”ì„¸ì— ëŒ€í•´ ë§ì”€í•´ ì£¼ì‹œê² ìŠµë‹ˆê¹Œ? 25ë…„ì„ ë§ˆë¬´ë¦¬í•˜ê³  26ë…„ìœ¼ë¡œ ë„˜ì–´ê°€ë©´ì„œ, ì‹ ê·œ í™˜ì, ê²½ìŸì‚¬ë¡œë¶€í„°ì˜ ì „í™˜ ë“±ê³¼ ê´€ë ¨í•œ ì„±ì¥ ë™ë ¥ì— ëŒ€í•œ ê²¬í•´ë¥¼ ë“£ê³  ì‹¶ìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  í”„ë¦¬í•„ë“œ ì‹œë¦°ì§€(prefilled syringe)ì™€ ê´€ë ¨í•´ì„œëŠ”, ì´ê²ƒì´ ì¼ì¢…ì˜ ì „í™˜ì ì´ ë  ê²ƒìœ¼ë¡œ ë³´ì‹œëŠ”ì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤. ì´ë¥¼ ê¸°ë‹¤ë¦¬ê³  ìˆëŠ” ì•ˆê³¼ ì˜ì‚¬ë‚˜ ë³‘ì›ë“¤ì´ ìˆìŠµë‹ˆê¹Œ? ì´ê²ƒì´ ê¶ê·¹ì ì¸ ìˆ˜ìš”ì— ì–¼ë§ˆë‚˜ í° ì œì•½ ìš”ì¸ì´ ë˜ëŠ”ì§€ íŒŒì•…í•˜ê³  ì‹¶ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Marion McCourt: Executive Vice President of Commercial Thank you, Geoff, for the question. And I'm going to start with the last portion on EYLEA HD and the prefilled syringe potential approval that we talked about today. And as you know, from the numbers that we shared, we're making good progress with EYLEA HD in the marketplace. The recent label enhancements with Q4 weekly dosing in RVO have been very well received. And of course, prefilled syringe, as I mentioned, will be a convenience factor for offices. So some that find that to be incredibly important. Obviously, we'll have a new opportunity to use EYLEA HD, but obviously, we have a lot of users today. It will only get better when we get and potentially have the prefilled syringe approval.</td><td>**Marion McCourt:** ì§ˆë¬¸ ê°ì‚¬í•©ë‹ˆë‹¤, Geoff. ë¨¼ì € ì˜¤ëŠ˜ ë§ì”€ë“œë¦° EYLEA HDì™€ í”„ë¦¬í•„ë“œ ì‹œë¦°ì§€(prefilled syringe) ìŠ¹ì¸ ê°€ëŠ¥ì„±ì— ëŒ€í•œ ë§ˆì§€ë§‰ ë¶€ë¶„ë¶€í„° ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ê³µìœ í•´ë“œë¦° ìˆ˜ì¹˜ì—ì„œ ë³´ì…¨ë“¯ì´, ì‹œì¥ì—ì„œ EYLEA HDê°€ ì¢‹ì€ ì„±ê³¼ë¥¼ ê±°ë‘ê³  ìˆìŠµë‹ˆë‹¤. ìµœê·¼ ë§ë§‰ì •ë§¥íì‡„(RVO)ì—ì„œ 4ì£¼ ê°„ê²© íˆ¬ì—¬ì— ëŒ€í•œ ë¼ë²¨ ê°œì„ ì´ ë§¤ìš° ê¸ì •ì ì¸ ë°˜ì‘ì„ ì–»ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì•ì„œ ë§ì”€ë“œë¦° ê²ƒì²˜ëŸ¼ í”„ë¦¬í•„ë“œ ì‹œë¦°ì§€ëŠ” ì˜ë£Œê¸°ê´€ì— í¸ì˜ì„±ì„ ì œê³µí•  ê²ƒì…ë‹ˆë‹¤. ì´ë¥¼ ë§¤ìš° ì¤‘ìš”í•˜ê²Œ ìƒê°í•˜ëŠ” ê³³ë“¤ì´ ìˆìŠµë‹ˆë‹¤. ë¶„ëª…íˆ EYLEA HDë¥¼ ì‚¬ìš©í•  ìƒˆë¡œìš´ ê¸°íšŒê°€ ìƒê¸¸ ê²ƒì´ì§€ë§Œ, ì´ë¯¸ ë§ì€ ì‚¬ìš©ìë“¤ì´ ìˆìŠµë‹ˆë‹¤. í”„ë¦¬í•„ë“œ ì‹œë¦°ì§€ ìŠ¹ì¸ì„ ë°›ê²Œ ë˜ë©´ ë”ìš± ì¢‹ì•„ì§ˆ ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>Ryan Crowe: Senior Vice President of Investor Relations & Strategic Analysis Okay. Let's move to the next question please, Shannon.</td><td>**Ryan Crowe:** ì¢‹ìŠµë‹ˆë‹¤. ë‹¤ìŒ ì§ˆë¬¸ìœ¼ë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤, Shannon.</td></tr>
<tr><td>Operator: Our next question comes from the line of Akash Tewari with Jefferies.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ Jefferiesì˜ Akash Tewarië¡œë¶€í„° ë°›ì•˜ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Akash Tewari: Jefferies LLC, Research Division On your PCSK9 and GIP/GLP combo, can you talk about the co-formulation here? How are you able to deliver both drugs in a single auto-injector versus something akin to an on-body infusion? And what are the chances you partner this asset out to share the development cost? Can you characterize any of those discussions so far?</td><td>**Akash Tewari:** PCSK9ì™€ GIP/GLP ë³µí•©ì œì— ëŒ€í•´ ì§ˆë¬¸ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ê³µë™ ì œí˜•í™”(co-formulation)ì— ëŒ€í•´ ì„¤ëª…í•´ ì£¼ì‹œê² ìŠµë‹ˆê¹Œ? ì˜¨ë°”ë”” ì¸í“¨ì „(on-body infusion) ë°©ì‹ì´ ì•„ë‹Œ ë‹¨ì¼ ìë™ì£¼ì…ê¸°ë¡œ ë‘ ì•½ë¬¼ì„ ëª¨ë‘ ì „ë‹¬í•  ìˆ˜ ìˆëŠ” ë°©ë²•ì€ ë¬´ì—‡ì…ë‹ˆê¹Œ? ê·¸ë¦¬ê³  ê°œë°œ ë¹„ìš©ì„ ë¶„ë‹´í•˜ê¸° ìœ„í•´ ì´ ìì‚°ì„ íŒŒíŠ¸ë„ˆë§í•  ê°€ëŠ¥ì„±ì€ ì–´ëŠ ì •ë„ì…ë‹ˆê¹Œ? ì§€ê¸ˆê¹Œì§€ ì§„í–‰ëœ ë…¼ì˜ì— ëŒ€í•´ ì„¤ëª…í•´ ì£¼ì‹¤ ìˆ˜ ìˆìŠµë‹ˆê¹Œ?</td></tr>
<tr><td>Leonard Schleifer: Co-Founder, President, CEO & Co-Chairman We don't comment on the status of discussions. We're always open-minded to deals that enhance our shareholder value...</td><td>**Leonard Schleifer:** ë…¼ì˜ ìƒí™©ì— ëŒ€í•´ì„œëŠ” ì–¸ê¸‰í•˜ì§€ ì•ŠìŠµë‹ˆë‹¤. ë‹¤ë§Œ ì €í¬ëŠ” í•­ìƒ ì£¼ì£¼ ê°€ì¹˜ë¥¼ ë†’ì¼ ìˆ˜ ìˆëŠ” ê±°ë˜ì— ëŒ€í•´ì„œëŠ” ì—´ë¦° ìì„¸ë¥¼ ì·¨í•˜ê³  ìˆìŠµë‹ˆë‹¤...</td></tr>
<tr><td>George Yancopoulos: Co-Founder, President, Chief Scientific Officer & Co-Chairman But as you touched on it, that's the magic, and that's the secret of our capabilities, best-in-class formulations group that delivered unprecedented formulation capability with EYLEA and EYLEA HD, it's the same people doing the same things that have figured out how to magically be able to get into an auto-injector, a very similar autoinjector that's used just for your GLP in a similar sort of volume, both the antibody and a peptide. And so we're very excited because Len is one who put it this way, imagine inventing a GLP that in addition to doing what the leading GLP does, it also just lowers cholesterol or bad cholesterol like 50% to 60%. Wouldn't everybody want to take that? Because we understand that so many people who suffer from obesity also suffer from cardiovascular risk. And while losing weight helps your cardiovascular risk, it also is dramatically driven by the bad cholesterol, which weight loss doesn't appreciably impact. So it's a very, very exciting opportunity. We're very excited that our scientists were able to figure out how to make this magic happen. And we think it's going to offer patients a really differentiated way of not only having their desirable weight loss, but also dramatically improving their hyperlipidemia associated cardiovascular risk as well. So we're very, very excited to be able to offer this opportunity and move forward with our clinical program to see if it's a reality.</td><td>**George Yancopoulos:** ê·€í•˜ê»˜ì„œ ì–¸ê¸‰í•˜ì‹  ê²ƒì²˜ëŸ¼, ê·¸ê²ƒì´ ë°”ë¡œ ìš°ë¦¬ì˜ í•µì‹¬ ì—­ëŸ‰ì´ì ë¹„ê²°ì…ë‹ˆë‹¤. EYLEAì™€ EYLEA HDë¡œ ì „ë¡€ ì—†ëŠ” ì œí˜• ì—­ëŸ‰ì„ ì…ì¦í•œ ìµœê³  ìˆ˜ì¤€ì˜ ì œí˜• ê·¸ë£¹, ë°”ë¡œ ê·¸ íŒ€ì´ ë™ì¼í•œ ë°©ì‹ìœ¼ë¡œ ìë™ì£¼ì…ê¸°ì— í•­ì²´ì™€ í©íƒ€ì´ë“œë¥¼ ëª¨ë‘ ë‹´ëŠ” ë°©ë²•ì„ ì°¾ì•„ëƒˆìŠµë‹ˆë‹¤. GLP-1 ì œì œì— ì‚¬ìš©ë˜ëŠ” ê²ƒê³¼ ë§¤ìš° ìœ ì‚¬í•œ ìë™ì£¼ì…ê¸°ì—, ë¹„ìŠ·í•œ ìš©ëŸ‰ìœ¼ë¡œ ë§ì´ì£ . ê·¸ë˜ì„œ ìš°ë¦¬ëŠ” ë§¤ìš° ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤. <br><br>Lenì´ ì´ë ‡ê²Œ í‘œí˜„í–ˆëŠ”ë°ìš”, ì‹œì¥ì„ ì„ ë„í•˜ëŠ” GLP-1 ì œì œê°€ í•˜ëŠ” ì¼ì„ ë‹¤ í•˜ë©´ì„œ, ë™ì‹œì— ì½œë ˆìŠ¤í…Œë¡¤, íŠ¹íˆ ë‚˜ìœ ì½œë ˆìŠ¤í…Œë¡¤ì„ 50%ì—ì„œ 60%ê¹Œì§€ ë‚®ì¶°ì£¼ëŠ” GLP-1 ì œì œë¥¼ ê°œë°œí–ˆë‹¤ê³  ìƒìƒí•´ë³´ì‹­ì‹œì˜¤. ëˆ„êµ¬ë‚˜ ê·¸ê±¸ ë³µìš©í•˜ê³  ì‹¶ì–´í•˜ì§€ ì•Šê² ìŠµë‹ˆê¹Œ? ë¹„ë§Œìœ¼ë¡œ ê³ í†µë°›ëŠ” ë§ì€ ë¶„ë“¤ì´ ì‹¬í˜ˆê´€ ìœ„í—˜ë„ í•¨ê»˜ ì•ˆê³  ìˆë‹¤ëŠ” ì ì„ ì˜ ì•Œê³  ìˆìŠµë‹ˆë‹¤. ì²´ì¤‘ ê°ëŸ‰ì´ ì‹¬í˜ˆê´€ ìœ„í—˜ì„ ê°œì„ í•˜ëŠ” ë° ë„ì›€ì´ ë˜ê¸´ í•˜ì§€ë§Œ, ë‚˜ìœ ì½œë ˆìŠ¤í…Œë¡¤(bad cholesterol)ì— ì˜í•´ì„œë„ í¬ê²Œ ì˜í–¥ì„ ë°›ëŠ”ë°, ì²´ì¤‘ ê°ëŸ‰ë§Œìœ¼ë¡œëŠ” ì´ë¥¼ ëˆˆì— ë„ê²Œ ê°œì„ í•˜ê¸° ì–´ë µìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ ì´ë²ˆ ê¸°íšŒê°€ ì •ë§ í¥ë¯¸ì§„ì§„í•œ ê²ƒì…ë‹ˆë‹¤. <br><br>ì €í¬ ê³¼í•™ìë“¤ì´ ì´ëŸ° ë†€ë¼ìš´ ì¼ì„ ê°€ëŠ¥í•˜ê²Œ ë§Œë“¤ì–´ë‚¸ ê²ƒì— ëŒ€í•´ ë§¤ìš° ìë‘ìŠ¤ëŸ½ê²Œ ìƒê°í•©ë‹ˆë‹¤. í™˜ìë¶„ë“¤ê»˜ ì›í•˜ì‹œëŠ” ì²´ì¤‘ ê°ëŸ‰ë¿ë§Œ ì•„ë‹ˆë¼ ê³ ì§€í˜ˆì¦(hyperlipidemia)ê³¼ ê´€ë ¨ëœ ì‹¬í˜ˆê´€ ìœ„í—˜ê¹Œì§€ íšê¸°ì ìœ¼ë¡œ ê°œì„ í•  ìˆ˜ ìˆëŠ” ì°¨ë³„í™”ëœ ë°©ë²•ì„ ì œê³µí•  ìˆ˜ ìˆì„ ê²ƒìœ¼ë¡œ ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ê¸°íšŒë¥¼ ì œê³µí•˜ê³  ì„ìƒ í”„ë¡œê·¸ë¨ì„ ì§„í–‰í•˜ë©´ì„œ ì‹¤ì œë¡œ ì´ê²ƒì´ í˜„ì‹¤ì´ ë  ìˆ˜ ìˆëŠ”ì§€ í™•ì¸í•  ìˆ˜ ìˆê²Œ ë˜ì–´ ì •ë§ ê¸°ì©ë‹ˆë‹¤.</td></tr>
<tr><td>Ryan Crowe: Senior Vice President of Investor Relations & Strategic Analysis Okay. Thank you. We have time for 2 more questions, Shannon.</td><td>**Ryan Crowe:** ì¢‹ìŠµë‹ˆë‹¤. ê°ì‚¬í•©ë‹ˆë‹¤. ì§ˆë¬¸ì„ ë‘ ê°œ ë” ë°›ì„ ìˆ˜ ìˆê² ìŠµë‹ˆë‹¤, Shannon.</td></tr>
<tr><td>Operator: Our next question comes from the line of Terence Flynn with Morgan Stanley.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ ëª¨ê±´ìŠ¤íƒ ë¦¬ì˜ í…Œë ŒìŠ¤ í”Œë¦°ìœ¼ë¡œë¶€í„° ë°›ì•˜ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Terence Flynn: Morgan Stanley, Research Division Bayer is going to be presenting some Phase III SSP data for their oral Factor XI inhibitor, asundexian next week. Just wondering anything you'll be focused on in that data set as it pertains to your Factor XI antibody program in terms of development, et cetera.</td><td>**Terence Flynn:** <response><br><br>Morgan Stanley ë¦¬ì„œì¹˜ ë¶€ë¬¸ì—ì„œ ì§ˆë¬¸ ì£¼ì‹  ë‚´ìš©ì€ Bayerê°€ ë‹¤ìŒ ì£¼ì— ê²½êµ¬ìš© Factor XI ì–µì œì œì¸ asundexianì˜ 3ìƒ SSP ë°ì´í„°ë¥¼ ë°œí‘œí•  ì˜ˆì •ì¸ë°, ê·€ì‚¬ì˜ Factor XI í•­ì²´ í”„ë¡œê·¸ë¨ ê°œë°œ ì¸¡ë©´ì—ì„œ í•´ë‹¹ ë°ì´í„°ì—ì„œ íŠ¹ë³„íˆ ì£¼ëª©í•˜ì‹¤ ë¶€ë¶„ì´ ìˆëŠ”ì§€ì— ê´€í•œ ê²ƒì…ë‹ˆë‹¤.<br><br>ì €í¬ë„ ê·¸ ë°ì´í„° ë°œí‘œë¥¼ ë§¤ìš° ì£¼ì˜ ê¹Šê²Œ ì§€ì¼œë³¼ ì˜ˆì •ì…ë‹ˆë‹¤. íŠ¹íˆ ëª‡ ê°€ì§€ í•µì‹¬ ì‚¬í•­ë“¤ì„ ë©´ë°€íˆ ê²€í† í•  ê²ƒì…ë‹ˆë‹¤. ìš°ì„  efficacy(ìœ íš¨ì„±) í”„ë¡œíŒŒì¼, íŠ¹íˆ ë‡Œì¡¸ì¤‘ ì˜ˆë°© íš¨ê³¼ê°€ ì–´ëŠ ì •ë„ì¸ì§€ í™•ì¸í•˜ê³ ì í•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì¶œí˜ˆ ì•ˆì „ì„± ë°ì´í„°ê°€ ë§¤ìš° ì¤‘ìš”í•œë°, Factor XI ê²½ë¡œ ì–µì œì˜ í•µì‹¬ ê°€ì¹˜ ì œì•ˆì´ ë°”ë¡œ ì¶œí˜ˆ ìœ„í—˜ ê°ì†Œì´ê¸° ë•Œë¬¸ì…ë‹ˆë‹¤.<br><br>ì €í¬ í•­ì²´ í”„ë¡œê·¸ë¨ê³¼ ê´€ë ¨í•´ì„œëŠ”, ê²½êµ¬ìš© ì†Œë¶„ìì™€ í•­ì²´ ì ‘ê·¼ë²• ê°„ì˜ ì°¨ë³„í™” ìš”ì†Œë“¤ì„ ê³„ì† ì£¼ëª©í•˜ê³  ìˆìŠµë‹ˆë‹¤. í•­ì²´ì˜ ê²½ìš° ë” ê¸´ ë°˜ê°ê¸°ì™€ ì§€ì†ì ì¸ ì–µì œ íš¨ê³¼ë¥¼ ì œê³µí•  ìˆ˜ ìˆìœ¼ë©°, ì´ëŠ” í™˜ì ìˆœì‘ë„ ì¸¡ë©´ì—ì„œ ì¥ì ì´ ë  ìˆ˜ ìˆìŠµë‹ˆë‹¤. ë˜í•œ íˆ¬ì—¬ ë¹ˆë„ì™€ ì•½ë™í•™ì  íŠ¹ì„±ì˜ ì°¨ì´ë„ íŠ¹ì • í™˜ìêµ°ì—ì„œëŠ” ì¤‘ìš”í•œ ê³ ë ¤ì‚¬í•­ì´ ë  ê²ƒì…ë‹ˆë‹¤.<br><br>ì–´ë–¤ ê²°ê³¼ê°€ ë‚˜ì˜¤ë“ , ì´ëŠ” Factor XI ì–µì œë¼ëŠ” ë©”ì»¤ë‹ˆì¦˜ ì „ì²´ì— ëŒ€í•œ ì„ìƒì  ê²€ì¦ì„ ì œê³µí•˜ëŠ” ì¤‘ìš”í•œ ë°ì´í„°ê°€ ë  ê²ƒì´ë©°, ì €í¬ í”„ë¡œê·¸ë¨ì˜ ì „ëµì  ë°©í–¥ ì„¤ì •ì—ë„ ê·€ì¤‘í•œ ì •ë³´ê°€ ë  ê²ƒì…ë‹ˆë‹¤.<br><br></response></td></tr>
<tr><td>George Yancopoulos: Co-Founder, President, Chief Scientific Officer & Co-Chairman Yes. I mean it is very hard to compare these small molecules with antibodies. As we know, historically, and it's the case here, small molecules suffer from both lack of specificity, we know they inhibit multiple proteases, including the target of interest here. And they also have off-target effects as well. And so the hope here is by having an antibody, which we think is very, very different than a small molecule, the specificity as well as the efficacy may allow you to have a very different profile where you will actually have better anticoagulation, but also hopefully, better safety, less bleeding, which we think what it's all about. And so there will be some read-through. There will be some usefulness to following that. On the other hand, we believe our antibody has a very substantially differentiated and potentially advantageous profile. And so the key thing is if our antibodies really can deliver what we believe they can with dramatic decreases in the overall bleeding risk, then they should allow somebody to essentially get an occasional shot once after a procedure, let's say, or once a month eventually, things like that, that won't require these patients to be either having to worry about making sure they stay on their meds or monitoring and so forth. So very different opportunity. Of course, there's some read-through, but we think our antibody is going to be very different.</td><td>**George Yancopoulos:** ë„¤, ì†Œë¶„ì ì˜ì•½í’ˆê³¼ í•­ì²´ë¥¼ ë¹„êµí•˜ëŠ” ê²ƒì€ ë§¤ìš° ì–´ë µìŠµë‹ˆë‹¤. ì—­ì‚¬ì ìœ¼ë¡œ ì•Œë ¤ì§„ ë°”ì™€ ê°™ì´, ê·¸ë¦¬ê³  ì´ë²ˆ ê²½ìš°ë„ ë§ˆì°¬ê°€ì§€ì¸ë°, ì†Œë¶„ì ì˜ì•½í’ˆì€ íŠ¹ì´ì„± ë¶€ì¡± ë¬¸ì œë¥¼ ê²ªê³  ìˆìŠµë‹ˆë‹¤. ì—¬ê¸°ì„œ ê´€ì‹¬ í‘œì ì„ í¬í•¨í•´ ì—¬ëŸ¬ í”„ë¡œí…Œì•„ì œë¥¼ ì–µì œí•˜ëŠ” ê²ƒìœ¼ë¡œ ì•Œë ¤ì ¸ ìˆì£ . ë˜í•œ í‘œì  ì™¸ íš¨ê³¼(off-target effects)ë„ ìˆìŠµë‹ˆë‹¤. <br><br>ê·¸ë˜ì„œ ì—¬ê¸°ì„œ ìš°ë¦¬ì˜ ê¸°ëŒ€ëŠ” í•­ì²´ë¥¼ ì‚¬ìš©í•˜ëŠ” ê²ƒì¸ë°, ì´ëŠ” ì†Œë¶„ì ì˜ì•½í’ˆê³¼ëŠ” ë§¤ìš° ë‹¤ë¥´ë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. íŠ¹ì´ì„±ê³¼ íš¨ëŠ¥ ì¸¡ë©´ì—ì„œ ì™„ì „íˆ ë‹¤ë¥¸ í”„ë¡œíŒŒì¼ì„ ê°€ì§ˆ ìˆ˜ ìˆì–´ì„œ, ì‹¤ì œë¡œ ë” ë‚˜ì€ í•­ì‘ê³  íš¨ê³¼ë¥¼ ì–»ì„ ìˆ˜ ìˆì„ ë¿ë§Œ ì•„ë‹ˆë¼, ë” ë‚˜ì€ ì•ˆì „ì„±, ì¦‰ ì¶œí˜ˆ ê°ì†Œ íš¨ê³¼ë„ ê¸°ëŒ€í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì´ê²ƒì´ í•µì‹¬ì´ë¼ê³  ìƒê°í•©ë‹ˆë‹¤. ë”°ë¼ì„œ ì–´ëŠ ì •ë„ ì—°ê´€ì„±ì´ ìˆì„ ê²ƒì´ê³ , ê·¸ ê²°ê³¼ë¥¼ ì¶”ì í•˜ëŠ” ê²ƒì´ ìœ ìš©í•  ê²ƒì…ë‹ˆë‹¤. ë°˜ë©´ì— ì €í¬ í•­ì²´ëŠ” ë§¤ìš° ì°¨ë³„í™”ë˜ê³  ì ì¬ì ìœ¼ë¡œ ìœ ë¦¬í•œ í”„ë¡œíŒŒì¼ì„ ê°€ì§€ê³  ìˆë‹¤ê³  ë¯¿ìŠµë‹ˆë‹¤. í•µì‹¬ì€ ì €í¬ í•­ì²´ê°€ ì¶œí˜ˆ ìœ„í—˜ì„ ê·¹ì ìœ¼ë¡œ ê°ì†Œì‹œí‚¬ ìˆ˜ ìˆë‹¤ë©´, í™˜ìë“¤ì´ ì‹œìˆ  í›„ í•œ ë²ˆ, ë˜ëŠ” ê¶ê·¹ì ìœ¼ë¡œëŠ” í•œ ë‹¬ì— í•œ ë²ˆ ì •ë„ë§Œ íˆ¬ì•½í•˜ë©´ ë˜ëŠ” ê²ƒì…ë‹ˆë‹¤. í™˜ìë“¤ì´ ì•½ë¬¼ ë³µìš©ì„ ì§€ì†ì ìœ¼ë¡œ ì‹ ê²½ ì“°ê±°ë‚˜ ëª¨ë‹ˆí„°ë§ì„ í•´ì•¼ í•˜ëŠ” ë¶€ë‹´ì´ ì—†ì–´ì§€ëŠ” ê²ƒì´ì£ . ê·¸ë˜ì„œ ë§¤ìš° ë‹¤ë¥¸ ê¸°íšŒë¼ê³  ë´…ë‹ˆë‹¤. ë¬¼ë¡  ì–´ëŠ ì •ë„ ì—°ê´€ì„±ì€ ìˆì§€ë§Œ, ì €í¬ í•­ì²´ëŠ” í™•ì—°íˆ ë‹¤ë¥¼ ê²ƒìœ¼ë¡œ ìƒê°í•©ë‹ˆë‹¤.</td></tr>
<tr><td>Ryan Crowe: Senior Vice President of Investor Relations & Strategic Analysis Thanks, George. Shannon, let's go to the last question, please.</td><td>**Ryan Crowe:** íˆ¬ìì ê´€ê³„ ë° ì „ëµ ë¶„ì„ ë‹´ë‹¹ ìˆ˜ì„ ë¶€ì‚¬ì¥ì˜ ë°œì–¸ì…ë‹ˆë‹¤.<br><br>ê°ì‚¬í•©ë‹ˆë‹¤, George. Shannon, ë§ˆì§€ë§‰ ì§ˆë¬¸ìœ¼ë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Our last question comes from the line of Evan Seigerman with BMO Capital Markets.</td><td>**Operator:** ë§ˆì§€ë§‰ ì§ˆë¬¸ì€ BMO ìºí”¼íƒˆ ë§ˆì¼“ì˜ ì—ë°˜ ì‹œê±°ë¨¼ìœ¼ë¡œë¶€í„° ë°›ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Evan Seigerman: BMO Capital Markets Equity Research I'd love for you to talk a little bit about the confidence that gives you to move your GLP-1/GIP into Phase III clinical trials globally, just given how rapidly this market is evolving. Put another way, what's differentiated about this asset from currently available standard of care and other advanced assets in development?</td><td>**Evan Seigerman:** <response><br><br>BMO ìºí”¼íƒˆ ë§ˆì¼“ ì´í€´í‹° ë¦¬ì„œì¹˜ì…ë‹ˆë‹¤. GLP-1/GIP ì œì œë¥¼ ê¸€ë¡œë²Œ 3ìƒ ì„ìƒì‹œí—˜ìœ¼ë¡œ ì§„í–‰í•˜ì‹œëŠ” ê²ƒì— ëŒ€í•œ í™•ì‹ ì— ëŒ€í•´ ë§ì”€í•´ ì£¼ì‹œë©´ ê°ì‚¬í•˜ê² ìŠµë‹ˆë‹¤. íŠ¹íˆ ì´ ì‹œì¥ì´ ë§¤ìš° ë¹ ë¥´ê²Œ ë³€í™”í•˜ê³  ìˆëŠ” ìƒí™©ì—ì„œ ë§ì´ì£ . ë‹¤ì‹œ ë§ì”€ë“œë¦¬ë©´, í˜„ì¬ ì‹œíŒ ì¤‘ì¸ í‘œì¤€ì¹˜ë£Œì œë‚˜ ê°œë°œ ì¤‘ì¸ ë‹¤ë¥¸ í›„ë³´ë¬¼ì§ˆë“¤ê³¼ ë¹„êµí–ˆì„ ë•Œ ê·€ì‚¬ì˜ ìì‚°ì´ ê°€ì§„ ì°¨ë³„ì ì€ ë¬´ì—‡ì¸ê°€ìš”?<br><br></response></td></tr>
<tr><td>Leonard Schleifer: Co-Founder, President, CEO & Co-Chairman So I think if you go back and listen carefully to what George was saying that the biggest advance here from our perspective is the ability to combine this with our PCSK9 inhibitor. There are only 2 approved PCSK9 antibodies and the ability to combine this antibody with these peptides in the same syringe at the same dosing interval, I think that's highly differentiated for the 15% -- 50% or more of people who are obese and have high cholesterol. We know several hundred thousand people already take both a GLP and a PCSK9 inhibitor. And that's without the convenience of having to put them together in a single shot and without really focusing any marketing on the obese group. So I think, Evan, that's what the core of the differentiation could be. Obviously, it's -- we're considering putting it together with other assets in our pipeline, other combinations, we can't imagine directly competing, but I do think we should have data that's competitive to the best-in-class. But the commercial strategy is not to directly compete without the combination. George, do you want to add something?</td><td>**Leonard Schleifer:** ê°€ì¥ ì¤‘ìš”í•œ ì§„ì „ì€ ì´ê²ƒì„ ìš°ë¦¬ì˜ PCSK9 ì–µì œì œì™€ ê²°í•©í•  ìˆ˜ ìˆë‹¤ëŠ” ì ì…ë‹ˆë‹¤. í˜„ì¬ ìŠ¹ì¸ëœ PCSK9 í•­ì²´ëŠ” ë‹¨ 2ê°œë¿ì´ê³ , ì´ í•­ì²´ì™€ í©íƒ€ì´ë“œë¥¼ ë™ì¼í•œ ì£¼ì‚¬ê¸°ì—ì„œ ë™ì¼í•œ íˆ¬ì—¬ ê°„ê²©ìœ¼ë¡œ ê²°í•©í•  ìˆ˜ ìˆë‹¤ëŠ” ê²ƒì€ ë¹„ë§Œì´ë©´ì„œ ê³ ì½œë ˆìŠ¤í…Œë¡¤ ìˆ˜ì¹˜ë¥¼ ê°€ì§„ 15%ì—ì„œ 50% ì´ìƒì˜ í™˜ìë“¤ì—ê²Œ ë§¤ìš° ì°¨ë³„í™”ëœ ì ‘ê·¼ë²•ì´ë¼ê³  ìƒê°í•©ë‹ˆë‹¤. ì´ë¯¸ ìˆ˜ì‹­ë§Œ ëª…ì˜ í™˜ìë“¤ì´ GLPì™€ PCSK9 ì–µì œì œë¥¼ í•¨ê»˜ ë³µìš©í•˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì´ê²ƒì€ ë‘ ê°€ì§€ë¥¼ í•œ ë²ˆì˜ ì£¼ì‚¬ë¡œ í¸ë¦¬í•˜ê²Œ íˆ¬ì—¬í•  ìˆ˜ ìˆê²Œ ë˜ê¸° ì „ì´ê³ , ë¹„ë§Œ ê·¸ë£¹ì„ ëŒ€ìƒìœ¼ë¡œ í•œ ë§ˆì¼€íŒ…ì— ì§‘ì¤‘í•˜ê¸°ë„ ì „ì˜ ìˆ˜ì¹˜ì…ë‹ˆë‹¤. ë”°ë¼ì„œ ì´ê²ƒì´ í•µì‹¬ì ì¸ ì°¨ë³„í™” ìš”ì†Œê°€ ë  ìˆ˜ ìˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. ëª…í™•íˆ ë§ì”€ë“œë¦¬ë©´, ì €í¬ëŠ” íŒŒì´í”„ë¼ì¸ì— ìˆëŠ” ë‹¤ë¥¸ ìì‚°ë“¤ê³¼ì˜ ê²°í•©, ë‹¤ì–‘í•œ ì¡°í•© ë°©ì•ˆë“¤ì„ ê²€í† í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì§ì ‘ì ì¸ ê²½ìŸì€ ìƒì •í•˜ê¸° ì–´ë µì§€ë§Œ, ë² ìŠ¤íŠ¸ì¸í´ë˜ìŠ¤(best-in-class)ì™€ ê²½ìŸë ¥ ìˆëŠ” ë°ì´í„°ë¥¼ í™•ë³´í•´ì•¼ í•œë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. ë‹¤ë§Œ ìƒì—…í™” ì „ëµì€ ì¡°í•© ì—†ì´ ì§ì ‘ ê²½ìŸí•˜ëŠ” ë°©í–¥ì€ ì•„ë‹™ë‹ˆë‹¤. George, ì¶”ê°€í•˜ì‹¤ ë‚´ìš© ìˆìœ¼ì‹ ê°€ìš”?</td></tr>
<tr><td>George Yancopoulos: Co-Founder, President, Chief Scientific Officer & Co-Chairman Yes. So remember, one of the reasons we have confidence is this has already been extensively studied in China. And it's designed to be and the clinical data suggests it is very tirzepatide-like in its efficacy and safety profile when compared in the same populations. And it is already in advanced Phase III trials in China. That's why we think we have very much a tirzepatide-like or a best-in-class type agent. But as Len said, we don't necessarily want to just compete just for the weight loss. A lot of people are just so focused on the weight loss and they're trying to say, oh, let me get a little bit more weight loss, a little less nauseousness, a little less vomiting. Oh, my God, they're all competing around the weight loss. They're all fighting in that space. We want to take this to a whole another place where we're adding a completely new benefit, a completely different benefit to the weight loss. So let everybody else fight for an extra 1% or 2% of weight loss. We're going to give you 50% to 60% LDL lowering with the associated expected cardiovascular benefit. That's highly differentiated. So we didn't get this to compete just by itself in the obesity space, though we think we have an agent here that is very similar to the best-in-class type of reagent. It's all about the combinations. And the first combination that we're rolling out, we think is this very, very exciting one that, frankly, honestly, every obese patient should take this, okay, regardless of their lipid status because lower lipids is better. And that would be better. It would frankly be better for the entire population. Why do we know? Because cardiovascular disease driven by hyperlipidemia is still the #1 killer in America and people are not taking it. So it may be almost a Trojan horse. Imagine, they just -- they want to lose their weight and they're not even going to realize that they're going to be helping their hearts and they're going to be decreasing the overall rate of cardiovascular disease and death in this country, a Trojan horse to really make an impact for society. This is what we're trying to do. Everybody, frankly, in America should be on a PCSK9. This is a way to actually do it and do it in a way that people will actually want to take. And we think we have a variety of other ways, not to compete on the weight loss side, but to give another important benefit on top of the weight loss.</td><td>**George Yancopoulos:** ë„¤, ê¸°ì–µí•˜ì‹¤ ì ì€ ìš°ë¦¬ê°€ í™•ì‹ ì„ ê°–ëŠ” ì´ìœ  ì¤‘ í•˜ë‚˜ê°€ ì´ë¯¸ ì¤‘êµ­ì—ì„œ ê´‘ë²”ìœ„í•˜ê²Œ ì—°êµ¬ë˜ì—ˆë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì´ ì•½ë¬¼ì€ ë™ì¼í•œ í™˜ìêµ°ì—ì„œ ë¹„êµí–ˆì„ ë•Œ íš¨ëŠ¥ê³¼ ì•ˆì „ì„± í”„ë¡œíŒŒì¼ ë©´ì—ì„œ í‹°ë¥´ì œíŒŒíƒ€ì´ë“œ(tirzepatide)ì™€ ë§¤ìš° ìœ ì‚¬í•˜ë„ë¡ ì„¤ê³„ë˜ì—ˆê³ , ì„ìƒ ë°ì´í„°ë„ ê·¸ë ‡ê²Œ ë‚˜íƒ€ë‚˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ë¯¸ ì¤‘êµ­ì—ì„œ 3ìƒ í›„ê¸° ì„ìƒì‹œí—˜ì´ ì§„í–‰ ì¤‘ì…ë‹ˆë‹¤. ê·¸ë˜ì„œ ìš°ë¦¬ëŠ” í‹°ë¥´ì œíŒŒíƒ€ì´ë“œì™€ ìœ ì‚¬í•˜ê±°ë‚˜ ë™ê¸‰ ìµœê³  ìˆ˜ì¤€ì˜ ì•½ë¬¼ì„ ë³´ìœ í•˜ê³  ìˆë‹¤ê³  ìƒê°í•˜ëŠ” ê²ë‹ˆë‹¤. <br><br>í•˜ì§€ë§Œ ë Œì´ ë§í–ˆë“¯ì´, ìš°ë¦¬ëŠ” ë‹¨ìˆœíˆ ì²´ì¤‘ ê°ëŸ‰ ë¶€ë¬¸ì—ì„œë§Œ ê²½ìŸí•˜ê³  ì‹¶ì§€ ì•ŠìŠµë‹ˆë‹¤. ë§ì€ ì‚¬ëŒë“¤ì´ ì²´ì¤‘ ê°ëŸ‰ì—ë§Œ ë„ˆë¬´ ì§‘ì¤‘í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì¡°ê¸ˆ ë” ë§ì€ ì²´ì¤‘ ê°ëŸ‰, ì¡°ê¸ˆ ëœí•œ ë©”ìŠ¤êº¼ì›€, ì¡°ê¸ˆ ëœí•œ êµ¬í† , ì´ëŸ° ì‹ìœ¼ë¡œ ëª¨ë‘ê°€ ì²´ì¤‘ ê°ëŸ‰ì„ ì¤‘ì‹¬ìœ¼ë¡œ ê²½ìŸí•˜ê³  ìˆìŠµë‹ˆë‹¤. ëª¨ë‘ê°€ ê·¸ ì‹œì¥ì—ì„œ ê²½ìŸí•˜ê³  ìˆìŠµë‹ˆë‹¤. ìš°ë¦¬ëŠ” ì´ê²ƒì„ ì™„ì „íˆ ë‹¤ë¥¸ ì°¨ì›ìœ¼ë¡œ ê°€ì ¸ê°€ê³ ì í•©ë‹ˆë‹¤. ì²´ì¤‘ ê°ëŸ‰ì— ì™„ì „íˆ ìƒˆë¡œìš´ í˜œíƒ, ì™„ì „íˆ ë‹¤ë¥¸ í˜œíƒì„ ë”í•˜ëŠ” ê²ƒì´ì£ . ê·¸ëŸ¬ë‹ˆ ë‹¤ë¥¸ íšŒì‚¬ë“¤ì€ 1~2%ì˜ ì¶”ê°€ ì²´ì¤‘ ê°ëŸ‰ì„ ë†“ê³  ê²½ìŸí•˜ê²Œ ë‘ì‹­ì‹œì˜¤. ìš°ë¦¬ëŠ” 50~60%ì˜ LDL ì €í•˜ì™€ í•¨ê»˜ ê·¸ì— ë”°ë¥¸ ê¸°ëŒ€ë˜ëŠ” ì‹¬í˜ˆê´€ íš¨ê³¼ë¥¼ ì œê³µí•  ê²ƒì…ë‹ˆë‹¤. ì´ê²ƒì´ ë°”ë¡œ ê³ ë„ì˜ ì°¨ë³„í™”ì…ë‹ˆë‹¤. <br><br>ìš°ë¦¬ëŠ” ë‹¨ìˆœíˆ ë¹„ë§Œ ì‹œì¥ì—ì„œë§Œ ê²½ìŸí•˜ê¸° ìœ„í•´ ì´ê²ƒì„ ê°œë°œí•œ ê²Œ ì•„ë‹™ë‹ˆë‹¤. ë¬¼ë¡  ìš°ë¦¬ê°€ ì—¬ê¸°ì„œ ë³´ìœ í•œ ì•½ë¬¼ì´ ìµœê³  ìˆ˜ì¤€ì˜ ì•½ë¬¼ê³¼ ë§¤ìš° ìœ ì‚¬í•˜ë‹¤ê³  ìƒê°í•˜ì§€ë§Œìš”. í•µì‹¬ì€ ë³‘ìš©ìš”ë²•ì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ìš°ë¦¬ê°€ ì²˜ìŒìœ¼ë¡œ ì„ ë³´ì´ëŠ” ì´ ë³‘ìš©ìš”ë²•ì€ ì •ë§ë¡œ, ì†”ì§íˆ ë§ì”€ë“œë¦¬ë©´, ëª¨ë“  ë¹„ë§Œ í™˜ìê°€ ë³µìš©í•´ì•¼ í•œë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. ì§€ì§ˆ ìˆ˜ì¹˜ì™€ ê´€ê³„ì—†ì´ ë§ì´ì£ . ì™œëƒí•˜ë©´ ì§€ì§ˆ ìˆ˜ì¹˜ê°€ ë‚®ì„ìˆ˜ë¡ ë” ì¢‹ìœ¼ë‹ˆê¹Œìš”. ê·¸ë¦¬ê³  ê·¸ê²Œ ë” ë‚˜ì„ ê²ƒì…ë‹ˆë‹¤. ì†”ì§íˆ ë§í•´ì„œ ì „ì²´ ì¸êµ¬ì—ê²Œ ë” ë‚˜ì„ ê²ƒì…ë‹ˆë‹¤. ì™œ ê·¸ê±¸ ì•Œ ìˆ˜ ìˆëƒê³ ìš”? ê³ ì§€í˜ˆì¦ìœ¼ë¡œ ì¸í•œ ì‹¬í˜ˆê´€ ì§ˆí™˜ì´ ì—¬ì „íˆ ë¯¸êµ­ì—ì„œ ì‚¬ë§ ì›ì¸ 1ìœ„ì¸ë°ë„ ì‚¬ëŒë“¤ì´ ì•½ì„ ë³µìš©í•˜ì§€ ì•Šê³  ìˆê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. ê·¸ë˜ì„œ ì´ê±´ ê±°ì˜ íŠ¸ë¡œì´ ëª©ë§ˆ ê°™ì€ ì „ëµì´ ë  ìˆ˜ ìˆìŠµë‹ˆë‹¤. ìƒìƒí•´ë³´ì„¸ìš”. ì‚¬ëŒë“¤ì€ ê·¸ëƒ¥ ì²´ì¤‘ì„ ê°ëŸ‰í•˜ê³  ì‹¶ì–´í•˜ëŠ”ë°, ìì‹ ë“¤ì´ ì‹¬ì¥ ê±´ê°•ì—ë„ ë„ì›€ì„ ì£¼ê³  ìˆë‹¤ëŠ” ê±¸ ê¹¨ë‹«ì§€ë„ ëª»í•  ê²ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì´ ë‚˜ë¼ì˜ ì „ë°˜ì ì¸ ì‹¬í˜ˆê´€ ì§ˆí™˜ê³¼ ì‚¬ë§ë¥ ì„ ë‚®ì¶”ê²Œ ë  ê²ƒì…ë‹ˆë‹¤. ì‚¬íšŒì— ì§„ì •í•œ ì˜í–¥ì„ ë¯¸ì¹˜ê¸° ìœ„í•œ íŠ¸ë¡œì´ ëª©ë§ˆì¸ ì…ˆì´ì£ . ì´ê²ƒì´ ìš°ë¦¬ê°€ í•˜ë ¤ëŠ” ì¼ì…ë‹ˆë‹¤. ì†”ì§íˆ ë§í•˜ë©´ ë¯¸êµ­ì˜ ëª¨ë“  ì‚¬ëŒë“¤ì´ PCSK9 ì–µì œì œë¥¼ ë³µìš©í•´ì•¼ í•©ë‹ˆë‹¤. ì´ê²ƒì´ ì‹¤ì œë¡œ ê·¸ê±¸ ì‹¤í˜„í•˜ëŠ” ë°©ë²•ì´ê³ , ì‚¬ëŒë“¤ì´ ì‹¤ì œë¡œ ë³µìš©í•˜ê³  ì‹¶ì–´í•  ë°©ì‹ìœ¼ë¡œ í•˜ëŠ” ë°©ë²•ì…ë‹ˆë‹¤. <response><br><br>ì €í¬ëŠ” ì²´ì¤‘ ê°ëŸ‰ ì¸¡ë©´ì—ì„œ ê²½ìŸí•˜ëŠ” ê²ƒì´ ì•„ë‹ˆë¼, ì²´ì¤‘ ê°ëŸ‰ì— ë”í•´ ë˜ ë‹¤ë¥¸ ì¤‘ìš”í•œ ì´ì ì„ ì œê³µí•  ìˆ˜ ìˆëŠ” ë‹¤ì–‘í•œ ë°©ë²•ë“¤ì„ ê°€ì§€ê³  ìˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤.<br><br></response></td></tr>
<tr><td>Ryan Crowe: Senior Vice President of Investor Relations & Strategic Analysis All right. Thank you, George, and thanks to everyone who dialed in today for your interest in Regeneron. We apologize to those remaining in the Q&A queue who did not have a chance to hear from today. As always, the IR team is available to answer any remaining questions that you may have. Once again, have a great day and a nice weekend.</td><td>**Ryan Crowe:** ì˜¤ëŠ˜ ë¦¬ì œë„¤ë¡ ì— ê´€ì‹¬ì„ ê°€ì ¸ì£¼ì‹œê³  ì „í™” íšŒì˜ì— ì°¸ì—¬í•´ ì£¼ì‹  ëª¨ë“  ë¶„ë“¤ê»˜ ê°ì‚¬ë“œë¦½ë‹ˆë‹¤. ì˜¤ëŠ˜ ì§ˆì˜ì‘ë‹µ ì‹œê°„ì— ì§ˆë¬¸í•˜ì§€ ëª»í•˜ì‹  ë¶„ë“¤ê»˜ëŠ” ì–‘í•´ ë¶€íƒë“œë¦½ë‹ˆë‹¤. <br><br>ì–¸ì œë“ ì§€ IR íŒ€ì´ ì¶”ê°€ ì§ˆë¬¸ì‚¬í•­ì— ëŒ€í•´ ë‹µë³€í•´ ë“œë¦´ ì¤€ë¹„ê°€ ë˜ì–´ ìˆìœ¼ë‹ˆ í¸í•˜ê²Œ ì—°ë½ ì£¼ì‹œê¸° ë°”ëë‹ˆë‹¤. ë‹¤ì‹œ í•œë²ˆ ê°ì‚¬ë“œë¦¬ë©°, ì¢‹ì€ í•˜ë£¨ ë˜ì‹œê³  ì¦ê±°ìš´ ì£¼ë§ ë³´ë‚´ì‹œê¸° ë°”ëë‹ˆë‹¤.</td></tr>
<tr><td>Operator: This concludes today's conference. Thank you for your participation. You may now disconnect.</td><td>**Operator:** ì´ê²ƒìœ¼ë¡œ ì˜¤ëŠ˜ ì»¨í¼ëŸ°ìŠ¤ë¥¼ ë§ˆì¹˜ê² ìŠµë‹ˆë‹¤. ì°¸ì—¬í•´ ì£¼ì…”ì„œ ê°ì‚¬í•©ë‹ˆë‹¤. ì´ì œ ì—°ê²°ì„ ì¢…ë£Œí•˜ì…”ë„ ë©ë‹ˆë‹¤.</td></tr>
    </table>
    <h3>ğŸ“Œ ìš”ì•½</h3>
    <p style="background:#f0f0f0; padding:15px; border-left: 5px solid #333;"># Regeneron ì‹¤ì  ë°œí‘œ ì£¼ìš” ìš”ì•½<br><br>## í•µì‹¬ ë‚´ìš©<br><br>â€¢ **LIBTAYO + fianlimab ì„ìƒ ê²°ê³¼ ë°œí‘œ ì˜ˆì •**: ì „ì´ì„± í‘ìƒ‰ì¢… ë° ë³´ì¡°ìš”ë²• ë°ì´í„°ê°€ ìƒë°˜ê¸° ì¤‘ ë°œí‘œ ì˜ˆì •ì´ë‚˜, êµ¬ì²´ì  ì‹œê¸°ëŠ” ë¯¸ì •. ë‘ ì ì‘ì¦ ê²°ê³¼ê°€ ë™ì‹œì— ë‚˜ì˜¬ ìˆ˜ë„ ìˆìœ¼ë©°, ë°ì´í„° í™•ë³´ ì¦‰ì‹œ ê³µê°œ ê³„íš<br><br>â€¢ **DUPIXENT IP ë³´í˜¸ ë° í›„ì† íŒŒì´í”„ë¼ì¸ ê°•í™”**: Sanofiì˜ íŠ¹í—ˆ ì—°ì¥ ê°€ëŠ¥ì„±(2040ë…„ ì´í›„) ì–¸ê¸‰ì— ë™ì˜. ì¥ê¸° ì§€ì†í˜• IL-13/IL-4 ì´ì¤‘í•­ì²´ ë° ê°œì„ ëœ ì°¨ì„¸ëŒ€ DUPIXENT("supi-dupi") ê°œë°œ ì¤‘. DUPIXENTì˜ ì°¨ë³„ì ì€ ì•Œë ˆë¥´ê¸° ê²½ë¡œë§Œ ì„ íƒì ìœ¼ë¡œ ì–µì œí•˜ì—¬ ì „ë°˜ì  ë©´ì—­ì–µì œ ì—†ì´ ë›°ì–´ë‚œ ì•ˆì „ì„± í”„ë¡œíŒŒì¼ ì œê³µ<br><br>â€¢ **ì§€ë¦¬ì  ìœ„ì¶•ì¦(GA) í”„ë¡œê·¸ë¨ì˜ ì°¨ë³„í™” ì „ëµ**: í•˜ë°˜ê¸° ì½”í˜¸íŠ¸ ê²°ê³¼ ë°œí‘œ ì˜ˆì •. ê¸°ì¡´ ìŠ¹ì¸ ì•½ë¬¼(aptamer, í©íƒ€ì´ë“œ)ë³´ë‹¤ ê°•ë ¥í•œ í•­ì²´/siRNA ê¸°ìˆ ë¡œ ë” ë‚˜ì€ íš¨ëŠ¥ ê¸°ëŒ€. ì „ì‹  íˆ¬ì—¬ ë°©ì‹ìœ¼ë¡œ ì–‘ì•ˆ ì§ˆí™˜ ë° ë§ë§‰ í˜ˆê´€ì—¼ ë“± êµ­ì†Œ ë¶€ì‘ìš© íšŒí”¼ ê°€ëŠ¥. 1ì°¨ í‰ê°€ë³€ìˆ˜ëŠ” GA ë³‘ë³€ ì„±ì¥ë¥ ì´ë‚˜, ì‹œë ¥ ì†ì‹¤(15-letter loss)ë„ ì „í–¥ì  2ì°¨ í‰ê°€ë³€ìˆ˜ë¡œ í¬í•¨<br><br>â€¢ **GLP-1/G</p>
    <hr style="margin:50px 0;">
    
</body></html>